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 ABSTRACT 
The Genetic Architecture of Alopecia Areata 
Lynn Petukhova 
 
Alopecia areata (AA) is the most prevalent autoimmune disease in the US. With An 
estimated lifetime risk of 1.7%, it affects both genders with similar frequencies and people of all 
ages. AA affects more individuals than most other autoimmune diseases combined, and yet 
despite its prevalence, there is an enormous unmet medical need, in part due to the dearth of 
information about the underlying pathogenesis.  In AA, autoimmunity arises against the hair 
follicles in the skin, which causes hair loss associated with an aberrant accumulation of 
immune-response cells around the affected hair follicles.  Evidence supporting a genetic basis 
for AA stems from multiple lines of research, including increased risk of disease in first degree 
relatives, twin studies,  and more recently, our initial family-based linkage study and genome 
wide association study (GWAS) in a cohort of unrelated individuals.  Importantly, our GWAS 
identified a set of 16 statistically independent risk haplotypes across 8 loci, implicating specific 
genes that increase risk of AA, all of which have been validated.  Genome wide genetic studies 
can provide critical insight into disease mechanisms, especially when little is known about the 
underlying causes of disease.  In this study, I use complementary gene mapping methods, 
performing one study in a cohort of families and a second study in a cohort of unrelated cases 
and controls.  Using these two approaches, I obtain new evidence about the genetic influences 
on AA.  Our family cohort contains statistically significant evidence for linkage at a new locus, on 
chromosome 2q36.1-q37.3 (LOD=4.17) and family-based tests of association implicate 47 
genes.  I then conducted a GWAS that expanded our initial cohort with the addition of 800 cases 
and obtained statistically significant evidence for a new locus at chromosome 16p13.13 
(p=4.6x10-7).  This region has been implicated in several other autoimmune diseases and 
contains several genes that are known to be involved with immune processes.  Taken together, 
these two studies demonstrate the presence of both rare and common variants are contributing 
to AA etiology and support emerging evidence that suggests the genetic architecture of 
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Alopecia areata is an autoimmune disease that targets the hair follicles in the skin, 
causing disfiguring hair loss marked histologically by an accumulation of immune-response cells 
around the affected hair follicles. AA is the most prevalent autoimmune disease in the United 
States.1,2 With a lifetime risk of 1.7%,3 it targets both men and women and affects people of all 
ages.4-6 AA affects more individuals than most other autoimmune diseases combined, yet 
despite its prevalence, there is an enormous unmet medical need7 that arises primarily from the 
dearth of information about its underlying pathogenesis and is compounded by a lack of studies 
on its natural history, which presents challenges in designing robust and efficient clinical trials. 
As an autoimmune disease, AA falls within a broader category of related disorders that 
are characterized by an aberrant targeted immune attack on cells, tissues or organs.  
Collectively autoimmune diseases carry a tremendous public health burden in the US and 
globally.8-11  In the US, 5-8% of the population is affected by an autoimmune disease,1 which 
results in annual direct health care costs of at least $100 billion,2 and additional economic 
burden due to lost earnings.  The chronic nature and unpredictable courses of these diseases 
impart severe physical and emotional burdens to the patients and their family members. 
There are more than 100 autoimmune diseases when classified on the basis of the 
target of the immune attack.2,11  Historically, treatment is based on organ involvement, and as a 
consequence, clinically distinct diseases have been studied as separate entities. However, 
emerging epidemiological12-14 and genetic evidence15-19 links sets of autoimmune diseases, 
revealing common mechanisms involving a discrete set of pathways that operate to dysregulate 
immune tolerance at different end organ sites.  Importantly, such emerging evidence places AA 
within the larger context of autoimmune diseases, such that novel discoveries in AA may hold 
broader implications for disease mechanisms and therapeutic responses in related diseases, 
such as type 1 diabetes and rheumatoid arthritis.  Additionally, since the target organ in AA (the 
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hair follicle) is readily observable and biopsied with minimal risk to the patient, AA is easier to 
study than other autoimmune diseases and more amenable to molecular investigations. 
Understanding the causes of AA will allow us to redress the enormous unmet medical 
need of patients and may provide insight about other autoimmune diseases.  Defining the 
causal structure of a disease begins by identifying a set of risk factors that exist within a given 
population.  For an individual in that population, disease occurs when a particular 
configuration of risk factors converges. Thus, an important component of the causal structure 
is the relationship among risk factors.  Identifying components of the causal structure will help 
to elucidate underlying pathogenesis and may reveal novel therapeutic interventions.  
Understanding how specific risk factors work together to promote disease can improve the 
management of AA, and may lead towards the development of effective and efficient prevention 
strategies. 
In the field of human genetics, the term ‘genetic architecture’ is commonly used to 
describe the set of alleles that influences a disease or trait.  It is defined as a catalogue of 
genes that contribute to trait variation and the characteristics of the alleles that reside at those 
loci, generally described in terms of their frequencies and effect sizes,20,21 and sometimes 
expanded to include the interactions among environmental and genetic components of the 
variation.22-25  Thus, its definition has come to capture not only the genomic structure that 
contributes to trait variation, but also all variables that influence the relationship between 
genetic and phenotypic variations.  This current notion is somewhat removed from its original 
use, which was more narrowly focused only on the composition and organization of genetic 
material within populations of model organisms.26  I have chosen to use the term ‘causal 
structure’ rather than genetic architecture, because it is more accurate and inclusive.  
Furthermore, it clarifies that environmental effects not only contribute to disease risk for 
common diseases, but also influence our estimates of genetic effects for risk alleles.  I reserve 
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the use of genetic architecture to describe the genomic content that is capable of influencing 
disease.  The intent of this review is describe what is known about causes of AA, both 
environmental and genetic; e.g. its causal structure. 
As for other chronic diseases, etiological clues about the underlying biology that 
promotes and drives AA may be found in clinical manifestations of disease, treatment 
responses, epidemiological descriptions of population patterns of disease, and investigations 
into environmental and genetic sources of risk.  However, of all of these avenues for research, 
gene mapping methods have proven to be most successful for gaining critical insight into 
disease mechanisms.  The development of efficient technologies for scanning the genome has 
greatly accelerated the acquisition of knowledge about genetic risk factors, and certainly for AA, 
the insight we have gained from genetic studies has transformed both what we know about 
disease pathogenesis and how we think about therapeutic interventions.  Genetic insight not 
only provides valuable information in and of itself, but also promises to resolve ambiguous or 
inconclusive evidence collected from more traditional epidemiological studies, and of particular 
importance, helps to clarify environmental influences on disease.  For example, when genetic 
evidence implicates a physiological process that is known to respond to particular environmental 
stimuli, evidence for an etiological role of environmental factors is strengthened.  Alternatively, 
genetic associations that have been established for environmental exposures can be used as 
instrumental variables in Mendelian randomization analyses.  The power to detect the effect of 
an environmental exposure on AA would be enhanced by using a genetic instrumental variable 
as a proxy for the environmental exposure.27 
In this review, I will provide a comprehensive description of what is either suggested or 
known about the causal structure of AA.  In identifying critical gaps in the literature, I hope to lay 
out a roadmap for advancement of our understanding of AA pathogenesis and treatment and to 
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demonstrate that the integration of genetic studies into causal investigations can significantly 
enhance the strength of our conclusions. 
 
Clinical Manifestations of Alopecia Areata 
The current paradigm for AA is that an individual inherits a set of risk alleles that confers 
some level of disease susceptibility, and over the life-course, environmental factors are 
encountered that increase the probability of developing AA.  At some point a particular 
configuration of risk alleles and environmental factors converges and disease onset occurs.  
Severity of disease and time course are highly variable within and across patients and are thus 
unpredictable (Figure 1a). 
Although the immune attack can occur anywhere on the body, it is typically first brought 
to medical attention when it occurs as one or several patches of non-scarring hair loss on the 
scalp or face (Figure 1d).  The initial regions of hair loss can appear either suddenly or more 
gradually over several days, and may regress as a result of spontaneous disease remission, or 
alternatively, the patches may grow (Figure 1c) and coalesce (Figure 1b), progressing to cover 
the entire scalp (alopecia totalis, AT) or eventually the entire body (alopecia universalis, AU). 
While some patients only ever experience a single episode of hair loss (transient AA- AAT), the 
disease can cycle through periods of spontaneous or therapeutically-induced remission, 
followed by relapse (patchy AA- AAP) (as in Figure 1a).  These AAP patients experience bouts 
of hair loss and regrowth at several points throughout their lifetime, although the number and 
duration of relapse and remission have never been rigorously examined within a well-powered 
epidemiological study. The prognosis for AT and AU patients is generally poor, although there 
are reports of transient or permanent partial or full regrowth of hair. Furthermore, hair regrowth 
remains possible for all patients, because the immune attack targets the lower portion of the hair 
follicle, sparing the stem cell compartment of the organ.  Nonetheless, it is difficult to estimate 
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how often complete remission occurs, as no study has prospectively followed patients.  
Currently, there are no biomarkers of prognosis and it is impossible to predict which patients will 
undergo spontaneous remission and which ones will experience relapsing/remitting hair loss or 
advancement to total hair loss. 
Interestingly, the phenomenon of ‘sudden whitening of the hair’ is ascribed to the acute 
onset of AA at times of profound grief, stress or fear.28 The immune attack preferentially targets 
pigmented hair follicles in the anagen (growth) phase of the hair cycle, and when regrowth 
occurs within lesions, the new hair is often white or colorless.  When the disease occurs in 
individuals with a pre-existing blend of dark and white hair, so-called “salt and pepper” hair, the 
pigmented hair is selectively shed while the white hair is spared.  In addition to the distinctive 
pattern of hair loss, short broken hairs known as ‘exclamation mark’ hairs may be found in 
active AA due to distal breakage of the hair shaft just above its exit from the scalp. Finally, AA is 
sometimes accompanied by nail changes in the form of pitting, brittleness and splitting. 
Some of these clinical features may offer clues about underlying molecular pathology of 
AA.  For example, the lack of pigment in hair follicles recovering from an autoimmune attack 
suggests that the synchronization of hair follicle stem cells and melanocyte stem cells, which 
occurs during normal hair cycling,29 may become disrupted or uncoupled during AA 
pathogenesis. 
In addition to providing etiological clues, distinctive and obvious clinical features allow for 
the simple, reliable diagnosis and robust phenotyping of patients.  Stringent criteria for the 
classification of AA are published and have been incorporated into guidelines for the 
assessment of AA severity.30,31  Thus, the ease of diagnosis and classification of AA confers a 
great advantage for epidemiologic studies of AA over other autoimmune diseases.  
Furthermore, as a dermatological disease, AA is particularly amenable to remote monitoring.  
When patients can transmit information and digital photographic images that document disease 
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status, it becomes possible to collect much more data than would be feasible with clinic visits, 
and greatly increases power, precision and sensitivity of both observational studies and 
randomized clinical trials (RCTs).32-42  Patient reported outcomes can enable more frequent 
reporting at significantly lower cost, and mitigate recall bias by reducing the interval between 
occurrence and report and allowing the reporting to be done in the patient’s natural 
environment.  Finally, unambiguous classification of disease activity and minimal risk in 
performing skin biopsies greatly facilitate molecular investigation of disease mechanisms 
involved in autoimmunity.  Thus, the study of AA is an ideal model for a multifaceted approach 
to studies of autoimmunity holds the potential to transform our understanding of the 
pathobiology and treatment of other autoimmune disorders that share disease mechanisms. 
 
Treatment 
An estimated 2.4 million dermatology office visits occur annually for the treatment of AA.5  
The repertoire of therapeutic options has not changed over the previous fifty years and remains 
limited.  While some dermatologists advocate observation for mild cases, first-line treatment 
typically includes intralesional corticosteroids and topical immunotherapy for adults.  Because of 
the extreme physical discomfort incurred from these therapies, first-line treatment for children is 
limited to topical corticosteroids and sometimes includes minoxidil.43 
The exact mechanisms by which corticosteroids and topical immunotherapy ameliorate 
disease for some patients remain elusive.  Corticosteroids have wide-ranging effects on a 
number of physiological responses, including the down-regulation of inflammatory and stress 
pathways.  Topical immunotherapy involves the application of chemicals such as diphencyprone 
(DPCP), dinitrochlorobenzene (DNCB), or squaric acid dibutyl ester (SADBE) to the scalp to 
produce an allergic rash which resembles poison oak or ivy.  It is thought that the induced 
allergic reaction shifts distributions of lymphocytes within the skin, and this either directly or 
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indirectly interferes with the autoimmune attack.44  Despite the widespread use of both 
treatments, there is no evidence base for their effectiveness.  No RCTs have been conducted 
for most of the drugs that are commonly used for AA treatment, and poor efficacy is 
demonstrated in the clinic. Approximately 20-30% of patients do not respond at all to standard 
treatments and complete recovery for 10–15 years is only achieved for one third of all cases.45  
Studies aimed at understanding the mechanisms that underlie therapeutic responses to these 
treatments could provide insight to the pathogenesis of disease and could assist with unraveling 
the genetic complexity of the disease.  For example, the failure to respond to a particular 
treatment could reflect a particular mechanistic defect shared among nonresponders and 
distinct from disease mechanisms operating in patients that do have a therapeutic response.46,47  
Genetic analyses that are stratified for this subset of patients could increase the power to detect 
genetic effects that are specific to the underlying dysregulated physiological process.  
There is a paucity of RCTs for the treatment of AA.  A recent Cochrane analysis 
identified 17 RCTs involving a total of 540 participants and concluded that there is no proven 
treatment.7  Each trial included from 6 to 85 participants and none of the assessed interventions 
showed significant treatment benefit in terms of hair growth when compared with placebo. Most 
trials have been poorly reported and/or are inadequately powered so that any important clinical 
benefits are inconclusive.  The weak evidence-base for AA treatments contributes to the 
enormous unmet medical need for the 5.3 million people who live with AA in the United States. 
Despite this precedent in RCTs for AA, the potential to evaluate the efficacy of 
treatments in AA is greatly enhanced by an unambiguous and easily observable treatment 
response.  Hair regrowth can be objectively measured and remotely monitored, decreasing 
measurement error and trial cost, while greatly enhancing the power to detect a treatment 
effect.  Currently, the main limitation in designing a well-powered RCT in AA is the lack of 
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information about the natural history of the disease, in particular, the rate of spontaneous 
remission. 
It is challenging to design a well-powered trial and complicated to interpret treatment 
responses when naturally occurring remission in AA has never been rigorously evaluated.  The 
few studies in the literature are not well-powered and arrive at highly variable rates, ranging 
from 20%-80%.3,6,48-51  All of these studies ascertained patients through treatment centers and it 
was sometimes unclear whether remission was spontaneous or treatment induced.  Finally, little 
attention was given to study design parameters that could contribute to the variability in 
estimates, such as length of observation and inclusion requirements.  Spontaneous remission 
estimates in the placebo arms of published AA RCTs suffer from many of the same limitations 
as the epidemiological studies of remission, and also indicate high variability, ranging from 0%-
80%.52  Poor characterization of spontaneous remission in AA presents a major challenge in 
translational research for AA.  Valid estimates would allow for more precise power estimates, 
insuring that sufficient numbers of controls without spontaneous remission would remain at the 
end of the trail.  High placebo response rates in small studies could obscure effect estimates 
and mask the benefits of a truly efficacious treatment.47  A natural history study of AA would be 
an invaluable addition to the literature and greatly facilitate translational research in AA. 
 
Epidemiological Studies in Alopecia Areata 
Descriptive Epidemiology 
AA is estimated to be among the most prevalent autoimmune diseases, affecting 5.3 
million people in the United States, and targeting both genders equally across all ethnic 
backgrounds.  The disease affects people of all ages, with a median age of onset estimated to 
be in the second or third decade of life.  It is the most common form of hair loss for children. 
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There is sparse literature on the epidemiology of AA.  Only two studies have been 
published that characterize the distribution of AA in the US and only one of these has been 
population based.3,53  The population-based study estimated the point prevalence of the 
disease. However, due to the episodic nature of AA, cumulative incidence better characterizes 
disease burden, as it estimates the probability of experiencing the disease over a lifetime.  
There has been one study of AA incidence the US3, as well as several smaller studies 
conducted in other countries.3,48,54-59 The main limitation of these studies is that patients were 
ascertained through treatment centers.  Such studies underestimate the cumulative incidence 
because they exclude people without access to healthcare, people with less severe disease, 
and people who are not motivated to seek treatment because of prior knowledge of the 
inefficacy and physical discomfort of treatments that are currently available for AA. 
The estimate of AA point prevalence in the US was obtained in the First National Health 
and Nutrition Examination study (NHANES-I).53  In a probability sample of the US population, 
20,794 people underwent a general dermatologic examination.  While these exams identified 37 
people with active AA, 11 cases were excluded from the estimate, as they were diagnosed in 
one center.  The prevalence was then determined to be 122 per 100,000, 0.1%-0.2% of the 
population.  Importantly, as noted by the study authors, this was likely to be an underestimate, 
primarily because the data collection method limited the number of dermatological diagnoses 
that could be recorded in the survey.  Additionally, the variance in the number of cases 
ascertained across centers calls into question the validity of their estimate; inter-observer 
reliability was shown to be problematic with several data sets collected through NHANES-I. 
The one incidence study that was conducted in the US utilized the medical records 
linkage system of the Rochester Epidemiology Project to obtain a population-based estimate. 
This study reviewed medical records over a 15 year period from 1975-1989 and identified 627 
patients with any diagnosis related to AA, of whom 292 were Olmsted Country residents who 
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had received an initial diagnosis of AA within the study period.  Incidence rates were determined 
by utilizing estimates of the total population of Olmsted County over the time period, assuming 
that the entire population was at risk. The overall age and gender-adjusted incidence was 
determined to be 20.2 per 100,000 person-years and the life-time cumulative incidence was 
estimated at 1.7%.  Although this study did not find differences in the racial distribution of cases, 
the demographics of Olmsted county was 96% Caucasian, and so there is uncertainty in this 
estimate.  Finally, the main limitation of the study is that it reflects only cases brought to medical 
attention and so is likely to underestimate the true cumulative incidence. 
Comorbidities 
The pathology of AA extends far beyond the physical aspects of hair loss, and the 
disease exerts a deeply disturbing impact on the psychological, emotional and social well-being 
of affected individuals.60-62  Importantly, clinical severity is poorly correlated with impaired quality 
of life, such that even in patients with minimal hair loss in AA, the loss carries significant 
emotional and psychological meaning that pertains not only to hair, but also to quality of life, the 
ability to function in society, self-esteem, and psychological disturbances as profound as 
suicide. A number of studies have demonstrated high comorbidity of psychiatric disorders, in 
particular generalized anxiety, depression and phobic states.63-74  Interestingly, a recent study 
that examined disease co-occurrences among a collection of 1.5 million patient records found 
statistically significant correlations between AA and a number of neuropsychological disorders, 
including migraines, depression, attention deficit, epilepsy, and bipolar disorder.14  While this the 
size of the study provides good power to detect associations, the effect of medical utilization 
patterns on detected associations was not adequately explored.  Furthermore, it remains 
unclear how neuropsychological comorbidities could relate to AA, for example developing as a 
consequence or being linked by shared dysregulated physiological processes.  Temporal 
ordering of the onset of disorders within patients or analysis of cosegregation of neurological 
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disorders within large AA families are two study designs that could help to distinguish such 
hypotheses.  To date, there are no such reports in the literature.  Nonetheless, 
recommendations for the management of AA include attention to the psychosocial well-being of 
the patient.75,76 
The public health burden imparted by AA thus encompasses not only people with active 
hair loss at a given point in time, but also people who suffer the psychological consequences of 
the disease, which may or may not correlate with actual hair loss.  Because of the relapsing 
nature of AA, the highly unpredictable course of the disease, and the lack of prognostic 
biomarkers, even people who have only ever experienced a single resolved episode of hair loss 
continue to live in fear that their insidious condition could progress to total and irreversible 
hairlessness.  Thus, the burden of disease for AA patients is heavily weighted with detrimental 
psychological ramifications that persist when hair loss is not evident. 
AA patients have an increased risk of comorbid autoimmune disease.77  Specific 
reported associations include AA with thyroid disease,68,78-82 celiac disease (CeD),83 rheumatoid 
arthritis (RA),14,68,78 vitiligo68,78-80,84,85 and type 1 diabetes (T1D).14,68,81,86 Interestingly, in addition 
to reports of increased prevalence of T1D among AA patients, there are two family history 
studies that report a decreased prevalence of T1D among AA probands, but an increased 
prevalence of T1D among siblings of AA probands.78,80  These studies surveyed a  large 
number of AA patients (800 and 500 respectively) with a questionnaire about comorbidities in 
themselves and family members. However, the two largest and most recent studies to examine 
the joint distribution of AA and T1D in patients both found significant associations. The Denmark 
Patient Registry study also looked at co-occurrence of autoimmune diseases within individuals 
and found that T1D was the second most frequent autoimmune disease among AA patients with 
at least one comorbidity.77 A study that explored pairwise disease correlations among a 
collection of 1.5 million patient records from Columbia University Medical Center found 
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statistically significant correlations between AA and T1D, RA, and Psoriasis.14  Even though this 
study may be vulnerable to bias arising from medical service utilization, its findings are 
consistent with recent GWAS in AA and other autoimmune diseases have identified a number of 
alleles that increase risk for sets of autoimmune disorders, providing corroborating evidence for 
shared disease mechanisms.87  Thus, discrepancies in the epidemiological literature could have 
arisen from the small sample sizes of the earlier studies, or limitations inherent to family history 
study designs.  Consistencies among some of the epidemiological studies and genetic studies 
suggest biological validity.  The rapid advancement in knowledge about the genetic architecture 
of autoimmune diseases and molecular studies that follow up on statistical associations will help 
to clarify mechanistic relationships among this class of diseases. 
 
Etiology 
Sources of risk for AA are both found within the genome and in the environment. The 
measurement of genetic risk factors has been greatly enhanced in recent years due to 
technological advances which make it cost effective to perform genome-wide analysis in large 
cohorts.  As a consequence, our knowledge of the genome’s influence on AA greatly exceeds 
our understanding of environmental risk. 
Environmental Risk Factors 
While the insight gained from genetic studies has transformed our understanding of AA 
pathogenesis, the first investigations into causes of AA focused on environmental causes.  
These studies were guided by findings in other autoimmune diseases, which had demonstrated 
associations with infectious and pharmaceutical agents, nutritional status, occupational 
exposures, sun exposure, smoking, and stress.88 The scope of investigation into environmental 
causes of AA is much smaller, with only a few studies focused on nutritional factors, viral 
infection and stress. 
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There have been limited studies of the influence of nutrients.  Two reports have found 
decreased serum levels of zinc in AA patients and one study demonstrated that zinc 
supplements shift the distribution of circulating lymphocytes in AA patients.89-91  A recent study 
found decreased levels of zinc and copper in the hair of AA patients relative to controls.92  Some 
physicians screen for iron or zinc deficiencies in AA patients.93 
Cytomegalovirus (CMV) is a common viral infection that has been associated with a 
number of autoimmune diseases including systemic lupus erythomatosis (SLE), type 1 diabetes 
(T1D) and inflammatory bowel disease (IBD).  CMV has been studied as a possible trigger for 
AA since it can infect the hair follicle matrix fibroblasts, and in mice, such infection leads to hair 
loss and expression of HLA-DR in thyroid epithelium.94 An initial investigation in humans found 
CMV in AA lesions by PCR,95 while a second study failed to find evidence for infection of viral 
members of the beta-herpes viridae family (CMV, EBV, HSV) in mRNA extracted from active 
lesions in patchy AA.96  Finally, a third study investigated evidence for prior CMV infection in the 
blood, and found no correlation between CMV and AA.94  These inconsistent findings may be 
attributed to small sample sizes, differences in experimental strategies across studies, and/or 
limitations inherent to study designs.  For example, the prevalence of CMV is highly variable 
among geographic regions, ethnic populations and socioeconomic groups, requiring that 
association studies be well-powered and provide some means to control for these potential 
confounders.  None of the published AA studies addressed these challenges. Despite the 
inconsistencies of these initial studies, it may be worthwhile to revisit the role of CMV in AA 
onset, given the validated finding of genetic associations of UL16 binding protein (ULBP) 
genes.87,97  This gene family was initially discovered because the proteins transcribed from 
these loci are able to bind to a protein expressed by CMV-infected cells.98  Thus, recent genetic 
evidence warrants reconsidering the possibility that CMV is capable of triggering AA onset.  
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Stress has been the most widely investigated potential environmental trigger to AA. The 
concept of stress has evolved since its original inception in 1950 and is in general recognized to 
be a broad construct encompassing a number of domains.99 The ambiguity in its use has 
created confusion in the literature and may account for some of the inconsistencies in findings 
related to its influence on human physiology and health, and the scope of this problem extends 
to studies in AA. It is generally acknowledged that stress arises as a response to a stressor, 
which may be an event, encountered or conceived, i.e., a stressor. In the autoimmune literature, 
stress is generally defined as an event or condition which is perceived as threatening to an 
individual’s well-being and which adversely affects thoughts, emotions, behavior, and/or 
physiological functioning.100 This definition includes both the stressors that are encountered, as 
well as the person’s response to it.  The vast majority of stress studies in AA examine the 
influence of stressors. 
Many AA patients report the coincidence of stressful life events (SLE) or emotional 
trauma with the onset or exacerbation of AA, but the few formal epidemiological studies have 
produced inconsistent results. Four published case series reported elevated occurrences of 
emotional trauma at onset (12%, 23%, 23% and 30% of patients),48,68,101,102 while one reported a 
decreased rate (6.7%).103  Similarly, one case control study found a significant difference in 
reporting stressful events between cases and controls, (66% v. 22%),104 while a second study 
found no difference between groups,105 and a third study found an increase in SLEs only among 
patients with recurrent disease.106 A more recent study in adolescents found an increase is 
stressful life events in AA patients relative to their healthy siblings and none relative to age 
matched epilepsy patients. Epilepsy patients were utilized as controls to account for possible 
secondary effects due to experiencing a chronic illness that is mechanistically unrelated to AA. 
107  The fact that epilepsy was very recently identified as a possible comorbid feature of AA14 
suggests that there could be shared physiological features to these two disorders and 
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complicates the interpretation of their finding that SLEs were similar between the AA and 
epilepsy groups. Limitations of this study include a small sample size, with each group 
containing fewer than 30 participants, and the retrospective reporting of life events by 
mothers.107  In conclusion, inconsistencies in the epidemiological literature with regard to the 
role of stress in the development of AA likely result from methodological limitations inherent to 
study designs, as small numbers of patients with retrospective reporting limit the power to detect 
effects. Importantly, there has never been a prospective epidemiological study that rigorously 
evaluated the relationship between stress encounters and AA. 
There is experimental evidence to support a role of stress in AA onset and/or 
exacerbation, which arises from stress response. Stressors that are encountered in the 
environment exert physiological responses through activation of nervous system pathways, 
including activation of the sympathetic nervous system which results in the release of 
epinephrine and norepinephrine; upregulation of hormones such as prolactin, growth hormone, 
and nerve growth factor; and activation of the hypothalamic-pituitary-adrenal (HPA) axis, which 
results in the release of glucocorticoids from the adrenal gland through the intermediate 
hormones corticotropin releasing hormone (CRH), produced in the hypothalamus, and 
adrenocorticotropic hormone (ACTH) produced by the pituitary gland. The literature contains a 
number of studies that point to a physiological interaction between the hair follicle and nervous 
system, some of which have examined this within the context of AA. Interestingly, studies of hair 
follicle organ culture indicate that human hair follicles synthesize cortisol and respond to CRH 
and ACTH,108-110 suggesting that the hair follicle has locally operating stress-response systems 
which may execute and coordinate peripheral stress responses. Furthermore, CRH significantly 
inhibits hair shaft production, induces apoptosis-driven hair follicle regression, and increases 
melanin production in the anagen hair bulb.109  Additionally, there are a number of studies 
demonstrating that cortisol levels in hair provide a biomarker for stress.111-120  A recent study in 
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an animal model for AA showed that disease is accompanied by altered stress responses in the 
animal.121 Finally, the ability of corticosteroids to reverse disease for some patients suggests 
that stress response pathways contribute to disease.  Cumulatively, these findings suggest that 
physiological interactions between the hair follicle and nervous system could contribute to the 
development of AA.122,123 
While epidemiological evidence for the influence of environmental risk factors is limited 
and sometimes contradictory, our enhanced understanding of how genes influence AA and 
related physiological traits promises to resolve discrepancies and clarify etiological roles. For 
example, experiments to test the hypothesis that a dysregulated stress-response contributes to 
AA risk are facilitated by the recent identification of inherited genetic variants that correlate with 
levels of stress hormones and their receptors in humans124,125 with the use Mendelian 
randomization methods.  In such experiments, SNPs are used as instrumental variables, or 
proxy measures of stress response.  Such variants account for individual differences in 
hormone levels and have fewer sources of measurement error and confounding relative to 
measurement of hormones in blood, saliva or urine.  Similarly, SNPs associated with stress 
reactivity can be used to help clarify the role of stress in disease onset or progression.126  
Genomics offers a lens through which we can better understand the impact of environmental 
influences on chronic diseases, and understanding how the genome and the environment 
interact can help to clarify both the genetic and environmental influences on disease risk. 
Genetic Risk Factors 
By far, the greatest insights into disease mechanisms that operate in AA have been 
obtained from genetic studies.  Initial evidence supporting a genetic basis for AA was obtained 
from multiple lines of research, including increased risk of disease in first degree relatives,4,127 
twin studies,94,128 and studies in animal models.129  The first genetic studies in AA were 
candidate-gene association studies, which investigated one or a few genes, chosen on the 
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basis of a prior hypothesis about its function, and typically based on the involvement of the gene 
in other autoimmune diseases.  Although these initial genetic studies tended to be limited in 
terms of sample size and by definition, biased by choices of candidate genes,  they nonetheless 
demonstrated associations with genes located within the human leukocyte antigen (HLA) 
complex: HLA-DQB1, HLA-DRB1, HLA-A, HLA-B, HLA-C, NOTCH4, MICA; as well as genes 
outside of the HLA: PTPN22, and AIRE (reviewed in 123). 
In contrast to candidate gene methods, genome-wide studies survey the entire genome 
for evidence of genetic contributions to disease without the a priori exclusion of any loci. Thus, 
these are particularly powerful methods for resolving disease mechanisms when much remains 
unknown about why or how the disease occurs.  Currently, genome-wide methods can be 
categorized into marker-based or sequencing-based methods.  Marker-based methods, such as 
linkage analysis and genome-wide association studies (GWAS), type genetic markers in 
families or cohorts of unrelated people to identify genomic regions with evidence for the 
presence of a proximal risk variant.  In contrast, genome-wide sequencing-based methods 
generate whole-genome or whole-exome data, obviating the assumption that a risk variant is in 
physical proximity to a genetic marker and allow all variants to be directly tested.  These 
methods have only recently become feasible, with the emergence of next generation 
sequencing technologies.130,131  The pivotal challenge with these studies is to design a filtering 
strategy to prioritize a small number of variants from the massive lists generated by the 
experiment (reviewed in 132,133). 
To date, genome-wide studies in AA have employed marker-based methods and include 
a genome-wide linkage analysis, and two GWAS in AA.87,134,135  Results from these studies 
confirm that: (1) there is a genetic basis to AA, (2) it is likely to be polygenic and (3) the genetic 
architecture is composed of both rare and common risk alleles.  This last conclusion can be 
inferred from the success of both linkage and GWAS in AA. 
19 
 
The two marker-based approaches are complementary to each other, targeting different 
sets of disease alleles, because different sets of assumptions underlie each method. 
Linkage methods identify genetic markers that cosegregate with disease in families and 
have the greatest power for detection of disease alleles that are rare in the population and have 
a strong correlation with disease expression (i.e., have large effect estimates in terms of ratio 
measures).  Power to detect linkage is also influenced by the causal structure of the disease 
and will be weakened by etiologic heterogeneity and interaction among exposures, including 
gene-gene interaction (GxG) or gene-environment interaction (GxE).  First, when there are 
many independent causes of a disease in the population, as is possible for common diseases, 
some families may have multiple independent causes of disease among family members, which 
would obscure co-segregation of any one locus with the disease.  Some affected family 
members will not have disease alleles at the locus being analyzed.  These independent causes 
could include either environmental exposures or genetic variants at different loci.  Secondly, 
genetic variants that influence disease only when acting in concert with other variants or 
environmental factors will display reduced penetrance within families, and some family 
members who have the disease allele under investigation will not have the disease.  Therefore, 
etiologic heterogeneity, as well as GxG and GxE, can generate inheritance patterns in 
pedigrees that are inconsistent with Mendel’s Laws of Inheritance, reducing power to detect 
linkage. Linkage evidence is generally robust to biases that can influence association studies, 
such as population stratification.  Genomic regions identified in linkage studies tend to be quite 
large, and so generally preclude the immediate identification of specific genes, but rather serve 
as a starting point for further positional mapping or sequencing of candidate genes within the 
linkage interval. 
GWAS compares allele frequencies for large numbers of genetic markers across groups 
of unrelated cases and controls and is best suited for detecting disease alleles that are common 
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in the population.  Power to detect linkage is reduced when there is a difference in allele 
frequency between the tagSNP and risk variant, even if the two alleles are in perfect linkage 
disequilibrium (LD=1).136 Because most commercial genotyping arrays exclusively or 
predominantly type common alleles (p>0.01), GWAS have the greatest power to detect 
common risk variants.  Furthermore, disease alleles that are common in the population are not 
likely to have strong phenotypic effects. GWAS tend to be more sensitive to confounding from 
ancestry, although there are analytic methods to test and correct for such biases.  Finally, 
associated regions tend to be much smaller than linkage regions, therefore this method has the 
potential identify individual genes or small clusters of functionally related genes.  In conclusion, 
linkage methods target rare disease alleles with strong effect estimates, while association 
methods target common disease alleles with weak effect estimates.  Importantly, emerging 
empirical evidence, which is augmented by theoretical arguments, suggests that the genetic 
architecture of common diseases contains niches for both rare and common alleles.137-149 
We conducted the first genome-wide linkage study in AA and identified several genomic 
regions that cosegregated in families.150  Microsatellite markers were used to genotype a cohort 
of 20 US and Israeli families. We demonstrated strong evidence for linkage on chromosome 
6q23.2 (Z=3.6) and suggestive evidence in several additional regions. Finemapping with 
microsatellite markers was then performed in an expanded cohort of 38 families for six regions.  
This analysis upheld evidence on chromosomes 6q23.3-q24.1 (Z=2.89) and 16q12.2 (Z=3.12), 
and strengthened evidence on chromosome 18p11.31-p11.21 (max multipoint LOD=3.93). This 
study provided robust evidence for a genetic component of AA, and because we identified at 
least four distinct regions in the genome, this study supports the notion that AA is a 
heterogeneous disease, with contributions to risk from several genes. 
Next, we completed the first GWAS for AA, comparing allele frequencies across nearly 
500,000 genetic markers, between a group of 1,054 unrelated AA patients and 3,278 unrelated 
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controls.87 Our study identified 139 genotyped and more than 175 imputed SNPs with 
statistically significant association to AA (p<5x10-7), which primarily cluster in eight regions of  
the genome, implicating genes of the immune system, as well as genes that are unique to the 
hair follicle: (1) 2q33.2 containing the CTLA4 gene; (2) 4q27 containing the IL2/IL21 locus; (3) 
6p21.32 containing the HLA class II region; (4) 6q25.1 which harbors the ULBP gene cluster; (5) 
9q31.1 containing syntaxin 17 (STX17); (6) 10p15.1 containing IL2RA; (7) 11q13 containing 
peroxiredoxin 5 (PRDX5); and (8) 12q13 containing Eos.  Additionally, an imputed SNP in 
18p11.21 exceeded our threshold for statistical significance and is located downstream of 
PTPN2.  Each of these regions has been confirmed through independent studies.87,97 The 
biological and therapeutic implications of these discoveries have been reviewed elsewhere.151 
Because associated SNPs cluster within regions, statistical analysis was performed to 
identify independent association signals within each region, such that we were able to choose 
16 SNPs that captured the majority of these associations.  Further analysis revealed that the 
distribution of these risk alleles was significantly different between cases and controls 
(p=1.1x10-107), such that on average, cases carried a greater genetic liability than controls.87 
Importantly, the genes that have been implicated by our first GWAS align AA within the 
broader context of autoimmunity and suggest new therapeutic avenues to explore.  For 
example, our GWAS revealed a number of risk loci in common with other forms of 
autoimmunity, such as type I diabetes, rheumatoid arthritis, and celiac disease, in particular, 
CTLA4, IL2/IL2RA, IL21 and genes critical to Treg maintenance.  A gene cluster that our GWAS 
implicated for the first time in any human disease, containing ULBP3/ULBP6, further unites this 
set of autoimmune diseases, as the receptor for these genes, NKG2D, has been implicated by 
genetic and/or immunological evidence for each disease.87,152,153  Finally, several of the genes 
implicated by our GWAS are targets for drugs that are in development or already available to 
treat other autoimmune diseases.  For example, Abatacept is a form of recombinant CTLA4-Ig 
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used in the treatment of rheumatoid arthritis and currently in clinical trials for treatment of 
several other autoimmune diseases.  Additionally, there is compelling preclinical data in AA 
demonstrating that CTLA4-Ig prevents disease onset in the mouse model for AA.154  The 
findings from this initial GWAS in AA provide initial clues that are likely to transform the 
development of treatments for this disease. 
 
Future Directions 
Genetic studies in humans have proven to be a robust method for gaining insight into the 
pathogenesis of disease, implicating unanticipated biological pathways across a broad spectrum 
of human disorders.  For AA, similar to other common diseases, our genetic studies suggest 
that there are risk alleles that are rare in the population and have a strong impact on disease,134 
as well as risk alleles that are common in the population and less strongly correlated with 
disease.87 The identification of new risk genes for AA will help to clarify the biological pathways 
that underlie disease and substantially enhance our understanding of the causal structure of this 
prevalent and psychologically devastating disease. 
Our linkage studies provide strong evidence for the existence of alleles cosegregating 
with disease, and also provide a critical starting point for methods that utilize next generation 
sequencing technologies to generate whole exome or whole genome sequence data.  The 
integration of whole exome/genome sequencing data with linkage evidence is emerging as a 
powerful new means to identify disease alleles, providing an economical and efficient way to 
catalogue all linkage-interval variants, and a robust strategy for prioritizing the vast number of 
novel variants revealed by whole exome/genome sequencing.155 The ongoing efforts of the 
National Alopecia Areata Registry have substantially expanded our family cohort since the 
completion of our first genome-wide linkage scan.  Additionally, while our first linkage study 
utilized microsatellite markers, commercial genotyping arrays of SNPs offer increased 
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information content, which increases the power to detect linkage.  Additionally, having both our 
family cohort and our GWAS cohort of unrelated individuals genotyped on a common platform 
will allow us to integrate the two data sets and better characterize the genetic architecture of 
AA.  Therefore, we have begun SNP linkage analysis in this expanded cohort of AA families. 
Importantly, emerging evidence from many different human disorders suggests that the 
genetic architecture of human disease comprises both rare and common disease alleles and 
thus argues for pursuit of both strategies when the goal is to comprehensively illuminate the 
genetic architecture of a disorder.  As an illustrative example, GWAS have been tremendously 
successfully for identifying loci that contribute to inflammatory bowel disease (IBD), with more 
than 100 loci demonstrating statistically significant association,156 and yet one gene with strong 
functional evidence for involvement has never exceeded the threshold for statistical significance 
in any GWAS or meta-analysis.  X-box binding protein 1 (XBP1) was initially identified in a 
molecular screen for proteins that bind to X-box elements, a regulator of human major 
histocompatibility complex (MHC) genes.  The selective knock out of this gene in mouse 
intestinal epithelium recapitulates many of the traits associated with IBD in humans, including 
spontaneous intestinal inflammations accompanied by lamina propria polymorphonuclear 
infiltrates, crypt abscesses and frank ulcerations, and an increase in intraepithelial lymphocyte 
numbers.  Following phenotypic characterization of this mouse model, a candidate gene 
association study was performed in a cohort of 1100 IBD cases and 1100 controls identified a 
SNP with evidence for association that exceeded a candidate gene threshold (p=1.6x10-5), but 
would have not exceeded a genome-wide significance level.157  Importantly, the region in the 
genome that harbors XBP1 was implicated with nominal evidence for linkage in three 
independent family-based studies,158-160 and sequencing of the gene found a three-fold increase 
of rare SNPs in IBD patients relative to controls and identified five rare nonsynonomous variants 
that were not seen in control patients.157  Cumulatively, this evidence suggests that pursuing 
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linkage studies in combination with deep sequencing will identify genes that contribute to 
common disease and escape detection with GWAS. 
The trajectory for gene discoveries by GWAS in other autoimmune diseases suggests 
that there are many more risk alleles that are common in the population and await discovery 
from GWAS in larger cohorts.  For example, the initial GWAS in Crohn’s disease, which each 
analyzed less than 1000 patients increased the number of causal loci to approximately ten.  
When meta-analyses began to be performed across increasingly larger data sets, the number of 
loci increased dramatically, such that today, there are 79 bona fide disease loci (Figure 2). This 
sequence has been remarkably similar across a number of autoimmune diseases.  Clearly, 
there is much more biological insight to be gained by continuing to conduct AA GWAS in 
independent samples and performing meta-analyses across studies. 
Finally, the epidemiological and genetic evidence for shared disease mechanisms 
provides rationale for performing GWAS meta-analyses across aligned autoimmune diseases.  
For instance, thousands of samples have already been genotyped for GWAS in T1D and CeD, 
and these data sit in public repositories.  A substantial number of loci implicated in our initial 
GWAS had previously been shown to increase risk of these diseases and suggests that a meta-
analysis across diseases could provide greater resolution to AA disease mechanisms.   
While pathophysiological insight is an important endpoint to genetic studies, there are 
additional promises that loom on the horizon.  One of the earliest promises of the human 
genome project was that information contained within the genome could be used for the 
predictive assessment of health outcomes, including disease risk, prognosis and therapeutic 
response.161-164  Furthermore, a more complete understanding of the genetic underpinnings of 
human disease could contribute to the development of innovative strategies to leverage 
genomics for the improvement of public health.165  Correctly interpreting genomic data hinges 
on our understanding of the causal structure of a disease, which encompasses both 
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identification of a set of risk factors that exist within a given population, and an understanding 
of how specific factors act in concert to promote disease. Once this is understood, it becomes 
tractable to interpret a person’s genomic information and to devise innovative and efficient 
strategies for integrating genomics into public health initiatives to reduce disease burden.  A 
comprehensive understanding of the genetic architecture of a disease provides a robust starting 
point for evaluating relationships among all risk factors, both genetic and environmental.  
Moving forward, the prospective large-scale collection of data for environmental risk factors will 
significantly enhance our understanding of the causal structure of AA, and set the stage for 
analytic work that integrates genetic and non-genetic contributors to health, allowing us to 






Figures and Legends 
 
Figure 1. Trajectory of Disease (a) Model for AA disease trajectory in a patient. A person is 
born harboring a particular configuration of inherited risk alleles within his or her genome that 
sets a probability of developing disease.  Over the life-course, that individual encounters risk 
factors in the environment that can alter the inborn liability for disease and at some point in time, 
a set of risk factors that is sufficient for disease converges on the individual and onset occurs.  
The severity of disease for AA is measured by surface area of hairloss, and is variable over 
time.  (b,c,d) Clinical manifestation of disease varies greatly.  (b) The most severe forms of 
disease involve loss of all scalp hair (alopecia totalis) or all scalp and body hair (alopecia 
universalis). (c) Patchy forms of AA involve relapsing/remitting hair loss.  Disease can 
spontaneously remit in some regions while new patches develop elsewhere, or alternatively, 
patches can increase in size and coalesce. (d) Milder forms of AA present as one or a few small 





Figure 2.  Trajectory for the discovery of Crohn’s disease risk genes.  The first gene implicated 
in Crohn’s disease was identified by linkage analysis in 2001.  The advent of genome-wide 
association studies greatly accelerated the acquisition of information about risk conferred by the 
genome, such that the first three GWAS increased the number of loci to ten.  As the sample 
sizes increased and meta-analyses were performed across independent studies, the number of 
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SNP linkage scan in Alopecia Areata families confirms susceptibility loci and 





With a lifetime risk of approximately 2%, Alopecia Areata (AA) [MIM 104000] is one of 
the most common human autoimmune diseases, affecting approximately 5.3 million individuals 
in the US, including males and females of all ages and across ethnic groups. We previously 
found evidence for rare disease variants that cosegregate with AA in families by conducting a 
genome-wide linkage screen with microsatellite (ms) markers in 20 US and Israeli families. We 
demonstrated strong evidence for linkage on chromosome 6q (Z=3.6) and suggestive evidence 
(Z>1.5) on 6p near HLA and on an additional five chromosomes (1, 2, 9, 10, and 16). Fine 
mapping was then performed in an expanded cohort of 38 families for six regions with 
microsatellite markers, which upheld linkage evidence on chromosomes 6q (Z=2.89) and 16 
(Z=3.12), and increased the strength of evidence on chromosome 18 (Z=3.93). Here we sought 
to increase linkage information by conducting a genome-wide linkage scan using 300,000 SNPs 
on a commercial genotyping array in 38 US families, consisting of 8 from the original scan, 18 
which were added for the fine mapping project, and 12 new families. Linkage analysis identified 
eight regions with LOD scores >1.5, six of which coincide with regions identified in our first 
linkage scan, most notably on chromosomes 2 (Z=4.17), and two regions on chromosome 6q 
(Z=2.31 and 2.18). Two novel regions were identified, on chromosomes 5 (Z=1.71) and 20 
(Z=1.52).  Association analyses in these families implicate 47 genes, some of which map to 
biological processes implicated by our genome-wide association study (GWAS) which had been 
conducted in a cohort of unrelated AA patients and controls. Our data are consistent with 
emerging evidence in other complex diseases that the genetic architecture for common 
diseases consists of both rare mutations and common risk variants. These findings significantly 




Alopecia areata (AA; OMIM 10400) is one of the most common autoimmune diseases.  It 
affects approximately 5.3 million people in the US and shows no predilection towards a 
particular gender.  Although it can first strike at any age, the median age of onset is in the 
second or third decade of life, and it is the most common form of hair loss for children.  Despite 
the prevalence of AA, there are no evidence based treatments, which creates an enormous 
unmet medical need.1 
With AA, the autoimmune attack is targeted at the hair follicle and is characterized 
clinically by disfiguring hair loss and histologically by an accumulation of infiltrating lymphocytes 
at the base of the hair follicle.  Because the stem cell compartment of the hair follicle is spared 
from the attack, hair regrowth remains possible.  The disease is typically first identified as one or 
a few small circumscribed regions of hair loss on the scalp, although it can occur anywhere on 
the body.  Prognosis is highly variable and unpredictable.  For some patients, remission occurs 
and hair regrows within lesions and is never lost again (transient AA; AAT).  For a subset of 
patients, the disease persists as a chronic relapsing remitting disorder, with regrowth occurring 
in some lesions, as new patches of hair loss arise (patchy alopecia areata; AAP).  Finally, in 
severe forms of AA, the regions of hair loss increase in size and coalesce, eventually causing 
complete hair loss of the scalp (alopecia totalis; AT) or in extreme cases, the scalp and body 
(alopecia universalis; AU). 
Initial evidence supporting a genetic basis for AA was obtained from multiple lines of 
research, including increased risk of disease in first degree relatives,2,3 increased disease 
concordance among monozygotic twins relative to dizygotic twins,4,5 studies in animal models,6 
and candidate gene studies that demonstrated associations between genes within the human 
leukocyte antigen complex (HLA): HLA-DQB1, HLA-DRB1, HLA-A, HLA-B, HLA-C, NOTCH4, 
MICA; as well as genes outside of the HLA: PTPN22, and AIRE (reviewed in 7).  The most 
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robust evidence for genetic contributions to AA was obtained from the first genome-wide linkage 
scan that we conducted by analyzing microsatellite markers in a small cohort of families.  This 
study demonstrated significant evidence (LOD>3.0) for cosegregation of AA with at least three 
independent loci and thus firmly established a genetic basis and further supports a 
heterogeneous architecture, as the evidence is inconsistent with a single-gene disorder.8  The 
sizes of the linkage intervals coupled with technological limitations precluded identification of 
particular genes in that study. 
More recently, we conducted a genome-wide association study (GWAS), which 
implicated nine regions of the genome that contained 139 typed SNPs and 174 imputed SNPs 
with statistically significant association to AA (p≤5x10-7).9  Some of these regions only contained 
one or a small set of functionally related genes, which highlights the importance of T cell 
activation and maintenance of regulatory T cells in disease pathogenesis, in particular CTLA4, 
IL2/IL21, and IL2RA.  This study also implicated ULBP3/ULBP6, PRDX5, STX17, Eos/ERBB3 
and PTPN2, in addition to the HLA. The biological and therapeutic implications of these findings 
are extensively reviewed elsewhere.10  Importantly, a number of identified genes had been 
previously shown to increase risk for other autoimmune diseases such as type 1 diabetes, 
rheumatoid arthritis and celiac disease, corroborating epidemiological evidence for an increased 
risk of these disorders among AA patients.11-17  While these findings have transformed our 
understanding of the underlying pathology and suggest new therapeutic interventions for AA, 
they pertain to only a subset of components to the genetic architecture of the disease: those 
amenable to detection by GWAS. 
Disease alleles that are amenable to detection by GWAS are common in the population 
and tend to have small effects on the distribution of disease. GWAS methods rely on an 
assumption that the typed or imputed markers, intended to serve as tagSNPs, will adequately 
capture the distribution of disease alleles within the study cohort.  Power to detect association is 
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therefore greatest when high linkage disequilibrium (LD) exists between disease alleles and 
tagSNPs, and when the disease alleles are at similar frequencies to the tagSNPs.18  Disease 
alleles that are rare in the population are less likely to demonstrate association via tagSNPs and 
are therefore not likely to be detected by this method. Such rare disease alleles are expected to 
have stronger phenotypic effects and thus to be more likely to demonstrate evidence for 
cosegregation with disease in families. So while our GWAS was successful in illuminating 
previously unsuspected and pathologically important biological pathways, the method is limited 
to detecting select components of the genetic architecture, i.e., disease alleles that are common 
in the population.  Emerging empirical evidence, which is augmented by theoretical arguments, 
suggests that the genetic architecture of chronic diseases contains niches for both rare and 
common alleles.19-32 Furthermore, while it is theoretically plausible that loci carrying common 
disease variants will also harbor rare disease variants, it is less likely that the reverse may be 
found. For example, if a locus is under strong purifying selection, disease alleles will be 
maintained at low frequencies.  Therefore, although it remains unclear how these classes of 
alleles together influence the distribution of disease within populations, identifying a full 
spectrum of disease alleles will allow for a more complete illumination of the genetic architecture 
of disease, and in turn drive a more comprehensive understanding of the underlying 
pathophysiology.33,34 
Our previous linkage analysis was small in scope, including only 20 families that were 
genotyped with 400 microsatellite markers.  A number of independent groups have 
demonstrated that dense commercial genotyping arrays of SNP markers increase information 
content relative to panels of microsatellite markers.35-39  Therefore, in this study, we expanded 
our linkage study by increasing the size of our cohort and utilizing a commercial genotyping 
array with 300,000 SNPs.  While previous GWAS in AA have illuminated risk loci that harbor 
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common disease variants, this current study will utilize a complementary approach that will 
focus on identifying rare variants with stronger phenotypic effects. 
 
Materials and Methods 
Ascertainment of Families 
Families were ascertained in the United States through the National Alopecia Areata 
Registry (NAAR) and recruited through a patient diagnosed with AA. NAAR inclusion criteria 
require that families have two or more affected relatives with confirmed diagnoses across at 
least two generations.  All family members willing to participate were recruited for the study.  All 
families that had completed enrollment at the time of genotyping were included in our study. 
 Clinical examiners diagnosed patients prior to the genetic studies in accordance with 
published criteria.40,41  Unaffected family members are given the option to self-report disease 
status and so were not necessarily screened by a dermatologist.  At the time of consultation, 
blood samples were drawn and written informed consent was obtained from all participants. The 
study was approved by the local IRB committees.  Overall, a total of 38 families were included in 
this study, consisting of 121 affected and 98 unaffected/unknown individuals (Figure 1).  Six of 
these families had been included in our previous linkage scan.8  These are all the families from 
that study that had been ascertained in the US.  On average, each family contained 
approximately 3 affected individuals.  Ancestry information was obtained from 26 of the families: 
18 self-report European descent and the remainder report race as African-American (n=2), 





Samples were genotyped on the Illumina HumanHap330V.2 genotyping Beadchip according to 





Data cleaning was performed by Wei V. Chen and Christopher I. Amos at University of 
Texas MD Anderson Cancer Center, Houston, Texas.  Mendelian inconsistencies were 
identified using a modified version of Pedcheck 43 that allows for the processing of more 
markers than the original version.  Monozygotic (MZ) twins were identified using an in-house 
Perl script.  Further relationship checking was performed using a version of Prest 44 that was 
modified to allow for more markers. 
 
Merlin Cluster Non-parametric Linkage Analysis 
 Non-parametric analysis was performed by MD Anderson collaborators on cleaned data 
using Merlin.45  Linkage analysis of markers in LD will increase the false positive rate.  Our data 
set included over 300,000 genotyped SNPs. Therefore, to mitigate type I error, clusters of tightly 
linked markers were identified first, and then non-parametric linkage analysis was performed on 
the clusters. Marker position information was obtained from NCBI, genome build 36. 
 
Tests of Association 
I performed several tests of association on SNPs, as described below. 
SNPs that were located within linkage regions were tested for evidence of allelic 
association by two methods.  First, I performed a pedigree-based association test (PBAT).46 
This test is an extension of the transmission disequilibrium test (TDT) that allows for analysis of 
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extended families, and identifies alleles that are overtransmitted to affected offspring.  It was run 
testing a null hypothesis of no association in the presence of linkage, under an assumption of an 
additive genetic model, as implemented in Helix Tree (Golden Helix).  Details about this 
methodology can be found at 
http://www.goldenhelix.com/SNP_Variation/Manual/pbat_overview.html#x119-72800023.1. 
Second, I evaluated evidence for joint and conditional linkage and LD with Pseudomarker47.  
This program uses a likelihood ratio test to perform five analyses: (1) test of linkage, (2) test of 
linkage in the presence of LD, (3) test of LD in the presence of linkage, (4) test of LD in the 
absence of linkage, and (5) joint test of linkage and LD.  SNPs were analyzed under recessive 
and dominant models.   
Finally, I ran PBAT on the full genome-wide data set, testing a null hypothesis of no 
association under the assumption of an additive genetic model. 
For all analyses, marker position information was obtained from NCBI, genome build 36. 






One pair of MZ twins was identified and subsequently confirmed; only one sib in the MZ 
twins was kept for subsequent analyses.  Analyses of Mendelian inconsistencies identified two 
families causing 59% and 36% of errors, respectively.  Further relationship checking was then 
performed and identified three sample switches in these two families.  Switching back the 
samples reduced the number of Mendelian inconsistencies, removing more than 90% of the 
errors originally detected in both families.  Genotypes involved in sporadic Mendelian 
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inconsistencies were recoded to missing to generate the clean data.  8567 SNPs of minor allele 
frequency (MAF) less than 0.05 were removed from all analyses. 
 
Non-parametric Linkage Analysis 
 Non-parametric linkage analysis was performed on 26,473 clusters of correlated SNPs 
using MERLIN.  Results are plotted for the whole genome in Figure 2.  A maximum LOD score 
of 4.17 is observed on chromosome 2q36.1-q37.3.  Two regions exceeded a LOD score of 2, 
both located on chromosome 6.  At 6p12.2-q15 LOD=2.31 and at 6q22.31-q24.1 LOD=2.18.  
Five additional regions exceed a LOD score threshold of 1.5: 5q33.1-q34, 8p23.1, 12q21.33-
q23.1, 9p24.3, and 20q13.12.  An additional 12 regions on 8 chromosomes exceeded a LOD 
score threshold of 1. These 20 regions are listed in Table 1 with region boundaries that are 
provided by the most distal marker comprising the clusters that exceed a LOD score of 1. 
 We also examined the results for individual families, in order to identify families that 
could be used in future whole-exome sequencing studies.  For the vast majority of families, 
linkage evidence did not permit prioritization of any reasonable number of regions in the 
genome.  For example, on average for each family the maximum LOD score occurred for more 
than 3800 SNP clusters (14% of the genome). However, in seven families, the maximum LOD 
score was observed for a small number of clusters, less than 360, implicating relatively few 
regions (5-50 per family).  This could allow a reasonable number of regions to be prioritized for 
follow-up sequencing (Figure 3).  Thus, across these seven families, there were a total of 107 
such regions, and 14 of these were shared by 2-4 of the families (Table 2).  Only five of these 
shared regions achieved a LOD score ≥1.0 in the cohort (1p13.2, 1q23.3, 6q22.31-q24.1, 
12q21.33-q23.1, 18p11.21).  The identification of these regions will allow us to prioritize variants 




Pedigree-based Association Tests 
We used PBAT to examine association, employing a null hypothesis no association in 
the presence of linkage.  All 20 regions that contained at least one cluster for which LOD>1.00 
were examined.  In total, these intervals contained 11,272 SNPs that form 863 clusters of highly 
correlated markers, as determined from our analysis of LD structure within our dataset in 
preparation for linkage analysis. Therefore we used 5.8x10-5 as our threshold for statistical 
significance (0.05/863). 
Of the 20 linkage intervals tested, eight contained at least one SNP with statistically 
significant association (p<4.4x10-6) (Figure 4).  In total 71 SNPs demonstrated association, 25 of 
which fell within intergenic regions, 6 of which fell within five pseudogenes, and 40 of which fell 
within transcripts, implicating four noncoding RNAs and 26 genes (Table 3).   
 
Pseudomarker 
Pseudomarker was used to test individual SNPs within several regions, including all 
regions for which LOD>1.5 in this study, three genomic regions that demonstrated 
cosegregation in our previous linkage study but not in this study (10p14-p11.23, 10q23.31-
q26.11, and 16p12.1-q13), and several additional regions that had weak to nominal evidence in 
this study.  In total, I analyzed 30,440 SNPs, which clustered into approximately 2600 groups of 
highly correlated SNPs across 15 genomic regions.  Because Pseudomarker runs five tests for 
each SNP, and I ran the program twice for each SNP, once under the assumption of a dominant 
mode of inheritance and once under the assumption of a recessive mode, I used a threshold for 
statistical significance of p≤1.9x10-6.  Only two of the evaluated SNPs exceeded this threshold 
for statistical significance: one at 2q36.1-q37.3, and one SNP in 6q22.31-q24.1 (Figure 4). 
Neither of these SNPs is located within a gene. 
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A comparison of the results across the five hypotheses evaluated with Pseudomarker 
supports NPL analysis and suggests allelic heterogeneity underlies these loci.  For the majority 
of SNPs tested, the strongest evidence was obtained for tests of linkage, while the tests for LD 
were consistently less significant (Figure 5).  In order to display results, for each SNP, I report 
only the smallest p-value over all tests (Table 4).  
 
Genome-wide Pedigree-based Association Test 
A genome-wide search for evidence of pedigree-based association (PBAT) was 
conducted by testing 300,277 informative SNPs against a null hypothesis of no association.  In 
estimating the LD structure for linkage analysis, we had determined that the genome-wide data 
set clustered into 26,473 independent sets of SNPs.  Therefore I set a threshold of statistical 
significance at 1.89x10-6 (0.05/26,473).  No evidence of association exceeded this threshold 
(min observed pvalue=2.78x10-6).  For the top 1% of scores (n=3003), p<0.008, 1232 SNPs fell 
within genes, including 53 genes that reside within loci that achieved at least nominal 
significance (p<0.001) in our GWAS (Table 5). 
 
Integration of Association Results 
The sample size and study design may contribute to a loss in power to detect 
association.  I hypothesize that variants with evidence for cosegregation with disease in families 
will have a strong impact on disease and are likely to have low frequencies in the population.  
The SNPs that are in this data set are common in the population, with frequencies greater than 
5%.  Therefore, it is possible that there are differences in allele frequencies between disease 
variants and genotyped SNPs, which is reducing power to detect association.18  Furthermore, 
linkage analysis identifies loci that cosegregate and is robust against allelic heterogeneity.  
Results from Pseudomarker suggest that there is allelic heterogeneity within the regions with 
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evidence for linkage, such that families are co-segregating different disease alleles within the 
linked loci.  The association tests conducted in this study are based on the assumption that a 
disease allele will be shared among a proportion of affected individuals within the cohort from 
different families, and the results from Psuedomarker do not support this hypothesis. Therefore, 
I next sought to identify variants and genes that showed weak but consistent evidence for 
association. 
For each of the three association analyses that I ran, I took the top 1% most significant 
associations and identified genes with evidence in more than one association statistic.  Of the 
3358 SNPs in the top 1% for at least one association analysis, 1470 are located within one of 
864 protein coding genes.  Thirty-nine genes are implicated by two or more of the association 
tests, 22 of which have at least one SNP that is significant for two different tests.  For the 
remaining 17 genes, different SNPs demonstrate association across test statistics.  In total, 
there are 111 SNPs that demonstrate association for these 39 genes, such that the majority of 





A cohort of 38 multiplex families, consisting of 121 affected and 98 unaffected/unknown 
individuals was genotyped with the Illumina 330v.2 genotyping chip.  Statistically significant 
evidence for linkage is observed at 2q36.1-q37.3 (LOD=4.17) and nominal evidence is observed 
at 6p12.2-q15 (LOD=2.31) and 6q22.31-q24.1 (LOD=2.18).  An additional 17 regions exceed a 
LOD score of 1 (Table 1).  The cumulative size of all linkage regions that we identified with 
LOD≥1 is 114,440,871 bp.  These regions contain 618 protein coding genes, whose transcripts 
account for 58,556,469 bp, or 51% of the regions.  It is estimated that the 20,000 genes in the 
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human genome span about 30Mb of DNA, or account for 1% of the genome.  Thus the linkage 
regions contain a much greater density of genes than expected, which suggests that variation in 
protein coding genes is driving evidence for linkage. 
Of the 618 protein coding genes within the linkage intervals, 14 are located within 
regions that achieved at least nominal significance (p≤0.001) in our previously published 
GWAS, 18 have been annotated as involved in an immune process in the Gene Ontology 
database, and 161 have been previously identified in a hair follicle gene expression experiment. 
 
Comparison with Microsatellite Scan 
 Of the 8 regions that exceeded a LOD score of 1.5 in this current study, six regions had 
at least suggestive evidence (LOD>1.0) in our initial microsatellite scan (2q36.1-q37.3, 6p12.2-
q15, 6q22.31-q24.1, 8p23.1, 9p24.3, and 12q21.33-q23.1) and two are completely novel 
(5q33.1-q34, and 20q13.12).  The three regions with the strongest evidence for linkage in this 
study, had different estimates in our previous study (Figure 7). In this study, the maximum LOD 
score is observed at 2q36.1-q37.3 (LOD=4.18).  In our previous linkage study, the maximimum 
LOD score observed in this region was 0.93.  Linkewise, region 6p12.1-q15 achieved a LOD 
score of 2.31 in this study, and 1.17 in our previous study.  Finally, region 6q22.31-q24.1 
demonstrated a LOD score of 2.18 in this study and 3.55 in our previous study. For three of the 
previously identified regions, SNP linkage evidence reduces the size of the linked interval from 
that implicated by the microsatellite data (6q22.31-q24.1, 9p24.3, 12q21.33-q23.1). 
Evidence of Association  
When I examined evidence for association with three analytic methods, only one 
provided statistically significant evidence.  Pedigree-based association tests (PBAT) within 
linkage intervals, employing a null hypothesis of no association in the presence of linkage, 
identified 71 SNPs for which p<5.8x10-5, 40 of which fell within a protein coding transcript, 
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implicating a total of 26 genes. When I next searched for nominal but consistent evidence for 
association by integrating the top 1% most significant SNPs for each of the three methods, 39 
genes were implicated by more than one association statistic, some of which were implicated by 
at least one statistically significant SNP with PBAT in linkage intervals.  Therefore, this study 
identifies a total of 47 genes that contain SNPs with evidence for association within our cohort of 
AA families (Table 7). 
Three of these genes are annotated as immune response genes in the Gene Ontology 
Database. Sec61 alpha form 2 isoform a (SEC61A2) is involved with antigen processing and 
presentation of peptide antigen via MHC class I (GO:0002474).  Integrin, alpha M (ITGAM) is 
involved with activated T cell proliferation (GO:0050798).  Pantetheinase (VNN1) is implicated in 
innate immune responses (GO:0045087), and T cell differentiation (GO:0033089), in addition to 
response to oxidative stress (GO:0006979), and anti-apoptosis (GO:0006916).  A third gene, 
methionine sulfoxide reductase A isoform a (MSRA), is also annotated as a gene that responds 
to oxidative stress. Finally, Abelson helper integration site 1 (AHI1), deleted in colorectal 
carcinoma (DCC), and collagen, type IV, alpha 3 (COL4A3) are all annotated as apoptosis 
genes (respectively GO:0043066, GO:0042981, and GO:0006917). 
It is interesting to note that all five of these pathways have been implicated by loci 
identified in our GWAS.   For example, MICA (p=1.2x10-7) and TAP2 (p=3.9x10-7) are both 
involved with MHC class I presentation of antigen; PRDX5 (p=4.1x10-7), MICB (1.7x10-5), and 
PARK2 (p=8.8x10-5) are oxidative stress response genes; lymphocyte differentiation genes 
include IL2RA (p=1.7x10-12), CTLA4 (3.6x10-13), and IL21 (p=4.27x10-8); innate immune 
response genes include CFB (p=3.2x10-8) and C2 (p=7.4x10-7); and anti-apoptosis genes 
include IL2 (p=2.7x10-6) and IER3 (p=2.8x10-7). 
Six of the genes implicated by association analyses are located with LD blocks that 
achieved nominal significance in our GWAS (p<0.001): AHI1, KN motif and ankyrin repeat 
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domains 1 (KANK1); eyes shut homolog (EYS); GLIS family zinc finger 3 (GLIS3), KIAA1217, 
and sarcoglycan, zeta (SGCZ).  GLIS3 is a particularly interesting candidate gene.  Rare 
mutations in this loci have been implicated in neonatal diabetes 48, while common variants 
confer risk to type 1 diabletes 49.  Our GWAS in AA identified several loci that increase risk for 
both type 1 diabetes and AA.9,10 
 
Comparison with GWAS  
We published the first GWAS in AA, identifying statistically significant association to nine 
regions in the genome, some of which contain only one or a few functionally related genes.  
This study confirmed association with the HLA region and additionally implicated IL2/IL21, 
CTLA4, ULBP3/ULBP6, IL2RA, STX17, PRDX5 and Eos/ERBB3. Each of these regions has 
since been confirmed through independent studies.9,50,51  Of these genes, only IL2RA came up 
as nominally significant in our genome-wide PBAT.  This is consistent with the notion that 
GWAS and linkage are complementary methods, targeting fundamentally different types of 
disease alleles.  GWAS alleles will be common in the population and have weak correlations 
with disease and so are not likely to demonstrate cosegregation in families.  Tests of 
association within families identify disease alleles that cosegregate with disease and are more 
strongly correlated with disease.  When I examined the distribution of GWAS risk alleles in our 
cohort of families, I found that the frequency of risk alleles was greater than what we found in a 
sample of unrelated unaffected people, but did not differ within families between affected and 
unaffected family members (Table 7).  This suggests that GWAS risk alleles are not sufficient 
for disease within these families and exemplifies the necessity of pursing both methods, GWAS 




In conclusion, by conducting this second genome-wide linkage study, we have found 
significant evidence for a disease locus that cosegregates with AA, located within a genomic 
region that only achieved suggestive evidence in our previous linkage scan, chromosome 
2q36.1-q37.3.  Association analyses within all regions of at least suggestive linkage evidence 
implicates 22 protein coding genes.  Furthermore, by identifying SNPs with nominal but 
consistent association evidence in at least two different analytic methods increases the total 
number of genes identified in this study to 47.  While there is very little overlap in the genes 
identified in this study and genes identified in our AA GWAS, there are extensive similarities in 
the biological processes implicated by each set of genes. Both studies identified genes involved 
with antigen presentation, lymphocyte differentiation, immune response, oxidative stress 
response, and apoptosis. This is consistent with emerging evidence that suggests both common 
and rare risk alleles underlie common diseases. It is interesting that while the the first three 
pathways predominate GWAS findings, association in families more strongly implicate the latter 
two pathways. This suggests that different biological pathways may be more compatible with 












Figure 1.  Pedigrees of Family-based Cohort.  Families with two or more affected individuals 
across three generations were ascertained in the United States through the National Alopecia 
Areata Registry.  Eight of these families had been included in our previously reported 




Figure 2.  Whole genome plot of nonparametric linkage analysis. A maximum LOD score of 
4.17 occurred on chromosome 2q36.1-q37.3.  Two regions exceeded a LOD score of 2, both 
located on chromosome 6.  A LOD score of 2.31 was observed at 6p12.2-q15, and a LOD score 
of 2.18 was observed at 6q22.31-q24.1.  Five additional regions exceed a LOD score threshold 
of 1.5: 5q33.1-q34, 8p23.1, 12q21.33-q23.1, 9p24.3, and 20q13.12.  An additional 12 regions on 





Figure 3.  Whole genome plot of nonparametric linkage analysis for seven families. For 
seven families, the maximum LOD score occurred at a small number of regions (5-50 per 
family), allowing regions to be prioritized for follow-up sequencing.  Across these seven families, 
there are a total of 107 such regions, 14 of which are shared by 2-4 of the families.  The y-axis 
display LOD scores and are not consistent across the seven plots.  The x-axis represents 





Figure 4.  Pedigree-based association tests identified significant associations within 
eight linkage intervals.  NPL results are plotted on the first Y-axis in red.  Association results 
are plotted on the second Y-axis in blue.  Y-axis values are consistent for all plots except for 












Figure 5.  Pseudomarker identified significant associations within three linkage intervals.  
NPL results are plotted on the first Y-axis in red.  Association results are plotted on the second 
Y-axis and color coded by the test with the minimum pvalue.  The scale for the LOD score axis 






Figure 6.  Pseudomarker Results across all regions tested. 30,440 SNPs, which clustered 
into approximately 2600 groups of highly correlated SNPs within 15 genomic regions were 
analyzed. Results are plotted as –log(pvalue), regions are delimited by red lines and labelled 





Figure 7.  A comparison of SNP linkage scan with microsatellite linkage scan.  Linkage 
analysis in this study identified three genomic regions on two different chromosomes with at 
least nominal evidence.  Results from both studies for these two chromosomes are presents.  
Results of NPL analysis from this study is shown in green, while results from the first linkage 
study conducted with microsatellites is plotted in black.  The Y-axis scales are different between 















Table 1. Nonparametric linkage results.  Regions with the top 20 highest LOD scores are 
shown. 
 
chr Cytoband snp start position start snp stop position stop region size max NPL LOD
1 1p36.1 rs10794531 26,694,245 rs9438620 26,716,136 21,891 1.08
1 1p13.2 rs155646 112,688,022 rs3128373 112,858,294 170,272 1.04
1 1q23.3 rs4657210 162,587,423 rs1704745 162,693,795 106,372 1.06
2 2q12.1 rs7571700 105,189,937 rs2679852 105,797,790 607,853 1.13
2 2q36.1-q37.3 rs2098533 225,182,419 rs12469535 243,044,147 17,861,728 4.17
4 4q34.3 rs1991983 182,454,723 rs6821430 182,499,174 44,451 1.31
5 5q13.1-q13.3 rs2047588 71,578,902 rs2114950 76,726,202 5,147,300 1.15
5 5q21.2 rs11955569 103,472,789 rs2034227 103,647,014 174,225 1.01
5 5q33.1-q34 rs4958486 151,058,334 rs10515827 160,754,957 9,696,623 1.71
6 6p12.2-q15 rs4715280 51,974,289 rs1504292 91,637,689 39,663,400 2.31
6 6q22.31-q24.1 rs9385268 123,041,722 rs7744152 139,663,885 16,622,163 2.18
8 8p23.1 rs7843504 8,439,068 rs7463440 12,652,105 4,213,037 1.9
9 9p24.3 rs10964134 204,201 rs755383 863,635 659,434 1.65
12 12q21.33-q23.1 rs2897852 90,768,440 rs11612901 96,221,318 5,452,878 1.71
15 15q22.2 rs11630244 60,021,637 rs7174483 60,123,836 102,199 1.02
17 17q25.3 rs1869932 77,318,565 rs2241886 78,113,832 795,267 1.13
18 18p11.21 rs1149360 13,540,713 rs3760534 13,874,975 334,262 1.09
18 18q21.2-q21.31 rs1105471 45,086,502 rs554192 55,784,763 10,698,261 1.27
20 20q13.11-q13.12 rs6065582 41,771,701 rs2179069 43,507,254 1,735,553 1.52




Table 2. Linkage evidence within families.  For each family, a list of regions with maximum 
LOD score was compiled.  Comparison across families identified a set of regions shared across 
families that achieved a LOD score greater than 1 for the entire cohort. 
 
Marker chr position MinP Gene Gene Type 
rs2262438 6 133,058,735 
3.9E-
09 CCNG1P1 pseudogene 
rs2745443 6 133,063,075 
4.2E-
09 CCNG1P1 pseudogene 
rs473728 18 53,348,005 
1.1E-
08     
rs4958676 5 153,132,470 
1.4E-
08 GRIA1 protein_coding 
rs1381119 5 153,138,879 
1.6E-
08 GRIA1 protein_coding 
rs11964693 6 68,425,331 
4.5E-
08     
rs985564 6 73,225,898 
4.8E-
08     





rs11249987 8 10,218,116 
1.0E-
07 MSRA protein_coding 





Chr Linkage Evidence >1Min of Region Start Max of Region Stop Family Count Family1 Family2 Family3 Family4
1 1p13.2 40.344 120.112 3 EDF M12 S1
1 1q23.3 144.184 178.478 2 EDF M12
2 140.385 222.478 4 EDF M12 S16 S1 
3 149.192 182.782 2 106 EDF
4 60.75 149.882 2 EDF M12
5 0.126 4.661 3 106 EDF M12
6 25.281 41.449 2 106 EDF
6 6q22.31-q24.1 106.549 141.653 3 130 EDF S16
6 145.188 156.341 3 107 130 EDF
7 4.443 30.475 3 106 107 EDF
7 149.164 158.812 2 106 EDF
10 72.394 75.425 2 S16 EDF
10 79.666 85.406 2 107 EDF
10 125.152 135.241 2 106 S16
11 62.773 111.852 2 106 EDF
12 12q21.33-q23.1 84.993 126.472 2 106 EDF
13 40.656 93.521 2 EDF M12
14 19.745 32.632 2 S16 EDF
14 41.511 55.661 2 EDF M12
14 94.976 106.285 2 107 130
18 18p11.21 7.873 48.008 4 106 130 EDF M12
20 5.491 15.991 2 130 EDF
20 49.624 62.375 2 106 EDF
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rs185634 6 72,293,749 
1.4E-
07     
rs10815567 9 723,049 
1.6E-
07 KANK1 protein_coding 
rs1534863 8 11,705,562 
1.6E-
07 FDFT1 protein_coding 
rs1000468 6 70,402,661 
1.7E-
07     
rs1293044 6 70,290,602 
1.8E-
07     
rs17742423 6 73,588,333 
2.0E-
07 KCNQ5 protein_coding 
rs9360664 6 74,098,145 
2.3E-
07 PAICSP3 pseudogene 
rs10871622 18 51,677,998 
4.2E-
07     
rs1736058 8 11,708,450 
4.3E-
07 FDFT1 protein_coding 
rs4430946 2 227,786,952 
4.7E-
07 COL4A3 protein_coding 
rs9342947 6 73,222,052 
5.5E-
07     
rs10737976 6 72,572,001 
5.7E-
07     
rs9342944 6 73,131,044 
5.9E-
07 RIMS1 protein_coding 
rs4307347 8 10,205,504 
8.1E-
07 MSRA protein_coding 
rs2670153 6 52,648,456 
1.0E-
06 TMEM14A protein_coding 
rs8094024 18 53,667,211 
1.5E-
06     
rs199635 6 72,282,724 
1.8E-
06     
rs2198229 18 50,520,401 
2.8E-
06     
rs10758863 9 732,642 
3.1E-
06 KANK1 protein_coding 
rs10499162 6 129,960,703 
3.1E-
06 ARHGAP18 protein_coding 
rs6601431 8 10,207,955 
3.5E-
06 MSRA protein_coding 
rs8192624 6 132,933,946 
5.1E-
06 TAAR6 protein_coding 
rs13200559 6 56,750,279 
5.6E-
06 DST protein_coding 
rs9216 5 159,708,625 
7.5E-
06 C1QTNF2 protein_coding 
rs9375796 6 131,382,691 
7.8E-
06 EPB41L2 protein_coding 
rs1037391 18 50,518,821 
7.9E-
06     
rs951251 6 131,432,905 
8.0E-
06     
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rs10491593 9 640,373 
8.2E-
06 KANK1 protein_coding 
rs12199650 6 52,232,503 
9.3E-
06 MCM3 protein_coding 
rs2178704 2 227,287,451 
1.3E-
05     
rs2294757 6 133,076,791 
1.4E-
05 VNN1 protein_coding 
rs1461241 5 153,285,631 
1.8E-
05     
rs1781011 6 52,230,899 
1.9E-
05     
rs9354868 6 63,043,165 
2.0E-
05 KHDRBS2 protein_coding 
rs4897336 6 130,123,754 
2.0E-
05 RP3-341I10.1 pseudogene 
rs12209342 6 65,936,970 
2.2E-
05 EYS protein_coding 
rs2493383 6 68,418,391 
2.4E-
05     
rs7746344 6 52,646,130 
2.8E-
05 TMEM14A protein_coding 
rs276550 6 137,443,470 
2.9E-
05     
rs9398976 6 131,446,361 
3.0E-
05     
rs9960795 18 51,983,082 
3.0E-
05 AC006305.1 protein_coding 





rs2219188 6 68,816,458 
3.3E-
05     
rs1328857 6 73,414,549 
3.3E-
05 KCNQ5-IT1 sense_intronic 





rs9342910 6 72,753,745 
3.5E-
05 RIMS1 protein_coding 
rs4707479 6 68,787,830 
3.6E-
05     
rs2300077 6 133,072,185 
3.7E-
05 VNN1 protein_coding 
rs4643531 2 227,993,717 
3.9E-
05     
rs6705042 2 228,088,692 
3.9E-
05 AGFG1 protein_coding 
rs10080737 6 53,997,540 
3.9E-
05 MLIP protein_coding 
rs6908735 6 70,953,236 
4.4E-
05 COL19A1 protein_coding 
rs4346276 18 53,668,370 
4.5E-
05     
rs276504 6 137,394,212 
4.6E-
05 IL20RA protein_coding 
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rs3806065 6 70,966,500 
4.7E-
05 COL19A1 protein_coding 










rs6570174 6 137,888,424 
5.3E-
05     
rs140616 5 155,743,532 
5.3E-
05 SGCD protein_coding 
rs9402168 6 130,108,429 
5.3E-
05 RP11-73O6.4 protein_coding 
rs2979269 8 8,938,550 
5.3E-
05 ERI1 protein_coding 





rs897405 6 68,867,259 
6.6E-
05     
rs824872 5 157,971,509 
6.9E-
05     





rs7704562 5 153,387,590 
6.9E-
05 FAM114A2 protein_coding 
rs1565247 18 44,223,758 
6.9E-
05     
rs10503019 18 53,605,375 
7.9E-
05 ATP8B1 protein_coding 
rs2816903 6 68,436,846 
8.1E-
05     
rs10503381 8 9,411,916 
8.2E-
05     
rs2270820 5 157,090,950 
9.1E-
05 THG1L protein_coding 
rs11877669 18 44,568,382 
9.1E-
05 CTIF protein_coding 
rs11750592 5 151,627,960 
9.8E-
05 CTB-12O2.1 lincRNA 
rs1898659 5 153,336,611 
1.0E-
04     
rs1011503 5 153,336,759 
1.0E-
04     
rs2106553 6 67,065,007 
1.1E-
04     
rs9360979 6 76,900,873 
1.1E-
04     
rs4246043 5 152,796,682 
1.2E-
04     





rs524207 6 52,194,855 
1.5E-
04     
rs2894593 2 226,898,561 
1.5E-
04     
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rs9321599 6 137,760,226 
1.5E-
04     
rs9398918 6 130,087,370 
1.5E-
04 RP11-73O6.4 protein_coding 
rs7231528 18 48,412,118 
1.5E-
04 DCC protein_coding 
rs1825651 6 76,983,174 
1.5E-
04     
rs2039523 6 52,174,886 
1.5E-
04     
rs332022 8 8,820,875 
1.6E-
04     










rs1221872 18 48,384,335 
1.8E-
04 DCC protein_coding 
rs1221874 18 48,385,108 
1.8E-
04 DCC protein_coding 
rs1221877 18 48,387,824 
1.8E-
04 DCC protein_coding 
rs1221884 18 48,389,344 
1.8E-
04 DCC protein_coding 
rs11154801 6 135,781,048 
1.8E-
04 AHI1 protein_coding 
rs7595911 2 104,621,738 
1.8E-
04     
rs6749383 2 104,626,334 
1.8E-
04     
rs2249751 6 72,963,918 
1.9E-
04 RIMS1 protein_coding 
rs6937168 6 85,187,128 
2.0E-
04 RP1-90L14.1 processed_transcript 
rs4608504 2 229,640,616 
2.0E-
04 PID1 protein_coding 
rs489806 2 239,764,393 
2.2E-
04 HDAC4 protein_coding 
rs477094 6 133,565,482 
2.2E-
04     
rs9494759 6 137,786,779 
2.2E-
04     
rs11877776 18 47,550,493 
2.3E-
04     
rs2119547 18 46,217,962 
2.4E-
04     
rs7761494 6 74,782,377 
2.4E-
04     
rs276585 6 137,418,306 
2.4E-
04     
rs10503002 18 51,260,200 
2.5E-
04 TCF4 protein_coding 













Table 3. Results of PBAT|Linkage.  Pedigree based association tests were performed across 
regions with evidence for linkage.  Significant results are displayed.  If the SNP falls within a 
transcript, it is annotated with a gene name and transcript type. 
 
Marker chr position MinP MinTest MinMOI Gene 
rs203691 6 137,909,141 
7.0E-
07 Linkage rec BTF3L4P3 
rs4073751 2 239,543,016 
7.1E-
07 Linkage|LD rec   
rs10203538 2 235,514,778 
3.0E-
06 Linkage|LD dom   
rs2975785 2 241,218,002 
4.0E-
06 Linkage|LD dom GPR35 
rs12694993 2 241,663,037 
4.0E-
06 Linkage dom SNED1 
rs11783751 8 13,474,949 
6.0E-
06 Linkage rec 
RP11-
145O15.3 
rs4940732 18 54,436,031 
7.0E-
06 Linkage dom ALPK2 
rs1535260 6 88,950,229 
8.0E-
06 Linkage rec   
rs10511454 9 3,733,938 
8.0E-
06 LD|Linkage dom   
rs11776120 8 6,877,045 
9.0E-
06 LD+Linkage rec DEFA11P 
rs1395608 18 11,008,926 
9.0E-
06 Linkage rec PIEZO2 
rs4573621 10 113,977,538 
1.0E-
05 LD|Linkage dom   
rs7447732 5 158,461,713 
1.1E-
05 Linkage|LD rec EBF1 
rs4591363 2 239,560,574 
1.3E-
05 Linkage|LD rec AC114788.1 
rs2474619 6 90,936,756 
1.5E-
05 Linkage dom BACH2 
rs4740731 9 3,737,376 
1.5E-
05 LD|Linkage dom   
rs4450678 20 41,152,010 
1.5E-
05 Linkage|LD dom PTPRT 
rs11693862 2 233,707,325 
1.7E-
05 Linkage dom INPP5D 
rs11752655 6 135,202,002 
1.8E-
05 Linkage rec   
rs1790994 18 2,903,431 
2.0E-
05 Linkage|LD rec LPIN2 
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rs3910253 5 162,993,830 
2.1E-
05 LD|Linkage dom   
rs31278 2 229,630,498 
2.5E-
05 Linkage|LD rec PID1 
rs10193614 2 240,589,309 
2.7E-
05 Linkage dom NDUFA10 
rs4672907 2 219,529,413 
2.8E-
05 LD+Linkage rec KRT8P30 
rs2720430 16 50,126,959 
2.8E-
05 LD|NoLinkage dom   
rs7597153 2 240,875,489 
2.9E-
05 Linkage|LD dom   
rs1437731 2 240,297,565 
3.0E-
05 Linkage dom   
rs7589895 2 240,873,613 
3.2E-
05 Linkage|LD dom   
rs10507058 12 94,622,878 
3.5E-
05 Linkage dom 
RP11-
410A13.3 
rs3088186 8 10,263,765 
3.6E-
05 Linkage|LD dom MSRA 
rs4747964 10 12,217,003 
3.8E-
05 Linkage|LD rec SEC61A2 
rs7239592 18 5,763,584 
3.8E-
05 Linkage|LD rec 
RP11-
945C19.1 
rs8083777 18 5,759,552 
4.1E-
05 Linkage|LD rec 
RP11-
945C19.1 
rs7368976 2 234,821,858 
4.1E-
05 Linkage dom   
rs10885330 10 114,062,134 
4.3E-
05 Linkage|LD dom GUCY2GP 
rs7760247 6 135,582,862 
4.4E-
05 Linkage rec MYB 
rs962189 6 135,251,875 
4.4E-
05 Linkage dom   
rs4446534 6 92,886,209 
4.7E-
05 Linkage dom U3 
rs4643485 2 239,336,345 
4.7E-
05 Linkage|LD dom   
rs9633625 10 21,406,784 
5.1E-
05 LD|Linkage rec NEBL 
rs203136 6 138,647,945 
5.4E-
05 Linkage rec KIAA1244 
rs7234567 18 3,410,806 
5.7E-
05 Linkage dom TGIF1 
rs9494139 6 135,456,486 
5.9E-
05 Linkage rec HBS1L 
rs1343484 6 78,291,084 
5.9E-
05 Linkage dom   
rs7595357 2 239,845,273 
5.9E-
05 Linkage dom HDAC4 
rs3791426 2 239,704,338 
6.0E-
05 Linkage dom HDAC4 
rs11154801 6 135,781,048 
6.1E-
05 Linkage rec AHI1 
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rs4628288 8 17,995,037 
6.1E-
05 LD|Linkage rec 
CTD-
2547L16.1 
rs10099571 8 8,322,712 
6.6E-
05 Linkage rec 
CTA-
398F10.1 
rs4890008 17 75,920,214 
6.7E-
05 Linkage|LD rec RNF213 
rs3791500 2 239,740,482 
6.8E-
05 Linkage dom HDAC4 
rs921281 2 225,562,364 
7.1E-
05 Linkage dom DOCK10 
rs9965626 18 5,757,540 
7.2E-
05 LD+Linkage rec 
RP11-
945C19.1 
rs4663712 2 237,873,814 
7.5E-
05 Linkage dom   
rs967411 8 15,080,072 
7.7E-
05 Linkage rec SGCZ 
rs893265 16 53,864,590 
7.8E-
05 LD|Linkage dom 
RP11-
26L20.3 
rs2757732 6 89,327,343 
7.9E-
05 Linkage|LD dom   
rs4942767 13 48,029,770 
8.0E-
05 Linkage|LD dom   
rs10084197 2 232,518,427 
8.1E-
05 Linkage rec 0 
rs7571643 2 240,132,491 
8.1E-
05 Linkage|LD dom   
rs2660278 18 10,999,337 
8.2E-
05 Linkage rec PIEZO2 
rs3849745 5 162,991,179 
8.2E-
05 Linkage|LD dom   
rs4128254 2 239,310,782 
8.3E-
05 Linkage|LD dom AC113618.2 
rs943265 10 114,037,385 
8.4E-
05 LD|Linkage dom TECTB 
rs10211191 2 236,503,077 
8.8E-
05 Linkage dom AGAP1 
rs2798509 6 78,267,482 
8.8E-
05 Linkage dom RPS6P7 
rs7594825 2 210,106,477 
9.1E-
05 Linkage rec MAP2 
rs12472274 2 238,760,161 
9.2E-
05 Linkage dom ILKAP 
rs7579382 2 238,880,147 
9.2E-
05 Linkage dom   
rs9494115 6 135,277,227 
9.9E-
05 Linkage rec ALDH8A1 
rs1984191 13 44,269,573 
1.0E-
04 Linkage dom LINC00330 
rs869385 20 55,972,383 
1.0E-
04 Linkage rec 
RP13-
379L11.2 
rs693405 18 8,728,849 
1.0E-
04 Linkage rec SOGA2 
rs12163992 5 148,889,270 
1.0E-
04 LD|Linkage dom CSNK1A1 
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rs3812813 12 94,451,893 
1.1E-
04 Linkage dom USP44 
rs1469375 2 235,614,926 
1.1E-
04 Linkage dom SH3BP4 
rs238135 18 3,438,979 
1.1E-
04 Linkage rec TGIF1 
rs9937837 16 31,206,440 
1.1E-
04 Linkage|LD rec ITGAM 
rs6923743 6 134,679,540 
1.1E-
04 Linkage|LD dom SGK1 
rs427056 5 162,782,337 
1.1E-
04 LD|Linkage dom 
RP11-
541P9.3 
rs3791399 2 239,690,698 
1.1E-
04 Linkage dom HDAC4 
rs3815291 2 241,681,213 
1.2E-
04 Linkage dom MTERFD2 
rs10189030 2 229,074,427 
1.2E-
04 LD+Linkage rec AC009410.1 
rs7086845 10 91,733,609 
1.2E-
04 LD|Linkage rec SNRPD2P1 
rs4543320 6 80,572,696 
1.2E-
04 Linkage dom 
RP1-
159G19.1 
rs7195219 16 27,184,557 
1.2E-
04 Linkage rec NSMCE1 
rs7193898 16 52,142,422 
1.2E-
04 Linkage|LD dom   
rs1040806 6 135,217,869 
1.2E-
04 Linkage|LD dom   
rs9376080 6 135,357,091 
1.2E-
04 Linkage rec HBS1L 
rs9493897 6 134,672,476 
1.2E-
04 Linkage|LD dom SGK1 
rs693845 5 163,000,520 
1.2E-
04 LD|Linkage dom   
rs10499200 6 138,813,645 
1.3E-
04 Linkage|LD rec NHSL1 
rs13439657 8 14,855,604 
1.3E-
04 Linkage rec SGCZ 
rs6914810 6 137,348,212 
1.3E-
04 Linkage rec 
RP11-
55K22.5 
rs4942780 13 48,214,742 
1.3E-
04 Linkage|LD dom   
rs2865387 20 55,500,243 
1.4E-
04 LD|NoLinkage rec CTCFL 
rs359980 2 219,537,450 
1.4E-
04 LD|Linkage rec AC097468.7 
rs3792069 2 231,380,816 
1.4E-
04 Linkage rec CAB39 
rs2109818 2 229,614,496 
1.4E-
04 LD+Linkage dom PID1 
rs17302436 12 93,217,382 
1.5E-
04 Linkage dom PLXNC1 
rs11756594 6 134,994,990 
1.5E-
04 Linkage|LD rec CTA-31J9.2 
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rs4797233 18 5,822,773 
1.5E-
04 Linkage rec   
rs1891487 6 137,343,274 
1.5E-
04 LD+Linkage dom 
RP11-
55K22.5 
rs1881191 2 236,272,663 
1.5E-
04 Linkage dom AGAP1 
rs4238922 16 25,694,112 
1.5E-
04 Linkage rec HS3ST4 
rs11081236 18 6,433,601 
1.5E-
04 LD|Linkage dom   
rs10205276 2 241,578,294 
1.5E-
04 Linkage dom AC104809.2 
rs4663910 2 239,152,081 
1.5E-
04 LD+Linkage dom   
rs10466280 10 12,231,939 
1.6E-
04 Linkage|LD rec SEC61A2 
rs2289529 17 75,636,840 
1.6E-
04 LD|NoLinkage dom CCDC40 
rs4497870 2 241,606,350 
1.6E-
04 Linkage dom AC005237.4 
rs47137 6 134,367,799 
1.6E-
04 Linkage dom SLC2A12 
rs13184089 5 148,912,761 
1.6E-
04 Linkage rec CSNK1A1 
rs4381835 20 56,052,150 
1.6E-
04 Linkage|LD dom   
rs12201016 6 90,205,994 
1.6E-
04 Linkage rec ANKRD6 
rs1037257 17 68,662,948 
1.6E-
04 Linkage dom   
rs683278 18 9,633,749 
1.6E-
04 Linkage dom   
rs2183147 6 138,826,610 
1.7E-
04 Linkage|LD rec NHSL1 
rs6918870 6 76,334,016 
1.7E-
04 Linkage dom   
rs646967 6 76,377,566 
1.7E-
04 Linkage dom 
RP11-
474L11.5 
rs11906 8 8,678,669 
1.7E-
04 Linkage rec 
RP11-
211C9.1 
rs3848999 8 13,219,316 
1.7E-
04 Linkage dom DLC1 
rs4390761 2 227,865,213 
1.7E-
04 Linkage dom AC097662.2 
rs4404876 8 10,440,498 
1.8E-
04 Linkage dom 
RP11-
981G7.4 
rs7600637 2 237,538,697 
1.8E-
04 Linkage|LD rec   
rs12526072 6 135,345,049 
1.8E-
04 Linkage rec HBS1L 
rs925100 18 9,347,786 
1.8E-
04 Linkage|LD rec TWSG1 
rs8083237 18 11,586,076 
1.8E-
04 LD+Linkage dom   
73 
 
rs7350066 8 10,898,795 
1.8E-
04 Linkage|LD dom XKR6 
rs969997 20 55,069,845 
1.8E-
04 Linkage dom   
rs3798461 6 76,473,375 
1.8E-
04 Linkage dom SENP6 
rs7008575 8 13,732,274 
1.9E-
04 Linkage rec   
rs209348 5 161,441,306 
1.9E-
04 LD|Linkage dom GABRG2 
rs4889940 17 75,553,402 
1.9E-
04 Linkage dom TBC1D16 
rs6723140 2 219,482,944 
2.0E-
04 LD+Linkage rec AC073128.10 
rs9321616 6 137,882,761 
2.0E-
04 Linkage dom   
rs607127 18 58,737,929 
2.0E-
04 Linkage dom PHLPP1 
rs6437268 2 240,649,535 
2.0E-
04 Linkage|LD dom   
rs12230722 12 94,480,909 
2.0E-
04 Linkage dom   
rs1227005 2 229,830,629 
2.1E-
04 Linkage|LD dom PID1 
rs6030998 20 41,692,374 
2.1E-
04 Linkage dom IFT52 
rs4546368 5 148,519,293 
2.1E-
04 Linkage rec ABLIM3 
rs10974470 9 4,318,940 
2.1E-
04 Linkage rec GLIS3 
rs3888260 8 14,056,650 
2.1E-
04 Linkage rec SGCZ 
rs4241236 2 240,405,549 
2.1E-
04 Linkage dom   
rs10509976 10 115,170,888 
2.1E-
04 LD|Linkage dom   
rs10803663 2 234,382,408 
2.2E-
04 Linkage dom HEATR7B1 
rs6538505 12 93,453,691 
2.2E-
04 Linkage rec   
rs6476878 9 4,553,316 
2.2E-
04 LD|Linkage dom SLC1A1 
rs7074995 10 100,965,619 
2.2E-
04 Linkage rec HPSE2 
rs12455606 18 2,511,602 
2.2E-
04 Linkage rec   
rs4800960 18 52,914,826 
2.3E-
04 Linkage dom   
rs1371552 2 224,074,704 
2.3E-
04 LD+Linkage dom AC013448.2 
rs7074881 10 21,409,713 
2.3E-
04 LD|Linkage rec NEBL 
rs1529370 13 48,376,029 
2.3E-
04 Linkage dom   
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rs4271760 2 227,875,788 
2.3E-
04 Linkage dom AC097662.2 
rs2963998 5 153,157,246 
2.3E-
04 Linkage dom GRIA1 
rs3795877 2 224,574,421 
2.3E-
04 Linkage dom SERPINE2 
rs9494155 6 135,510,584 
2.3E-
04 Linkage dom   
rs10944237 6 87,282,208 
2.4E-
04 Linkage|LD dom   
rs880769 5 149,135,070 
2.4E-
04 Linkage rec PPARGC1B 
rs1014174 2 229,660,208 
2.4E-
04 LD|NoLinkage rec PID1 
rs10883766 10 104,454,753 
2.4E-
04 Linkage rec ARL3 
rs7558942 2 242,157,685 
2.4E-
04 Linkage dom BOK 
rs8082554 17 75,654,462 
2.5E-
04 LD|Linkage rec CCDC40 
rs1009283 2 240,842,754 
2.5E-
04 Linkage dom AC124861.1 
rs1427167 13 48,357,698 
2.5E-
04 Linkage dom   
rs353237 5 148,812,043 
2.5E-
04 Linkage dom   
rs4310018 5 152,266,397 
2.5E-
04 Linkage rec AC091969.1 
rs1528628 8 13,157,347 
2.5E-
04 Linkage rec DLC1 
rs7830329 8 12,879,139 
2.5E-
04 Linkage dom KIAA1456 
rs27788 16 47,921,013 
2.5E-
04 Linkage|LD rec   
rs10039868 5 148,849,420 
2.5E-
04 Linkage dom CSNK1A1 
rs2027704 18 52,856,704 
2.5E-
04 Linkage rec   
rs4463219 5 152,268,750 
2.6E-
04 Linkage rec AC091969.1 
rs10859888 12 94,412,553 
2.6E-
04 LD|Linkage dom METAP2 
rs4831486 8 13,766,365 
2.6E-
04 Linkage dom   
rs578026 18 587,751 
2.6E-
04 Linkage|LD rec CLUL1 
rs11250154 8 11,534,095 
2.6E-
04 Linkage rec   
rs2078155 10 21,411,538 
2.6E-
04 LD|Linkage rec NEBL 
rs6718480 2 233,587,310 
2.6E-
04 LD+Linkage dom AC106876.2 
rs2964027 5 153,221,840 
2.6E-
04 Linkage dom   
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rs4478599 8 6,389,774 
2.7E-
04 LD|Linkage dom ANGPT2 
rs4149549 2 240,579,939 
2.7E-
04 Linkage dom NDUFA10 
rs3802554 10 114,455,760 
2.7E-
04 Linkage rec 
RP11-
25C19.1 
rs11787063 8 9,483,710 
2.8E-
04 Linkage rec TNKS 
rs13163929 5 148,882,531 
2.8E-
04 LD|Linkage dom CSNK1A1 
rs7590833 2 239,948,271 
2.8E-
04 Linkage dom HDAC4 
rs11691754 2 236,004,806 
2.8E-
04 Linkage dom   
rs11776235 8 8,987,303 
2.8E-
04 Linkage|LD rec ERI1 
rs2032165 18 8,978,701 
2.8E-
04 LD|NoLinkage rec   
rs2324934 6 87,293,586 
2.8E-
04 Linkage|LD dom   
rs334384 18 7,127,068 
2.9E-
04 Linkage|LD rec   
rs2425483 20 40,451,346 
2.9E-
04 Linkage dom PTPRT 
rs7185824 16 51,604,183 
2.9E-
04 Linkage rec 
RP11-
467J12.3 
rs6719451 2 238,001,541 
2.9E-
04 Linkage rec AC112721.2 
rs6506440 18 6,771,016 
2.9E-
04 Linkage rec ARHGAP28 
rs10490035 2 229,593,322 
3.0E-
04 LD|Linkage rec PID1 
rs2341697 2 238,785,391 
3.0E-
04 Linkage dom   
rs1922020 2 227,688,019 
3.0E-
04 Linkage rec COL4A4 
rs2504377 6 139,403,630 
3.0E-
04 Linkage rec ABRACL 
rs6501243 17 74,256,150 
3.1E-
04 LD|Linkage dom CYTH1 
rs10799 2 219,793,182 
3.1E-
04 Linkage dom ABCB6 
rs7232823 18 54,106,201 
3.1E-
04 LD+Linkage dom NEDD4L 
rs2181096 6 136,854,008 
3.1E-
04 Linkage dom MAP7 
rs4742608 9 959,044 
3.2E-
04 Linkage|LD rec DMRT1 
rs6752442 2 236,738,515 
3.2E-
04 Linkage dom GBX2 
rs9450463 6 87,243,160 
3.2E-
04 Linkage dom AL391417.1 
rs1036853 6 90,556,223 
3.2E-
04 Linkage rec MDN1 
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rs1402331 8 13,834,445 
3.3E-
04 Linkage|LD rec   
rs7445323 5 153,116,978 
3.3E-
04 Linkage dom GRIA1 
rs7565690 2 224,105,705 
3.3E-
04 LD+Linkage dom   
rs10484885 6 90,451,737 
3.3E-
04 Linkage rec MDN1 
rs1414684 10 24,676,562 
3.3E-
04 LD|Linkage rec KIAA1217 
rs7592582 2 235,110,992 
3.3E-
04 Linkage dom   
rs7588391 2 235,665,894 
3.3E-
04 Linkage dom AC114814.4 
rs4273649 5 153,100,241 
3.4E-
04 Linkage dom GRIA1 
rs6889794 5 153,103,648 
3.4E-
04 Linkage dom GRIA1 
rs8180663 6 138,068,047 
3.4E-
04 Linkage dom 
RP11-
95M15.2 
rs10105588 8 11,291,289 
3.4E-
04 Linkage rec C8orf12 
rs6937832 6 138,849,270 
3.4E-
04 Linkage|LD dom NHSL1 
rs11675161 2 227,686,723 
3.5E-
04 Linkage rec COL4A4 
rs10498886 6 73,678,955 
3.5E-
04 Linkage dom KCNQ5 
rs4797245 18 6,487,116 
3.5E-
04 Linkage|LD dom   
rs3820809 2 238,309,774 
3.5E-
04 Linkage dom LRRFIP1 
rs11662751 18 6,078,451 
3.5E-
04 LD|Linkage rec L3MBTL4 
rs4377285 2 236,726,693 
3.5E-
04 Linkage dom Y_RNA 
rs958358 8 13,570,617 
3.5E-
04 LD+Linkage rec   
rs7573905 2 213,799,751 
3.6E-
04 LD|NoLinkage rec   
rs1918674 18 10,719,880 
3.6E-
04 Linkage|LD dom PIEZO2 
rs12386051 17 68,922,486 
3.6E-
04 LD+Linkage rec SDK2 
rs4256890 10 26,068,819 
3.6E-
04 LD|Linkage rec   
rs1020694 18 59,415,278 
3.6E-
04 Linkage|LD rec SERPINB13 
rs10190128 2 235,952,005 
3.6E-
04 Linkage|LD dom 0 
rs7586477 2 235,303,819 
3.7E-
04 Linkage rec   
rs2059125 5 166,131,339 
3.7E-
04 Linkage rec   
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rs11203996 8 12,878,691 
3.7E-
04 Linkage dom KIAA1456 
rs2043358 8 16,476,834 
3.7E-
04 Linkage|LD rec   
rs975137 20 53,673,356 
3.7E-
04 Linkage dom   
rs2542145 18 12,762,318 
3.7E-
04 Linkage|LD rec 
RP11-
973H7.1 
rs4851975 2 240,008,450 
3.8E-
04 Linkage dom   
rs7604147 2 231,306,107 
3.8E-
04 Linkage dom CAB39 
rs353222 5 148,842,039 
3.8E-
04 Linkage dom   
rs666336 8 16,758,689 
3.8E-
04 Linkage rec 
RP11-
13N12.1 
rs2910288 5 160,747,917 
3.8E-
04 Linkage rec GABRB2 
rs2887401 2 240,685,626 
3.8E-
04 LD+Linkage dom   
rs3792074 2 231,374,190 
3.9E-
04 Linkage dom CAB39 
rs9960998 18 13,292,602 
3.9E-
04 Linkage dom C18orf1 
rs2902991 20 55,500,962 
3.9E-
04 LD|NoLinkage rec CTCFL 
rs9376314 6 138,376,730 
4.0E-
04 Linkage|LD rec   
rs1833710 5 147,947,939 
4.0E-
04 LD|Linkage dom HTR4 
rs1495922 2 240,865,032 
4.0E-
04 Linkage dom   
rs439115 20 41,704,335 
4.0E-
04 Linkage dom IFT52 
rs3748085 6 90,372,508 
4.1E-
04 Linkage rec ANKRD6 
rs861136 10 13,358,066 
4.1E-
04 LD|Linkage rec PHYH 
rs250973 2 234,647,740 
4.1E-
04 Linkage dom SPP2 
rs6454046 6 78,920,318 
4.1E-
04 LD+Linkage rec   
rs11616524 13 50,446,356 
4.1E-
04 LD|Linkage rec RNASEH2B 
rs12958345 18 5,756,006 
4.2E-
04 LD+Linkage rec 
RP11-
945C19.1 
rs10183172 2 241,643,687 
4.2E-
04 Linkage dom AC005237.4 
rs3900638 2 234,985,938 
4.2E-
04 Linkage|LD dom   
rs753943 5 154,552,621 
4.2E-
04 LD|Linkage dom   
rs1026580 10 14,021,168 
4.2E-
04 LD|Linkage dom FRMD4A 
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rs13254942 8 10,295,088 
4.3E-
04 Linkage|LD dom MSRA 
rs964818 2 226,840,024 
4.3E-
04 LD|Linkage rec   
rs6570053 6 136,258,992 
4.3E-
04 LD+Linkage dom PDE7B 
rs1062748 2 241,677,414 
4.3E-
04 Linkage dom MTERFD2 
rs10209413 2 234,884,275 
4.3E-
04 Linkage dom   
rs6936034 6 135,013,187 
4.3E-
04 Linkage|LD rec 
RP11-
557H15.4 
rs6436860 2 229,932,713 
4.3E-
04 Linkage|LD dom DNER 
rs9294143 6 80,167,823 
4.3E-
04 Linkage dom 
RP1-
232L24.4 
rs4973189 2 229,917,200 
4.3E-
04 Linkage|LD dom   
rs918149 8 5,113,756 
4.4E-
04 Linkage|LD dom   
rs867294 2 234,937,428 
4.4E-
04 Linkage dom   
rs11968144 6 88,875,684 
4.4E-
04 Linkage|LD dom   
rs2144218 6 134,912,743 
4.4E-
04 Linkage|LD dom 
RP11-
557H15.4 
rs2102795 2 235,965,246 
4.4E-
04 Linkage|LD dom   
rs7197521 16 47,031,763 
4.4E-
04 LD|Linkage rec SIAH1 
rs7235478 18 9,447,066 
4.4E-
04 Linkage|LD rec   
rs13282358 8 13,587,566 
4.5E-
04 Linkage|LD dom   
rs761011 20 40,749,905 
4.5E-
04 Linkage|LD dom 
RP1-
232N11.2 
rs12959212 18 60,327,866 
4.5E-
04 LD|Linkage dom   
rs10193128 2 233,695,966 
4.5E-
04 Linkage dom INPP5D 
rs6935503 6 85,291,123 
4.6E-
04 Linkage rec RP1-90L14.1 
rs6707071 2 233,526,575 
4.6E-
04 Linkage dom NGEF 
rs203138 6 138,640,978 
4.7E-
04 Linkage rec KIAA1244 
rs1174741 10 106,748,224 
4.7E-
04 Linkage|LD rec SORCS3 
rs205355 16 28,012,030 
4.7E-
04 Linkage|LD dom XPO6 
rs3799386 6 136,491,840 
4.8E-
04 Linkage|LD rec 
RP13-
143G15.4 
rs4921515 5 159,024,995 
4.8E-
04 Linkage rec   
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rs6903961 6 140,195,104 
4.8E-
04 Linkage|LD rec   
rs8084667 18 6,549,076 
4.9E-
04 LD|Linkage dom   
rs10515629 5 148,875,068 
4.9E-
04 LD|NoLinkage dom CSNK1A1 
rs903748 2 240,817,894 
4.9E-
04 Linkage|LD dom AC124861.1 
rs1692821 8 11,737,397 
4.9E-
04 Linkage rec FDFT1 
rs7585293 2 235,433,921 
4.9E-
04 Linkage|LD dom AC010148.1 
rs9342002 6 85,591,301 
4.9E-
04 Linkage|LD dom   
rs754111 5 159,654,250 
5.0E-
04 Linkage dom CCNJL 
rs797566 6 136,657,205 
5.0E-
04 Linkage dom BCLAF1 
rs4785201 16 48,646,693 
5.0E-
04 Linkage|LD dom 
RP11-
429P3.3 
rs3765259 6 137,031,976 
5.0E-
04 LD+Linkage dom MAP3K5 
rs2492303 6 134,388,701 
5.1E-
04 Linkage dom SLC2A12 
rs495005 18 58,748,488 
5.1E-
04 Linkage|LD dom PHLPP1 
rs3751812 16 52,375,961 
5.1E-
04 LD|NoLinkage rec FTO 
 
Table 4. Psuedomarker results.  Top 1% most significant results across all five tests 
performed by pseudomarker are organized by significance and annotated by gene name if the 
SNP falls within a gene.  The test and mode of inheritance for the test is also indicated. 
 
SNP Chr Position pvalue Gene GWAS min p for Gene 
rs1247096 10 30,078,618 2.8E-06     
rs2761743 9 9,806,955 5.4E-06 PTPRD   
rs1434478 9 26,739,094 6.0E-06 RP11-18A15.1   
rs923076 11 129,723,793 7.2E-06 RP11-121M22.1   
rs10738342 9 13,748,505 1.3E-05     
rs1322133 9 10,195,835 1.4E-05 PTPRD 4.7E-03 
rs2948068 2 128,461,050 1.7E-05 SAP130   
rs10222358 3 171,982,775 1.7E-05 CLDN11   
rs3783281 14 50,311,239 2.1E-05 NIN   
rs6530650 8 13,496,360 2.2E-05 RP11-145O15.3   
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rs1022538 1 165,892,276 2.5E-05 RCSD1   
rs1926050 10 25,458,413 2.9E-05     
rs10906652 10 14,431,720 3.7E-05 FRMD4A   
rs4725084 7 8,343,391 3.7E-05 AC007128.1   
rs9380700 6 12,099,225 3.8E-05 RP11-456H18.1   
rs1077734 13 105,926,360 4.7E-05     
rs16874 9 9,850,735 4.9E-05 PTPRD 4.7E-03 
rs3901866 8 18,089,629 5.4E-05 NAT1 5.2E-03 
rs1409288 6 12,082,826 5.5E-05     
rs1411872 9 32,248,600 5.7E-05     
rs1328238 13 108,866,662 5.7E-05     
rs2498399 6 26,814,523 5.9E-05     
rs7012951 8 18,084,041 5.9E-05 NAT1 5.2E-03 
rs10514569 16 82,033,605 6.0E-05 CDH13 1.9E-03 
rs10977327 9 8,855,925 6.0E-05 RP11-75C9.1 4.7E-03 
rs10815567 9 723,049 6.2E-05 KANK1 4.4E-04 
rs2229869 14 49,686,628 6.3E-05 SOS2   
rs11104516 12 86,398,520 6.3E-05     
rs2360192 9 29,979,597 6.6E-05     
rs2451741 6 26,737,383 6.8E-05 VN1R14P   
rs4397737 10 30,130,754 7.1E-05     
rs1408118 9 9,848,060 7.2E-05 PTPRD 4.7E-03 
rs6545031 2 48,411,764 7.6E-05 FOXN2   
rs3242 8 41,238,711 8.0E-05 SFRP1   
rs458664 6 25,163,144 8.1E-05 RP3-425P12.1   
rs6022196 20 51,031,721 9.1E-05 TSHZ2 6.7E-04 
rs4749487 10 30,074,383 9.2E-05     
rs12646389 4 14,536,106 9.3E-05 AC006296.3   
rs4772174 13 98,565,578 9.5E-05     
rs4363255 9 9,259,284 9.9E-05 PTPRD 4.7E-03 
rs2451731 6 26,732,801 1.0E-04     
rs4978101 9 26,741,101 1.0E-04 RP11-18A15.1   
rs7857851 9 28,499,969 1.1E-04 LINGO2 2.2E-03 
rs6733871 2 80,383,467 1.1E-04 CTNNA2   
rs1867551 10 60,274,889 1.2E-04     
rs11104481 12 86,353,732 1.2E-04     
rs10756511 9 13,780,202 1.2E-04     
rs11774662 8 41,256,599 1.2E-04 CTD-3080F16.3   
rs4942965     1.3E-04 RPL5P31   
rs7611945 3 127,160,204 1.3E-04 RP11-666A20.3   
rs1956621 14 25,531,905 1.3E-04 RP11-314P15.2   
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rs12590252 14 56,082,358 1.5E-04 RP11-624J12.1   
rs288956 6 156,935,240 1.5E-04     
rs2183825 9 28,402,375 1.5E-04 LINGO2 2.2E-03 
rs7096525 10 120,538,129 1.6E-04 U3   
rs3904501 9 9,354,637 1.6E-04 PTPRD 4.7E-03 
rs6027571 20 58,395,771 1.7E-04 RP5-1043L13.1   
rs10758863 9 732,642 1.7E-04 KANK1 4.4E-04 
rs3904537 10 85,435,487 1.8E-04     
rs2521230 7 24,500,595 1.8E-04     
rs4503787 16 80,182,340 1.8E-04 CMIP   
rs10483610 14 50,295,474 1.9E-04 NIN   
rs1184626 1 76,865,768 1.9E-04 ST6GALNAC3 4.7E-03 
rs1902409 10 33,980,802 1.9E-04     
rs1684617 16 4,696,545 1.9E-04 ANKS3   
rs7200613 16 49,681,302 2.1E-04     
rs1913291 3 132,964,347 2.1E-04 CPNE4 1.5E-03 
rs6104663 20 10,721,298 2.1E-04     
rs9873588 3 110,293,726 2.2E-04 MORC1 3.6E-03 
rs8083237 18 11,586,076 2.2E-04     
rs33350 16 50,608,803 2.2E-04 RP11-152O14.5   
rs900768 16 83,987,411 2.2E-04 #N/A   
rs9348467 6 21,446,588 2.2E-04     
rs10521087 9 109,749,408 2.2E-04     
rs10031277 4 14,540,933 2.3E-04 AC006296.3   
rs4650112 1 69,370,007 2.3E-04 RP11-424D14.1   
rs12932558 16 54,600,670 2.3E-04     
rs10104990 8 136,202,757 2.3E-04     
rs10891611 11 113,356,623 2.4E-04 HTR3A   
rs9301233 13 107,025,880 2.4E-04 FAM155A 5.4E-04 
rs10756657 9 15,330,686 2.4E-04     
rs1564961 10 72,334,003 2.5E-04     
rs4492438 9 9,272,982 2.5E-04 PTPRD 4.7E-03 
rs4725047 7 7,912,925 2.5E-04 AC006465.4   
rs7147228 14 49,922,978 2.5E-04 CDKL1   
rs10486972 7 82,035,405 2.6E-04     
rs633596 6 153,107,180 2.6E-04     
rs10871622 18 51,677,998 2.6E-04     
rs4785239 16 49,758,032 2.6E-04     
rs2323624 4 22,164,415 2.6E-04     
rs2296170 9 9,793,954 2.6E-04 RP11-527D15.1 4.7E-03 
rs4711507 6 12,090,447 2.7E-04     
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rs6943258 7 8,299,180 2.7E-04 AC007128.1   
rs10817700 9 116,815,624 2.7E-04     
rs4909885 8 136,203,239 2.8E-04     
rs9364599 6 161,826,097 2.8E-04 PARK2 8.8E-05 
rs2881483 16 77,512,176 2.9E-04 WWOX 3.1E-03 
rs10919620 1 187,952,120 3.2E-04     
rs914987 10 10,318,853 3.2E-04 Y_RNA   
rs6015739 20 58,388,925 3.2E-04 RP5-1043L13.1   
rs12702671 7 7,909,920 3.2E-04 AC006465.3   
rs2438039 2 128,423,160 3.2E-04 SAP130   
rs7994366 13 110,474,921 3.2E-04     
rs2761752 9 9,809,028 3.3E-04 PTPRD 4.7E-03 
rs4949857 1 75,153,767 3.3E-04     
rs1927450 10 30,114,806 3.3E-04     
rs1545217 6 158,930,367 3.3E-04 TMEM181   
rs2761748 9 9,807,514 3.3E-04 PTPRD 4.7E-03 
rs7875247 9 16,232,088 3.4E-04 C9orf92   
rs4747064 10 72,018,762 3.4E-04     
rs10733060 1 187,990,113 3.4E-04     
rs10498662 6 3,356,110 3.4E-04 SLC22A23   
rs4915627 1 63,229,847 3.4E-04     
rs9884246 4 134,440,559 3.4E-04     
rs4779939 15 29,985,165 3.4E-04     
rs1921752 7 40,763,143 3.4E-04 C7orf10   
rs10517003 4 40,963,950 3.4E-04 UCHL1   
rs4356557 18 73,477,767 3.5E-04     
rs1247330 6 161,246,640 3.5E-04 RP11-235G24.1   
rs1008132 7 20,927,491 3.5E-04 AC006481.1   
rs2588209 8 17,428,639 3.6E-04 SLC7A2   
rs11257877 10 12,622,719 3.6E-04 CAMK1D 2.1E-03 
rs10997044 10 67,727,449 3.7E-04 CTNNA3 8.7E-04 
rs2125952 8 3,032,594 3.7E-04 CSMD1 8.6E-05 
rs10503019 18 53,605,375 3.7E-04 ATP8B1   
rs3736781 6 26,613,341 3.7E-04 BTN1A1   
rs2323982 12 131,652,594 3.8E-04 FBRSL1   
rs6572667 14 49,917,611 3.9E-04 CDKL1   
rs2155369 11 120,544,020 3.9E-04 TECTA   
rs1339287 9 8,223,804 3.9E-04     
rs8056477 16 86,156,751 3.9E-04     
rs7856322 9 9,821,142 4.0E-04 PTPRD 4.7E-03 
rs856003 10 119,393,553 4.0E-04     
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rs3014864 1 151,588,208 4.0E-04 PGLYRP4   
rs6122372 20 61,209,792 4.0E-04 HAR1A   
rs6026872 20 57,420,894 4.1E-04     
rs395371 4 72,791,238 4.1E-04     
rs9356895 6 23,883,847 4.1E-04     
rs942659 6 23,892,972 4.1E-04     
rs377687     4.2E-04     
rs185925 2 31,463,497 4.2E-04 XDH   
rs10513441 3 154,522,958 4.2E-04     
rs2906801 16 80,906,745 4.2E-04     
rs2794251 13 80,229,654 4.3E-04     
rs819571 5 72,863,969 4.3E-04     
rs3811992 5 161,049,520 4.4E-04 GABRA6 6.5E-03 
rs4953713 2 43,100,719 4.4E-04     
rs12447774 16 80,183,738 4.4E-04 CMIP   
rs2262438 6 133,058,735 4.5E-04 CCNG1P1   
rs4542003 9 109,962,839 4.5E-04     
rs954811 16 77,499,272 4.5E-04 WWOX 3.1E-03 
rs1432536 11 90,969,219 4.5E-04     
rs11249987 8 10,218,116 4.5E-04 MSRA 8.7E-03 
rs2745443 6 133,063,075 4.5E-04 CCNG1P1   
rs6659974     4.5E-04     
rs9348547 6 23,268,267 4.7E-04 RP1-209A6.1   
rs4142313 13 42,995,658 4.7E-04 ENOX1   
rs11014425 10 25,473,731 4.7E-04     
rs573946 11 125,968,781 4.7E-04 KIRREL3-AS1 1.6E-03 
rs1510218 16 77,515,978 4.7E-04 WWOX 3.1E-03 
rs598832 6 154,314,311 4.8E-04     
rs1523635 7 16,982,220 4.8E-04     
rs10217611 9 14,801,009 4.8E-04 FREM1   
rs1333108 9 9,449,099 4.8E-04 PTPRD 4.7E-03 
rs3006448 1 151,580,777 4.8E-04 PGLYRP4 6.5E-03 
rs4601425 9 27,142,292 4.9E-04 TEK 7.4E-03 
rs3858042 9 4,370,422 4.9E-04 AL162419.1   
rs912174 9 702,156 4.9E-04 KANK1 4.4E-04 
rs7752854 6 162,714,014 5.0E-04 PARK2 8.8E-05 
rs10498581 14 84,806,621 5.0E-04 RNU3P3   
rs2145997 10 80,828,991 5.0E-04 ZCCHC24   
rs16949651 17 43,374,600 5.0E-04 AC003665.1   
rs10946999 6 29,679,588 5.0E-04 GABBR1   
rs7211832 17 29,393,973 5.0E-04 TLK2P1 3.3E-03 
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rs646707 12 5,115,044 5.0E-04     
rs13253111 8 28,117,893 5.1E-04     
rs9342944 6 73,131,044 5.1E-04 RIMS1   
rs2501917 9 74,505,943 5.1E-04 TMC1   
rs901151 3 56,262,564 5.2E-04 ERC2   
rs484299 1 76,871,317 5.2E-04 ST6GALNAC3   
rs4818219 21 41,469,764 5.2E-04 BACE2-IT1   
rs2720492 8 17,428,016 5.2E-04 SLC7A2   
rs4541976 8 73,958,102 5.2E-04 RP11-1145L24.1   
rs2758767 6 153,027,201 5.3E-04     
rs13074670 3 151,911,821 5.3E-04 RP11-103G8.2   
rs9323505 14 67,856,540 5.3E-04 RAD51B 4.6E-04 
rs10814755 9 38,743,508 5.3E-04     
rs2720586 8 17,419,158 5.3E-04 SLC7A2   
rs10945816 6 162,699,141 5.3E-04 PARK2 8.8E-05 
rs2279830 3 148,588,480 5.3E-04 ZIC4-AS1   
rs7603997 2 24,378,462 5.4E-04 ITSN2   
rs17289605 3 171,930,731 5.4E-04 CLDN11   
rs12546427 8 6,592,314 5.4E-04 AGPAT5 7.3E-03 
rs7954341 12 79,943,528 5.4E-04 ACSS3   
rs12666612 7 18,341,770 5.4E-04 HDAC9   
rs538257 18 53,932,365 5.5E-04 NEDD4L   
rs13279789 8 17,420,156 5.5E-04 SLC7A2   
rs6900805 6 154,329,725 5.5E-04     
rs7322914 13 105,938,911 5.5E-04 EFNB2   
rs10511761 9 25,602,704 5.5E-04     
rs7098831 10 30,057,054 5.5E-04 SVIL   
rs11255096 10 7,458,399 5.5E-04 SFMBT2 6.1E-03 
rs3819340 3 150,097,977 5.6E-04 RP11-680B3.2   
rs10935734 3 150,108,496 5.6E-04 RP11-680B3.2   
rs318572 7 34,243,290 5.6E-04 AC009262.2   
rs1020138 4 41,398,145 5.7E-04 LIMCH1   
rs2749592 10 38,298,848 5.7E-04 ZNF25   
rs11962266 6 159,818,380 5.7E-04     
rs9378109 6 30,882,453 5.9E-04 LINC00243   
rs4797559 18 11,573,447 5.9E-04     
rs7123583 11 116,105,231 5.9E-04     
rs9393366 6 23,185,290 5.9E-04 RP1-209A6.1   
rs34198 7 31,722,195 6.0E-04     
rs9348465 6 21,438,787 6.0E-04     
rs7655641 4 60,203,770 6.0E-04     
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rs7913550 10 44,885,296 6.1E-04 RP11-445N18.3   
rs7819785 8 140,962,053 6.1E-04 TRAPPC9   
rs639790 12 51,194,521 6.1E-04 KRT5   
rs4775758 15 46,457,597 6.1E-04     
rs4376547 9 104,090,485 6.1E-04 RP11-402M4.1   
rs7023878 9 20,055,113 6.1E-04     
rs4908803 1 8,982,757 6.1E-04 SLC2A7   
rs2883739 14 49,649,885 6.2E-04 METTL21D   
rs9469003 6 31,515,807 6.2E-04 XXbac-BPG181B23.4   
rs4237860 12 70,922,902 6.2E-04 TRHDE   
rs426361 9 36,515,772 6.3E-04     
rs10980412 9 112,305,681 6.3E-04 SVEP1 5.0E-03 
rs12650313 4 41,401,850 6.3E-04     
rs277351 1 75,081,601 6.5E-04     
rs1006087 9 38,225,659 6.5E-04     
rs4937306 11 127,610,247 6.6E-04     
rs10510099 10 123,421,836 6.6E-04     
rs5759157 22 41,817,204 6.6E-04 AL022237.3   
rs2097585 8 18,063,184 6.7E-04     
rs10962912 9 17,209,242 6.7E-04 CNTLN   
rs4307347 8 10,205,504 6.7E-04 MSRA 8.7E-03 
rs9348260 6 170,358,048 6.7E-04 RP11-302L19.2   
rs11069780     6.7E-04     
rs969015 7 82,195,220 6.7E-04     
rs908978 16 84,558,240 6.8E-04     
rs2420382 2 60,750,244 6.8E-04     
rs12445310 16 61,444,459 6.8E-04     
rs228840 20 49,504,665 6.8E-04 NFATC2   
rs2918217 3 117,029,070 6.9E-04 LSAMP   
rs2064112 6 11,447,755 6.9E-04 NEDD9   
rs1376405 2 46,622,047 6.9E-04 ATP6V1E2   
rs11129896 3 41,270,771 6.9E-04 CTNNB1 3.9E-03 
rs2405748 3 163,565,423 6.9E-04     
rs12351299 9 30,144,925 6.9E-04     
rs10810013 9 13,736,595 7.0E-04     
rs761523 14 25,752,869 7.0E-04     
rs9847681 3 145,187,206 7.0E-04 C3orf58   
rs8141749 22 41,813,186 7.1E-04 AL022237.3   
rs3213881 16 47,930,306 7.2E-04 RP11-491F9.6   
rs471364     7.2E-04 TTC39B   
rs2788381 6 152,653,569 7.2E-04 SYNE1 4.8E-03 
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rs7350390 10 73,268,910 7.2E-04 PSAP 2.2E-03 
rs6027561 20 58,386,602 7.3E-04 RP5-1043L13.1   
rs1529482 19 17,302,488 7.3E-04 ANO8   
rs1369491 7 12,178,552 7.3E-04     
rs10971103 9 32,715,278 7.3E-04 RP11-462B18.1   
rs10512052 9 77,773,007 7.4E-04 PCSK5 9.0E-03 
rs1866657 2 127,157,628 7.4E-04 AC013474.4   
rs6923240 6 164,105,374 7.5E-04 RP1-230L10.1   
rs6494039 15 29,979,194 7.5E-04     
rs920818 2 80,410,180 7.5E-04 CTNNA2 6.0E-03 
rs6715376 2 149,780,195 7.5E-04 LYPD6B   
rs2627468 8 3,812,607 7.5E-04 CSMD1 8.6E-05 
rs4142055 6 152,592,176 7.5E-04 SYNE1 4.8E-03 
rs921070 2 43,060,347 7.5E-04     
rs484809 3 120,849,573 7.5E-04 POPDC2   
rs12420554 11 127,094,570 7.5E-04     
rs7613643 3 173,509,404 7.5E-04 FNDC3B 2.5E-03 
rs11969972 6 161,794,001 7.5E-04 PARK2 8.8E-05 
rs17405238 7 36,738,917 7.5E-04     
rs10484501 6 162,720,146 7.5E-04 PARK2 8.8E-05 
rs6942109 6 161,706,684 7.6E-04 PARK2 8.8E-05 
rs8118732 20 54,356,605 7.6E-04     
rs4952621 2 40,495,927 7.7E-04 SLC8A1 8.9E-04 
rs1909668 10 123,401,335 7.7E-04     
rs2670153 6 52,648,456 7.7E-04 TMEM14A   
rs2471544 12 86,994,149 7.7E-04 CEP290   
rs175238 2 161,314,813 7.8E-04     
rs689423 1 76,911,492 7.8E-04     
rs3786916 19 38,679,802 7.8E-04 PEPD   
rs10492892 16 79,611,798 7.8E-04 RP11-303E16.3   
rs17496685 6 66,063,541 7.8E-04 RP11-74E24.2 4.5E-04 
rs359980 2 219,537,450 7.9E-04 AC097468.7   
rs12770890 10 16,585,949 7.9E-04 PTER   
rs11198993 10 85,244,450 7.9E-04     
rs7746447 6 158,976,564 8.0E-04 DYNLT1   
rs12547387 8 136,206,752 8.0E-04     
rs1145536 1 161,888,649 8.0E-04     
rs11125238 2 49,496,567 8.0E-04     
rs10509258 10 67,453,443 8.1E-04 CTNNA3 8.7E-04 
rs855987 10 119,401,433 8.1E-04     
rs940120 9 14,896,868 8.1E-04 FREM1   
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rs914605 9 20,732,963 8.2E-04 KIAA1797   
rs10935735 3 150,115,954 8.2E-04 RP11-680B3.2   
rs6870053 5 74,312,322 8.2E-04 CTD-2503O16.4   
rs10115218 9 30,135,864 8.2E-04     
rs10498580 14 84,690,252 8.2E-04     
rs4760381 12 91,972,190 8.3E-04 RP11-511B23.2   
rs4076746 10 1,820,848 8.3E-04     
rs1472834 8 18,972,720 8.4E-04 PSD3   
rs10503303 8 5,312,389 8.4E-04     
rs11642029 16 84,922,333 8.4E-04 AC092327.1   
rs894520 9 38,179,527 8.4E-04 snoU13   
rs11166679 8 138,038,252 8.4E-04 RP11-30J20.1   
rs12675992 8 28,120,336 8.4E-04     
rs9935462 16 80,924,587 8.5E-04     
rs12286609 11 90,946,180 8.5E-04     
rs4840374 8 8,823,160 8.5E-04     
rs9940922 16 82,293,571 8.5E-04 CDH13 1.9E-03 
rs9541407 13 67,978,683 8.6E-04     
rs1229655 7 26,399,449 8.6E-04     
rs10483853 14 72,826,052 8.7E-04 NUMB   
rs11917772 3 145,149,515 8.8E-04     
rs4429143 12 86,933,325 8.8E-04 C12orf50 7.5E-03 
rs7624504 3 144,436,867 8.8E-04     
rs11205275 1 151,591,780 8.9E-04 PGLYRP4   
rs427048 3 42,494,564 9.0E-04     
rs11865624 16 82,878,275 9.0E-04     
rs1327793 9 111,574,677 9.1E-04 PALM2 5.6E-03 
rs4937504 11 129,752,910 9.1E-04 RP11-121M22.1   
rs2802490 10 43,919,019 9.2E-04     
rs12831250 12 87,097,672 9.2E-04 TMTC3   
rs1261234 2 79,036,329 9.3E-04     
rs1358863 10 89,416,488 9.3E-04 PAPSS2   
rs4688023 3 120,861,876 9.3E-04 POPDC2   
rs2283491 16 3,939,585 9.3E-04 RP11-462G12.1   
rs36982 5 1,556,205 9.3E-04 LPCAT1   
rs1366119 5 5,435,695 9.4E-04     
rs12000040 9 77,809,649 9.4E-04 PCSK5 9.0E-03 
rs17771443 10 49,595,617 9.4E-04 WDFY4 1.0E-03 
rs17153021 8 11,133,645 9.4E-04     
rs4398831 7 96,594,993 9.4E-04 ACN9   
rs7778021 7 40,753,457 9.5E-04 C7orf10   
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rs285480 1 163,670,527 9.6E-04 RXRG   
rs3803651 16 79,876,383 9.7E-04 BCMO1   
rs7645524 3 198,610,700 9.7E-04     
rs7742171 6 838,848 9.7E-04     
rs6476179 9 29,975,815 9.7E-04     
rs2387595 10 6,767,544 9.8E-04     
rs11996662 8 18,080,684 9.8E-04 NAT1 5.2E-03 
rs2793150 9 74,509,273 9.8E-04 TMC1   
rs7421353 2 29,495,378 9.8E-04 ALK 1.7E-03 
rs2759243 13 80,195,640 9.8E-04     
rs11880217 19 12,279,795 9.9E-04     
rs618541     9.9E-04     
rs17692472     9.9E-04     
rs983596 14 40,420,142 9.9E-04     
rs1393784 3 106,373,405 9.9E-04     
rs11964693 6 68,425,331 1.0E-03     
rs7212512 17 4,660,945 1.0E-03 RP11-81A22.5   
rs561168 13 109,682,209 1.0E-03 COL4A1 3.1E-03 
rs985564 6 73,225,898 1.0E-03     
rs1000198 3 120,596,510 1.0E-03 ARHGAP31   
rs4592392 11 39,560,586 1.0E-03     
rs1599796 3 120,726,624 1.0E-03 TIMMDC1 2.0E-03 
rs1509197 9 1,009,473 1.0E-03     
rs7843177 8 2,466,863 1.0E-03 RP11-378A12.1   
rs2188023 8 18,083,511 1.0E-03 NAT1 5.2E-03 
rs7188426 16 83,538,351 1.0E-03     
rs2584548 9 17,399,012 1.0E-03 CNTLN   
rs976796 14 40,380,655 1.0E-03     
rs7714420 5 74,376,083 1.0E-03 RP11-229C3.2   
rs587639 8 132,794,913 1.0E-03 CTD-2008O4.1   
rs2958492 8 145,889,935 1.0E-03 AF186192.1   
rs11974778 7 101,343,083 1.0E-03 CUX1 6.7E-03 
rs9283723 5 30,823,028 1.0E-03     
rs9695393 9 29,339,856 1.1E-03     
rs10756505 9 13,770,058 1.1E-03     
rs4740993 9 9,841,382 1.1E-03 PTPRD 4.7E-03 
rs12701134 7 31,739,647 1.1E-03     
rs2073001 6 21,440,915 1.1E-03     
rs10095543 8 23,187,341 1.1E-03 R3HCC1   
rs16941783 16 85,233,851 1.1E-03 RP11-58A18.1   
rs4577393 22 31,315,687 1.1E-03 SYN3   
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rs862456 19 44,030,503 1.1E-03 HNRNPL   
rs220723 6 160,246,557 1.1E-03 RP1-249F5.3   
rs636398 9 22,670,915 1.1E-03 RP11-399D6.2   
rs1161110 12 66,125,429 1.1E-03 RP11-473M14.3   
rs6030812 20 41,434,425 1.1E-03     
rs1000531 2 46,365,443 1.1E-03     
rs3759324 12 6,355,922 1.1E-03 SCNN1A   
rs2247278 2 37,957,293 1.1E-03 LINC00211   
rs4850933     1.1E-03     
rs4843628 16 86,141,814 1.1E-03     
rs883438 14 56,050,922 1.1E-03 RP11-624J12.1   
rs1938164 6 6,750,058 1.1E-03     
rs6040669 20 11,360,024 1.1E-03     
rs11647427 16 54,622,772 1.1E-03     
rs4852163 2 79,875,554 1.1E-03 CTNNA2 6.0E-03 
rs10962397 9 16,354,925 1.1E-03     
rs7170390 15 57,407,382 1.1E-03 MYO1E 4.2E-03 
rs6139948 20 622,962 1.1E-03     
rs2045812 4 22,152,992 1.1E-03     
rs7405014 16 86,643,348 1.1E-03 BANP   
rs2059098 5 163,340,393 1.1E-03     
rs10757817 9 29,182,125 1.1E-03     
rs1983764 14 50,262,409 1.1E-03 NIN   
rs602227 1 64,029,576 1.1E-03 RP4-597J3.1   
rs1445210 9 9,182,961 1.1E-03 PTPRD 4.7E-03 
rs11623335 14 56,102,829 1.1E-03 C14orf101   
rs3792298 3 169,024,676 1.1E-03 SERPINI1 5.2E-04 
rs4466762 10 47,167,032 1.1E-03 ANTXRL   
rs563850 13 50,325,146 1.1E-03 DLEU7-AS1   
rs244972 5 155,258,116 1.1E-03 SGCD   
rs7027471 9 29,954,976 1.1E-03     
rs1410351 13 105,217,814 1.2E-03     
rs17774360 9 30,004,366 1.2E-03     
rs3815571 12 15,154,326 1.2E-03 RERG   
rs6945523 7 114,314,605 1.2E-03     
rs4555301 2 29,493,183 1.2E-03 ALK 1.7E-03 
rs10511905 9 32,338,024 1.2E-03     
rs276550 6 137,443,470 1.2E-03     
rs11008423 10 19,415,497 1.2E-03     
rs4955755 3 171,977,103 1.2E-03 CLDN11   
rs10064872 5 125,021,832 1.2E-03     
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rs427896     1.2E-03 AL589825.1   
rs2109313 2 128,292,394 1.2E-03     
rs1436434 16 45,141,599 1.2E-03 ANKRD26P1   
rs7118508 11 124,478,042 1.2E-03 TMEM218   
rs2115925 11 120,687,058 1.2E-03 SC5DL   
rs1327080 1 75,083,945 1.2E-03     
rs10142258 14 72,879,970 1.2E-03 NUMB   
rs3747868 10 73,190,834 1.2E-03 CDH23   
rs3755579 3 120,697,239 1.2E-03 POGLUT1   
rs2723520 7 17,780,202 1.2E-03     
rs253155 12 9,902,102 1.2E-03 CLEC2B 9.0E-04 
rs11779707 8 41,247,867 1.2E-03 SFRP1   
rs10862220 12 79,954,730 1.2E-03 ACSS3   
rs1887866 9 7,253,702 1.2E-03     
rs7161541 14 49,670,230 1.2E-03 SOS2   
rs8060701 16 71,630,790 1.2E-03 ZFHX3 3.4E-03 
rs10959161 9 10,533,899 1.2E-03 PTPRD 4.7E-03 
rs6863278 5 72,727,144 1.2E-03 RP11-79P5.8   
rs3778333 6 7,254,149 1.2E-03 SSR1   
rs7746261 6 7,255,258 1.2E-03 #N/A   
rs7863381 9 30,862,374 1.2E-03     
rs2849576 6 162,506,056 1.2E-03 PARK2 8.8E-05 
rs4354369     1.2E-03     
rs12184535 13 110,890,000 1.2E-03     
rs742487 6 2,392,698 1.2E-03     
rs6026395 20 56,611,417 1.2E-03 RP5-907D15.3   
rs12189965 6 153,350,005 1.3E-03 RP1-101K10.6   
rs991335 3 56,209,972 1.3E-03 ERC2   
rs854771 17 18,000,917 1.3E-03 MYO15A   
rs10507539 13 45,732,707 1.3E-03 LRRC63   
rs12670250 7 27,543,628 1.3E-03 HIBADH   
rs1531228 12 13,520,648 1.3E-03     
rs489049 1 57,347,657 1.3E-03 DAB1 6.9E-03 
rs6530746 8 14,179,648 1.3E-03 SGCZ 5.9E-04 
rs575242 3 171,934,775 1.3E-03 CLDN11   
rs9405561 6 2,412,474 1.3E-03     
rs12316831 12 87,189,927 1.3E-03     
rs4843549 16 85,795,364 1.3E-03 C16orf95   
rs791589 10 6,129,577 1.3E-03 IL2RA 1.7E-12 
rs12423283 12 72,878,975 1.3E-03 RP11-81H3.2   
rs10996895 10 67,529,571 1.3E-03 CTNNA3 8.7E-04 
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rs6789549 3 40,996,267 1.3E-03     
rs2653330 3 188,751,659 1.3E-03     
rs2328472 20 19,894,076 1.3E-03 RIN2   
rs1018159 16 77,512,959 1.3E-03 WWOX 3.1E-03 
rs2367214 5 38,322,363 1.3E-03 EGFLAM-AS4   
rs11196905 10 116,518,284 1.3E-03 RP11-106M7.1   
rs289073 4 31,061,064 1.3E-03     
rs11988651 8 145,789,590 1.3E-03 ARHGAP39   
rs4879543     1.3E-03     
rs36987 5 1,552,175 1.3E-03 LPCAT1   
rs7617219     1.3E-03 CPHL1P   
rs250157 16 78,146,121 1.3E-03     
rs6480128 10 67,453,139 1.3E-03 CTNNA3 8.7E-04 
rs215006 6 152,797,321 1.3E-03 SYNE1 4.8E-03 
rs2283149 11 2,500,006 1.3E-03 KCNQ1 3.8E-03 
rs9368297 6 21,445,003 1.3E-03     
rs505480 8 12,923,214 1.3E-03 KIAA1456 6.9E-03 
rs474588 3 171,945,283 1.3E-03 RP11-373E16.4   
rs1915280 12 72,042,402 1.3E-03 RP11-314D7.4   
rs10763176 10 56,478,812 1.3E-03 PCDH15   
rs162870 3 78,959,907 1.3E-03 ROBO1   
rs7866438 9 33,954,118 1.3E-03 OSTCP8   
rs1922166 10 56,465,084 1.3E-03 PCDH15   
rs2112979 5 55,327,793 1.3E-03 IL6ST   
rs9693804 8 126,954,773 1.3E-03     
rs564598 3 171,940,031 1.3E-03 RP11-373E16.4   
rs16906775 8 80,409,145 1.3E-03     
rs7916379 10 4,764,610 1.3E-03     
rs16932846 12 28,487,596 1.3E-03 CCDC91   
rs4997129 6 856,832 1.3E-03 RP5-1077H22.2   
rs10242866 7 17,887,138 1.3E-03 SNX13   
rs708860 12 116,494,692 1.3E-03 KSR2 2.6E-04 
rs1485187 9 7,624,720 1.3E-03     
rs7011529 8 102,261,354 1.3E-03 ZNF706   
rs10249530 7 90,830,257 1.3E-03 RP11-115N4.1   
rs6664881 1 169,072,251 1.3E-03     
rs3016774 11 128,240,876 1.4E-03 KCNJ1   
rs7862217 9 27,141,645 1.4E-03 TEK 7.4E-03 
rs2064813 2 32,066,439 1.4E-03 DPY30   
rs559135 9 119,342,663 1.4E-03     
rs4672667 2 213,506,125 1.4E-03 AC093865.1   
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rs10502249 11 122,009,461 1.4E-03     
rs4839620 3 144,404,654 1.4E-03     
rs1796993 9 74,505,258 1.4E-03 TMC1   
rs9808084 2 80,396,255 1.4E-03 CTNNA2 6.0E-03 
rs900369 2 213,484,594 1.4E-03 AC108066.1   
rs7021584 9 3,358,111 1.4E-03 RP11-62E14.2   
rs2825663 21 19,877,775 1.4E-03     
rs6439099 3 129,114,251 1.4E-03 KBTBD12   
rs1356768 3 168,229,302 1.4E-03 AC092965.1   
rs1558905 12 14,112,158 1.4E-03     
rs12536822 7 12,162,916 1.4E-03     
rs4933782 10 83,179,160 1.4E-03     
rs1962503 18 30,360,416 1.4E-03 DTNA   
rs2656620 16 77,470,888 1.4E-03 WWOX 3.1E-03 
rs3922817 2 109,390,585 1.4E-03 SH3RF3   
rs1383852 3 100,598,897 1.4E-03     
rs9365324 6 162,107,902 1.4E-03 PARK2 8.8E-05 
rs11146960 12 131,532,533 1.4E-03     
rs7614661 3 169,619,384 1.4E-03 EGFEM1P   
rs7797908 7 142,351,329 1.4E-03 KEL   
rs4683806 3 141,327,360 1.4E-03 CLSTN2 1.3E-03 
rs534080 1 57,357,309 1.4E-03 DAB1 6.9E-03 
rs1360585 9 7,759,626 1.4E-03     
rs4502539 3 127,259,128 1.4E-03 SLC41A3   
rs6997118 8 17,415,784 1.4E-03 SLC7A2   
rs1009221 2 26,748,093 1.4E-03 AC015977.6   
rs4144431 14 50,820,213 1.4E-03     
rs9831023 3 120,594,452 1.4E-03 ARHGAP31   
rs4325703 2 128,512,647 1.4E-03     
rs702279 9 6,959,634 1.4E-03 RP11-403H13.1   
rs9315681 13 38,881,671 1.4E-03 LHFP 1.5E-03 
rs719804 11 112,739,985 1.4E-03 TTC12   
rs7635829 3 148,576,912 1.4E-03     
rs1942007 10 67,456,130 1.4E-03 CTNNA3 8.7E-04 
rs7234618 18 22,563,606 1.5E-03     
rs2795380 9 103,718,706 1.5E-03     
rs6934511 6 2,406,202 1.5E-03     
rs8099150 18 11,568,474 1.5E-03     
rs7857376 9 111,140,779 1.5E-03     
rs1460537 18 39,760,015 1.5E-03     
rs7250408 19 45,025,811 1.5E-03 FBL   
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rs2210539 9 17,158,867 1.5E-03 CNTLN   
rs10964182 9 19,484,098 1.5E-03 AL158206.1   
rs8012887 14 83,268,846 1.5E-03     
rs8045161 16 53,160,653 1.5E-03     
rs7780032 7 20,199,797 1.5E-03 MACC1 7.0E-03 
rs17780143 14 49,971,518 1.5E-03 MAP4K5   
rs3933328     1.5E-03     
rs328114 18 42,527,784 1.5E-03 ST8SIA5   
rs7633016 3 46,703,663 1.5E-03 ALS2CL   
rs7667847 4 7,389,753 1.5E-03 SORCS2   
rs1383453 8 136,143,126 1.5E-03     
rs10869675 9 77,779,855 1.5E-03 PCSK5 9.0E-03 
rs10756088 9 10,651,370 1.5E-03     
rs823918 9 103,703,117 1.5E-03     
rs1247336 6 161,297,547 1.5E-03 RP3-428L16.1   
rs10428541 5 52,760,915 1.5E-03     
rs4921804 8 17,594,903 1.5E-03 MTUS1   
rs2830927 21 27,712,794 1.5E-03 RPL10P1   
rs10937088 3 183,639,928 1.5E-03     
rs1645060 5 41,427,106 1.5E-03 PLCXD3   
rs2756916 9 103,717,772 1.5E-03     
rs5021764 13 23,496,757 1.5E-03 RP11-309I15.1   
rs2484918 9 26,354,526 1.5E-03     
rs2758774     1.5E-03     
rs7516390 1 160,957,563 1.6E-03 DDR2 6.8E-03 
rs1768575 9 8,225,513 1.6E-03     
rs7068134 10 67,450,904 1.6E-03 CTNNA3 8.7E-04 
rs11775938 8 40,053,601 1.6E-03     
rs4885145 13 73,497,210 1.6E-03 KLF12   
rs10928942 2 130,399,814 1.6E-03 AC079776.2   
rs2272571 17 17,987,914 1.6E-03 MYO15A   
rs823920 9 103,702,406 1.6E-03     
rs1038268 9 31,967,623 1.6E-03     
rs4364720 9 26,332,947 1.6E-03     
rs750669 16 84,470,371 1.6E-03     
rs2133886 3 56,917,110 1.6E-03 ARHGEF3   
rs1503161 3 106,288,374 1.6E-03     
rs951016 3 194,576,396 1.6E-03 ATP13A5   
rs10886432 10 85,217,844 1.6E-03     
rs2700586 3 100,577,480 1.6E-03     
rs697471 6 166,299,886 1.6E-03 LINC00473   
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rs7092223 10 56,556,926 1.6E-03 PCDH15   
rs1947223 2 225,654,301 1.6E-03     
rs2688647 3 120,813,592 1.6E-03 PLA1A   
rs2358657 10 20,344,631 1.6E-03 PLXDC2 6.4E-03 
rs1915762 2 79,000,216 1.6E-03     
rs713054 6 162,491,345 1.6E-03 PARK2 8.8E-05 
rs6547363 2 81,408,438 1.6E-03     
rs256845 5 155,852,825 1.6E-03 SGCD   
rs9458397 6 162,176,278 1.6E-03 PARK2 8.8E-05 
rs11785590 8 22,792,914 1.6E-03 RP11-87E22.2 1.7E-03 
rs13138213 4 30,424,187 1.6E-03 PCDH7   
rs9299090 9 9,254,932 1.6E-03 PTPRD 4.7E-03 
rs1320546 9 95,759,720 1.6E-03 BARX1   
rs1728171 17 39,028,855 1.7E-03     
rs625852 18 8,448,190 1.7E-03 AP001793.1   
rs975037 8 122,421,236 1.7E-03     
rs1855217 9 9,353,616 1.7E-03 PTPRD 4.7E-03 
rs4937626 11 130,844,247 1.7E-03 NTM   
rs3770306 2 80,473,746 1.7E-03 CTNNA2 6.0E-03 
rs792746 3 158,857,927 1.7E-03 C3orf55   
rs12493995 3 175,885,280 1.7E-03 NAALADL2   
rs2191041 7 13,152,407 1.7E-03 AC011288.2   
rs1951346 14 43,270,925 1.7E-03     
rs30425 16 78,159,425 1.7E-03     
rs915508 9 26,349,485 1.7E-03     
rs2756318     1.7E-03     
rs10737558 1 187,956,641 1.7E-03     
rs218769 4 14,037,640 1.7E-03     
rs17680996 7 12,823,244 1.7E-03     
rs17389100 2 18,361,324 1.7E-03 KCNS3   
rs10810127 9 14,284,350 1.7E-03 NFIB   
rs12887744 14 83,173,812 1.7E-03     
rs7895709 10 18,945,941 1.7E-03 NSUN6 3.7E-03 
rs10940495 5 55,298,417 1.7E-03 IL6ST   
rs1011427 5 147,968,170 1.7E-03 HTR4   
rs1331226 9 32,282,317 1.7E-03 RN5S281   
rs7076094 10 67,456,054 1.7E-03 CTNNA3 8.7E-04 
rs12548717 8 13,583,929 1.7E-03     
rs3736495 15 66,400,544 1.7E-03 ITGA11   
rs6779258 3 71,632,329 1.7E-03 FOXP1 2.2E-03 
rs1779 7 873,265 1.7E-03 SUN1   
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rs2118891 2 212,387,888 1.7E-03 ERBB4 1.1E-03 
rs1037459 15 22,549,328 1.7E-03     
rs2893978 10 67,452,838 1.7E-03 CTNNA3 8.7E-04 
rs10737976 6 72,572,001 1.7E-03     
rs1534863 8 11,705,562 1.7E-03 FDFT1   
rs1671078 11 129,662,255 1.7E-03 ZBTB44   
rs1929831 9 29,353,582 1.7E-03     
rs2740902 8 3,889,960 1.7E-03 CSMD1 8.6E-05 
rs9322304 6 151,537,080 1.7E-03 RP1-292B18.4   
rs354731 20 58,384,823 1.7E-03 RP5-1043L13.1   
rs1925191 6 23,943,322 1.7E-03     
rs1496248 11 133,057,322 1.7E-03     
rs156007 5 95,862,056 1.7E-03 CTD-2337A12.1   
rs7829474 8 73,957,878 1.7E-03 RP11-1145L24.1   
rs737590 9 30,217,140 1.7E-03     
rs1442514 9 17,409,319 1.7E-03 CNTLN   
rs2242310 4 53,518,828 1.7E-03 RP11-752D24.2 7.6E-03 
rs12637387 3 110,095,943 1.7E-03     
rs10861063 12 102,555,541 1.8E-03 STAB2 1.7E-03 
rs7778616 7 13,043,590 1.8E-03     
rs17444315 9 38,345,790 1.8E-03 RP11-113O24.3   
rs9814525 3 67,177,665 1.8E-03     
rs7159343     1.8E-03     
rs1333652 6 10,381,949 1.8E-03     
rs1877589 3 132,969,848 1.8E-03 CPNE4 1.5E-03 
rs2190935 7 7,249,542 1.8E-03 C1GALT1 5.7E-03 
rs2023073 6 162,552,161 1.8E-03 PARK2 8.8E-05 
rs912196 13 112,781,336 1.8E-03 MCF2L   
rs9789477 2 51,576,611 1.8E-03 AC007682.1   
rs1718861 4 57,644,456 1.8E-03 IGFBP7   
rs7977726 12 87,142,283 1.8E-03     
rs1753415 10 27,435,108 1.8E-03 YME1L1   
rs2101201 4 53,537,471 1.8E-03 SCFD2 7.6E-03 
rs1519654 2 100,463,392 1.8E-03 NMS   
rs2413975 15 47,976,595 1.8E-03 ATP8B4   
rs10937003 3 180,598,074 1.8E-03 MFN1   
rs12360468 10 43,618,874 1.8E-03     
rs1215130 9 15,333,709 1.8E-03     
rs4868825 5 163,313,622 1.8E-03     
rs2442863 10 26,073,064 1.8E-03     
rs3774332 3 37,049,672 1.8E-03 MLH1   
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rs7015700 8 9,565,117 1.8E-03 TNKS   
rs2105606 11 131,337,414 1.8E-03 NTM   
rs7624807 3 169,420,582 1.8E-03     
rs1667087 9 22,686,345 1.8E-03 RP11-399D6.2   
rs1138714 11 815,110 1.8E-03 AP006621.8   
rs1178118 7 18,718,523 1.8E-03 HDAC9 6.5E-03 
rs2037719 7 96,557,076 1.8E-03     
rs736707 7 102,917,639 1.8E-03 RELN   
rs2383154 9 20,857,809 1.8E-03 KIAA1797   
rs2001688 9 30,018,022 1.8E-03     
rs276585 6 137,418,306 1.8E-03     
rs2194657 7 7,825,773 1.8E-03 AC006465.3   
rs7684626 4 134,416,918 1.8E-03     
rs3119848 9 17,166,955 1.8E-03 CNTLN   
rs2960920 7 71,721,683 1.8E-03 TYW1B 3.2E-04 
rs10800319 1 165,820,273 1.8E-03     
rs973174 3 59,562,526 1.8E-03     
rs11779064 8 22,810,244 1.8E-03 RP11-87E22.1 1.7E-03 
rs12329577 20 4,795,010 1.8E-03 SLC23A2 2.8E-03 
rs10199869 2 36,187,574 1.8E-03     
rs11868497 17 42,820,734 1.8E-03 C17orf57   
rs10514929 17 42,859,869 1.8E-03 CTD-2026D20.2   
rs1407297 9 35,837,756 1.9E-03 TMEM8B   
rs9360664 6 74,098,145 1.9E-03 PAICSP3   
rs481297 18 42,533,661 1.9E-03 ST8SIA5   
rs4238558 15 29,933,027 1.9E-03 OTUD7A   
rs9440550 1 109,194,424 1.9E-03 AKNAD1   
rs1422429 5 149,146,627 1.9E-03 PPARGC1B   
rs6505669 18 11,649,501 1.9E-03     
rs4798428 18 6,012,319 1.9E-03 L3MBTL4 8.6E-03 
rs1796518 6 26,496,651 1.9E-03 BTN2A2   
rs1901548 6 159,818,518 1.9E-03     
rs4297265 1 67,624,923 1.9E-03 IL12RB2   
rs4856985 3 67,187,792 1.9E-03     
rs7632299 3 144,539,157 1.9E-03 SLC9A9-AS1 1.6E-04 
rs10425564 19 62,004,792 1.9E-03 ZIM2   
rs4238055     1.9E-03     
rs9939954 16 80,210,594 1.9E-03 CMIP   
rs1113401 9 21,002,170 1.9E-03 PTPLAD2   
rs2843157 1 2,230,243 1.9E-03 SKI   
rs1374650 4 30,429,864 1.9E-03 PCDH7   
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rs2761763 9 9,822,245 1.9E-03 PTPRD 4.7E-03 
rs7552405 1 104,915,372 1.9E-03     
rs2500286 1 3,265,998 1.9E-03 PRDM16   
rs7322524 13 75,638,199 1.9E-03     
rs6957548 7 20,106,813 1.9E-03 AC005062.2   
rs2054956 3 67,433,729 1.9E-03 RP11-85I21.1   
rs2270614 1 67,628,609 1.9E-03 IL12RB2   
rs1011531 9 13,745,192 1.9E-03     
rs4411234 10 85,211,638 1.9E-03     
rs10852172 15 90,526,504 1.9E-03 RP11-152L20.3   
rs4839805 6 102,746,163 1.9E-03     
rs1368686 9 8,858,684 2.0E-03 PTPRD 4.7E-03 
rs4679705 3 154,526,910 2.0E-03     
rs10890800 11 107,409,856 2.0E-03 CUL5   
rs6905741 6 152,601,496 2.0E-03 SYNE1 4.8E-03 
rs140616 5 155,743,532 2.0E-03 SGCD   
rs479137 1 187,919,867 2.0E-03     
rs11861610 16 25,715,369 2.0E-03 HS3ST4 4.3E-03 
rs11098778 4 80,758,025 2.0E-03     
rs4742630 9 9,853,227 2.0E-03 PTPRD 4.7E-03 
rs962319 11 131,638,578 2.0E-03 NTM   
rs1510716 4 28,138,936 2.0E-03 RP11-123O22.1   
rs1921467 3 177,348,511 2.0E-03     
rs4937917 11 133,960,488 2.0E-03     
rs673733 4 28,128,457 2.0E-03 RP11-123O22.1   
rs855314 1 63,867,699 2.0E-03 PGM1   
rs534795 1 187,911,942 2.0E-03     
rs842767 2 60,722,118 2.0E-03 AC012498.1   
rs842764 2 60,726,355 2.0E-03 AC012498.1   
rs3746228 19 62,496,174 2.0E-03 ZNF460   
rs9599855 13 71,023,642 2.0E-03 DACH1 1.7E-03 
rs30743 5 135,360,470 2.0E-03     
rs11586980 1 48,988,958 2.0E-03 BEND5   
rs1926937 10 7,816,837 2.0E-03 ITIH2 2.2E-03 
rs12003093 9 32,578,258 2.0E-03     
rs2128001 8 51,624,066 2.0E-03 SNTG1   
rs4960248 6 6,753,207 2.0E-03     
rs4261746 2 100,588,062 2.0E-03 AC068538.4   
rs2375811 9 31,979,998 2.0E-03     
rs2044726 11 131,644,038 2.0E-03 NTM   
rs1329851 9 24,616,089 2.0E-03     
98 
 
rs9815702 3 165,217,908 2.0E-03     
rs4747194 10 73,228,892 2.0E-03 CDH23 4.7E-03 
rs473728 18 53,348,005 2.0E-03     
rs1491099 9 108,548,141 2.0E-03     
rs6040638 20 11,338,446 2.0E-03     
rs1501157 4 14,206,930 2.0E-03 LINC00504   
rs244496 12 31,101,381 2.0E-03 RP11-551L14.5   
rs1428079 5 163,915,592 2.0E-03 CTC-340A15.2   
rs823907 9 103,734,745 2.0E-03     
rs7032682 9 35,199,763 2.0E-03 UNC13B   
rs10491775 9 14,433,784 2.0E-03     
rs4723018 7 30,809,187 2.0E-03 INMT-FAM188B   
rs2389411 7 15,504,962 2.1E-03 AGMO 1.6E-03 
rs17794012 2 128,756,194 2.1E-03 HS6ST1   
rs1500218 5 36,348,269 2.1E-03     
rs1257180 2 134,694,811 2.1E-03 MGAT5   
rs12357256 10 38,399,507 2.1E-03 ZNF33A   
rs2054894 3 178,025,981 2.1E-03 RP11-644C3.1   
rs12503047 4 80,793,266 2.1E-03     
rs12476995 2 127,512,490 2.1E-03     
rs10496978 2 145,806,644 2.1E-03 AC064865.2   
rs13031843 2 40,518,225 2.1E-03 SLC8A1 8.9E-04 
rs1891385 9 6,209,845 2.1E-03 IL33   
rs7695536 4 57,649,991 2.1E-03 IGFBP7   
rs10499305 6 155,450,109 2.1E-03 TIAM2   
rs2827308 21 22,545,897 2.1E-03 AP000705.7   
rs1888171 9 27,677,159 2.1E-03     
rs4977786 9 20,863,224 2.1E-03 KIAA1797   
rs4306251 10 34,050,796 2.1E-03     
rs2391333 13 105,964,695 2.1E-03 EFNB2 5.1E-03 
rs627222 7 6,094,981 2.1E-03 AC004895.4   
rs6441075 3 157,724,000 2.1E-03 KCNAB1   
rs7320401 13 71,051,569 2.1E-03 DACH1 1.7E-03 
rs1529252 7 53,913,754 2.1E-03     
rs9842314 3 163,261,159 2.1E-03     
rs10498611 14 86,598,814 2.1E-03     
rs4950949 1 201,077,185 2.1E-03     
rs7903907 10 67,541,780 2.1E-03 CTNNA3 8.7E-04 
rs206811 2 31,490,419 2.1E-03 XDH   
rs1417614 9 74,485,413 2.1E-03 TMC1   
rs9577637 13 111,876,415 2.1E-03     
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rs2815851 1 239,464,285 2.1E-03 RGS7   
rs719802 11 112,739,889 2.1E-03 TTC12   
rs11991859 8 145,809,866 2.1E-03 ARHGAP39   
rs2832877 21 30,738,594 2.1E-03 KRTAP15-1   
rs4777039 15 66,408,502 2.1E-03 ITGA11   
rs9993663 4 142,529,192 2.1E-03 #N/A   
rs454387     2.1E-03 KRT6A   
rs7336364 13 43,064,351 2.1E-03 ENOX1   
rs2995211 9 103,748,841 2.1E-03     
rs1830775 9 9,791,907 2.1E-03 RP11-527D15.1 4.7E-03 
rs610634     2.1E-03     
rs2842043 1 69,291,359 2.1E-03 RP11-424D14.1   
rs1009748 20 11,338,766 2.1E-03     
rs7557190 2 46,605,081 2.1E-03 ATP6V1E2   
rs4557782 9 38,694,680 2.1E-03     
rs1752582 10 30,031,941 2.1E-03 RP11-192N10.2   
rs2350277 3 141,326,327 2.2E-03 CLSTN2 1.3E-03 
rs1105314 16 77,130,043 2.2E-03 RP11-264L1.3 3.1E-03 
rs9563011 13 50,371,905 2.2E-03 RNASEH2B-AS1   
rs6099115 20 54,374,547 2.2E-03 AURKA 8.4E-03 
rs2011688 1 110,530,927 2.2E-03 SLC6A17   
rs1324568 6 18,604,350 2.2E-03     
rs9702737 10 1,743,194 2.2E-03 ADARB2 4.2E-03 
rs1859040 7 25,654,099 2.2E-03 AC003090.1   
rs1355782 3 132,970,356 2.2E-03 CPNE4 1.5E-03 
rs10889011 1 56,955,736 2.2E-03 C1orf168   
rs1247343 6 161,291,611 2.2E-03 RP3-428L16.1   
rs661891 10 6,567,350 2.2E-03 PRKCQ 2.1E-03 
rs2101634     2.2E-03     
rs593909 9 22,720,877 2.2E-03 RP11-399D6.2   
rs2959799 8 6,461,123 2.2E-03 CTD-2541M15.1 2.0E-03 
rs12551069 9 37,343,252 2.2E-03 ZCCHC7   
rs6928084 6 143,006,732 2.2E-03     
rs263125     2.2E-03 RP11-440G9.1   
rs2493383 6 68,418,391 2.2E-03     
rs1511476 6 23,959,285 2.2E-03     
rs8012283 14 50,303,910 2.2E-03 NIN   
rs3766186 1 1,152,298 2.2E-03 SDF4   
rs3742467 14 49,709,284 2.2E-03 SOS2   
rs4636555 10 18,943,611 2.2E-03 NSUN6 3.7E-03 
rs17241017 16 54,043,258 2.2E-03 RP11-212I21.2   
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rs1927430 6 167,120,803 2.2E-03 RPS6KA2   
rs4670230 2 38,099,220 2.2E-03 AC016689.1 8.4E-04 
rs1534154 3 120,793,720 2.2E-03 ADPRH   
rs1352671 9 32,033,985 2.2E-03     
rs17583618 10 122,496,218 2.2E-03     
rs1983208 3 163,236,803 2.2E-03     
rs1924353 13 107,923,485 2.2E-03     
rs10516278 4 14,129,536 2.2E-03 LINC00504   
rs11159412 14 79,235,135 2.2E-03 RP11-242P2.1 3.0E-03 
rs7036061 9 35,203,538 2.2E-03 UNC13B   
rs386574 19 6,600,564 2.2E-03     
rs2291382 3 132,671,218 2.2E-03 MRPL3   
rs10101045 8 3,055,131 2.2E-03 CSMD1 8.6E-05 
rs7647153 3 150,764,922 2.2E-03 WWTR1   
rs6601431 8 10,207,955 2.2E-03 MSRA 8.7E-03 
rs11137281 9 139,880,482 2.2E-03 EHMT1   
rs8018889 14 37,353,342 2.2E-03 TTC6   
rs955093 1 69,360,781 2.2E-03 RP11-424D14.1   
rs1336158 1 69,368,055 2.2E-03 RP11-424D14.1   
rs2720518 8 17,379,232 2.2E-03     
rs5762528 22 26,953,364 2.2E-03 TTC28   
rs10501120 11 29,853,673 2.2E-03 CTD-3138F19.1   
rs11864884 16 84,458,540 2.2E-03     
rs1110339 16 85,807,520 2.3E-03 RP11-899L11.3   
rs3813199 1 1,148,140 2.3E-03 SDF4   
rs1043469 12 102,690,890 2.3E-03 RP11-341G23.4   
rs12933937 16 86,306,049 2.3E-03 KLHDC4   
rs11714671 3 79,952,602 2.3E-03     
rs922306 1 238,240,914 2.3E-03 RPS7P5   
rs2973675 5 177,695,031 2.3E-03 COL23A1   
rs11110532 12 99,727,666 2.3E-03 ANO4   
rs2294757 6 133,076,791 2.3E-03 VNN1   
rs2744728 1 22,413,505 2.3E-03     
rs6908425 6 20,836,710 2.3E-03 CDKAL1 3.6E-03 
rs7002959 8 145,656,204 2.3E-03 CYHR1   
rs7783229 7 20,175,526 2.3E-03 MACC1 7.0E-03 
rs13177348 5 36,373,050 2.3E-03     
rs277576 9 34,796,065 2.3E-03     
rs4719495 7 17,289,208 2.3E-03 AC003075.4   
rs1364196 16 58,761,704 2.3E-03     
rs4872012 8 22,702,726 2.3E-03 RP11-459E5.1 1.7E-03 
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rs2236483 21 45,750,482 2.3E-03 COL18A1 2.6E-03 
rs6916705 6 15,135,265 2.3E-03 RP11-146I2.1   
rs1354298 10 111,195,892 2.3E-03     
rs10816129 9 9,445,711 2.3E-03 PTPRD 4.7E-03 
rs6451273 5 36,389,507 2.3E-03     
rs2888853 2 43,077,288 2.3E-03 AC016735.1   
rs7766508 6 161,713,309 2.3E-03 PARK2 8.8E-05 
rs3935137 12 89,833,922 2.3E-03 RP11-916O13.1   
rs4745127 9 70,386,196 2.3E-03 RP11-274B18.4   
rs4879956 9 36,136,652 2.3E-03 GLIPR2   
rs9852917 3 174,819,412 2.3E-03 NLGN1 1.9E-04 
rs12662891 6 22,683,075 2.3E-03 HDGFL1   
rs10732328 9 11,825,471 2.3E-03     
rs2862482 2 81,407,215 2.3E-03     
rs1420566 16 54,623,261 2.3E-03     
rs11720121 3 71,677,948 2.3E-03 FOXP1 2.2E-03 
rs4971588 2 49,408,487 2.3E-03     
rs7910208 10 15,362,323 2.3E-03 FAM171A1   
rs9423346 10 125,181,102 2.3E-03 RP11-338O1.2   
rs8024396 15 57,435,925 2.3E-03 RP11-356M20.3 4.2E-03 
rs944638 9 25,558,851 2.3E-03     
rs2189103 7 82,753,366 2.3E-03     
rs7248389 19 38,624,155 2.3E-03 PEPD   
rs288579 16 61,135,127 2.3E-03     
rs7040048 9 35,243,676 2.3E-03 UNC13B   
rs1543677 9 20,844,449 2.4E-03 KIAA1797   
rs10772682 12 13,516,717 2.4E-03     
rs1224147 13 107,754,759 2.4E-03 TNFSF13B   
rs1551411 9 2,621,932 2.4E-03 VLDLR   
rs1424223 16 26,216,163 2.4E-03     
rs9558743 13 105,793,586 2.4E-03     
rs391734 14 44,038,745 2.4E-03 FSCB   
rs1006146 17 66,872,466 2.4E-03     
rs964691 15 66,413,596 2.4E-03 ITGA11   
rs12057561 1 84,357,482 2.4E-03 PRKACB   
rs3771254 2 20,269,726 2.4E-03 SDC1   
rs3818532 6 33,787,785 2.4E-03 MNF1   
rs7089181 10 91,699,103 2.4E-03 RP11-478K7.2   
rs8001719 13 98,572,725 2.4E-03     
rs1451386 7 25,875,733 2.4E-03     
rs13090251 3 146,805,632 2.4E-03     
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rs1002154 20 36,511,034 2.4E-03 SNHG11   
rs1340721 13 68,498,950 2.4E-03     
rs1609516 16 78,843,385 2.4E-03 #N/A   
rs10505470 8 127,433,877 2.4E-03     
rs7674006 4 41,394,864 2.4E-03 LIMCH1   
rs3732568 3 135,998,026 2.4E-03 EPHB1 3.6E-03 
rs4843792 16 86,673,631 2.4E-03 RP11-863P13.5   
rs4746391 10 77,847,540 2.4E-03 C10orf11   
rs614705 4 31,051,457 2.4E-03     
rs517543 18 73,496,612 2.4E-03     
rs2383802 9 29,340,711 2.4E-03     
rs9873887 3 77,518,313 2.4E-03 ROBO2 2.5E-03 
rs7330144 13 48,154,504 2.4E-03     
rs225263 17 30,983,950 2.4E-03 AP2B1   
rs9925917 16 14,006,322 2.4E-03 CTD-2135D7.5   
rs921172 3 110,253,080 2.4E-03 MORC1 3.6E-03 
rs1105244 2 66,165,727 2.4E-03     
rs7645827 3 148,479,699 2.4E-03 RP11-635I10.1   
rs6590725 11 133,039,413 2.4E-03     
rs2396327 2 226,912,248 2.4E-03     
rs10971020 9 32,536,117 2.4E-03 AL353671.2   
rs4820001 22 16,207,684 2.4E-03     
rs4075049 16 28,150,790 2.5E-03     
rs10828834 10 18,852,440 2.5E-03 RP11-499P20.2 1.7E-03 
rs10518531 1 76,871,826 2.5E-03 ST6GALNAC3   
rs972246 7 8,551,314 2.5E-03 NXPH1 2.6E-03 
rs1452353 9 28,030,937 2.5E-03 LINGO2 2.2E-03 
rs1333657 6 10,404,322 2.5E-03     
rs632023     2.5E-03 KIRREL3-AS1   
rs12701401 7 4,099,925 2.5E-03 SDK1   
rs7593862 2 23,123,501 2.5E-03 AC016768.1   
rs12765658 10 65,214,873 2.5E-03 RP11-170M17.1   
rs10886106 10 119,382,644 2.5E-03     
rs10817039 9 112,349,358 2.5E-03 SVEP1 5.0E-03 
rs4366594 13 93,203,337 2.5E-03 GPC6 1.0E-03 
rs1384491 2 13,155,099 2.5E-03     
rs6100805 20 58,242,908 2.5E-03 RP5-1043L13.1   
rs8009813 14 67,896,272 2.5E-03 RAD51B 4.6E-04 
rs446149 4 31,099,803 2.5E-03     
rs2217843 12 70,431,403 2.5E-03 RAB21   
rs11790297 9 30,964,923 2.5E-03     
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rs7660498 4 2,214,663 2.5E-03 POLN   
rs2451255 6 159,430,804 2.5E-03     
rs185634 6 72,293,749 2.5E-03     
rs11011284 10 37,945,854 2.5E-03     
rs9564573 13 69,018,508 2.5E-03     
rs2893666 10 57,413,194 2.5E-03     
rs485028     2.5E-03     
rs10964759 9 20,915,921 2.5E-03 KIAA1797   
rs10758338 9 35,958,663 2.5E-03 YBX1P10   
rs9299057 9 7,819,623 2.5E-03 C9orf123   
rs1860394 12 3,309,312 2.5E-03 RP5-1063M23.2   
rs473773 1 187,893,806 2.5E-03     
rs6849536 4 20,049,574 2.5E-03 SLIT2   
rs2284757 1 166,629,786 2.6E-03     
rs11924144 3 187,328,277 2.6E-03 DGKG   
rs6539986 16 85,526,711 2.6E-03     
rs10483899 14 77,910,936 2.6E-03 NRXN3   
rs6414023 2 131,793,849 2.6E-03 PLEKHB2   
rs10773558 12 127,643,363 2.6E-03 TMEM132C   
rs2593943 3 110,172,911 2.6E-03 MORC1 3.6E-03 
rs7314616 12 97,280,155 2.6E-03     
rs288740 13 106,299,212 2.6E-03     
rs9559574 13 108,834,331 2.6E-03     
rs205185 16 25,484,728 2.6E-03     
rs7744253 6 31,131,503 2.6E-03 HCG22 7.4E-05 
rs1157392 3 117,997,607 2.6E-03 LSAMP   
rs1810807 9 32,774,838 2.6E-03 TMEM215   
rs4662808 2 128,895,709 2.6E-03     
rs8061866 16 25,713,267 2.6E-03 HS3ST4 4.3E-03 
rs17124656 14 51,395,835 2.6E-03 GNG2   
rs12220980 10 80,902,453 2.6E-03     
rs12454396 18 62,299,667 2.6E-03     
rs11843565 13 58,191,289 2.6E-03     
rs6122383 20 61,256,104 2.6E-03     
rs2902583 1 187,944,854 2.6E-03     
rs3827494 3 46,577,235 2.6E-03 LRRC2   
rs4132141 5 97,626,217 2.6E-03     
rs3904561 9 34,049,287 2.6E-03     
rs287548 13 72,803,784 2.6E-03     
rs7867247 9 8,695,964 2.6E-03 RP11-134K1.3 4.7E-03 
rs7838051 8 10,934,272 2.6E-03 XKR6   
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rs12116575 1 67,684,847 2.6E-03     
rs7527726 1 104,537,534 2.6E-03     
rs2585655 9 38,156,392 2.6E-03     
rs10919607 1 187,942,039 2.6E-03     
rs7638530 3 116,924,298 2.6E-03 GAP43   
rs7322238 13 107,355,800 2.6E-03     
rs4235137 4 43,411,555 2.6E-03     
rs813945 3 130,143,627 2.6E-03 KIAA1257   
rs1901744 8 27,990,118 2.6E-03 C8orf80   
rs9890721 17 45,958,502 2.6E-03 MYCBPAP   
rs4591550 4 162,223,074 2.6E-03     
rs10125105 9 110,266,009 2.6E-03     
rs328131 18 42,518,576 2.6E-03 ST8SIA5   
rs1330362 9 116,819,489 2.6E-03 TNC   
rs9322396 6 153,097,247 2.6E-03     
rs4854585 3 134,619,974 2.6E-03 BFSP2   
rs10810035 9 13,777,648 2.6E-03     
rs7865357     2.6E-03     
rs3012677 9 3,343,579 2.6E-03 RFX3   
rs1476081 7 17,245,819 2.6E-03     
rs3802217 8 141,177,159 2.6E-03 TRAPPC9   
rs1463230 3 151,517,246 2.6E-03     
rs10494624 1 188,004,012 2.6E-03     
rs945464 9 9,176,346 2.6E-03 PTPRD 4.7E-03 
rs9301099 13 105,483,574 2.6E-03     
rs11767557 7 142,819,261 2.6E-03 EPHA1   
rs1999603 13 70,881,342 2.7E-03     
rs6870249 5 145,652,624 2.7E-03 RBM27   
rs7922927 10 21,635,297 2.7E-03     
rs2740885 8 3,898,685 2.7E-03 CSMD1 8.6E-05 
rs4752360 10 121,732,421 2.7E-03     
rs1258094 9 77,863,413 2.7E-03 PCSK5 9.0E-03 
rs1521381 12 77,392,088 2.7E-03 RP11-171L9.1   
rs2767699 10 7,447,340 2.7E-03 SFMBT2 6.1E-03 
rs6064832 20 36,718,407 2.7E-03     
rs10486459 7 25,492,292 2.7E-03     
rs4337169 13 93,214,002 2.7E-03 GPC6 1.0E-03 
rs940222 15 59,156,777 2.7E-03 RORA 5.4E-04 
rs4866655 5 2,211,719 2.7E-03     
rs7511842 1 165,909,808 2.7E-03 RCSD1   
rs4466848 11 130,077,198 2.7E-03 C11orf44   
105 
 
rs10486725 7 41,839,234 2.7E-03     
rs12750699 1 165,540,384 2.7E-03 POU2F1   
rs1411418 9 10,978,308 2.7E-03     
rs7746344 6 52,646,130 2.7E-03 TMEM14A   
rs6075164 20 16,985,876 2.7E-03     
rs10494011 1 104,691,609 2.7E-03     
rs2999394 14 50,629,779 2.7E-03 RP11-1140I5.1 4.5E-03 
rs1337088 1 238,214,126 2.7E-03     
rs1829975 2 161,493,415 2.7E-03     
rs4463175 5 134,967,023 2.7E-03 CTC-321K16.1   
rs4937316 11 127,706,360 2.7E-03     
rs9877183 3 169,414,149 2.7E-03     
rs844030 12 100,209,553 2.7E-03 UTP20   
rs7635904 3 190,543,782 2.7E-03     
rs4574773 7 128,956,719 2.7E-03     
rs1202100 6 73,363,249 2.7E-03 RP3-474G15.1   
rs8017415 14 55,274,324 2.7E-03     
rs7045753 9 10,658,198 2.7E-03     
rs10869715 9 77,970,295 2.7E-03 PCSK5 9.0E-03 
rs2275612 1 95,140,004 2.7E-03 CNN3 1.8E-03 
rs2494711 6 26,757,400 2.7E-03 ZNF322   
rs359311 10 17,420,810 2.7E-03 ST8SIA6   
rs11733193 4 15,655,673 2.7E-03 PROM1   
rs7557891 2 77,623,499 2.8E-03 LRRTM4   
rs9625422 22 19,734,113 2.8E-03 P2RX6P   
rs181663 10 119,373,203 2.8E-03     
rs6958161 7 3,121,336 2.8E-03     
rs1833288 18 50,668,904 2.8E-03 RAB27B   
rs283832 2 79,090,597 2.8E-03     
rs2474589 10 38,461,927 2.8E-03     
rs9324756 5 153,044,424 2.8E-03 GRIA1 1.8E-03 
rs1057090 8 6,466,450 2.8E-03 CTD-2541M15.1 2.0E-03 
rs721936 9 89,472,969 2.8E-03 DAPK1   
rs4838650 10 49,664,276 2.8E-03 WDFY4 1.0E-03 
rs10904629 10 15,894,758 2.8E-03 FAM188A   
rs949664 12 69,368,222 2.8E-03 PTPRR   
rs2798616 10 91,661,625 2.8E-03 RP11-478K7.2   
rs625165 9 9,528,589 2.8E-03 PTPRD 4.7E-03 
rs6589938 11 122,011,218 2.8E-03     
rs4233734 2 29,490,544 2.8E-03 ALK 1.7E-03 
rs7805607 7 142,222,926 2.8E-03 TRBV30   
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rs3825644 14 64,481,252 2.8E-03 CHURC1   
rs294829 9 10,187,122 2.8E-03 PTPRD 4.7E-03 
rs2226409 21 19,390,523 2.8E-03     
rs6790188 3 26,612,410 2.8E-03     
rs4750334 10 13,339,929 2.8E-03     
rs2272631 8 144,406,670 2.8E-03 ZFP41   
rs1240891 13 67,980,008 2.8E-03     
rs2324805 13 40,740,546 2.8E-03 MTRF1   
rs4887794 16 73,521,965 2.8E-03 WDR59   
rs6571820 14 37,291,743 2.8E-03 TTC6   
rs2481556 9 30,253,627 2.8E-03     
rs1897499 3 14,726,880 2.8E-03 C3orf20 2.6E-03 
rs2014729 7 26,346,635 2.8E-03 SNX10   
rs8059958 16 63,780,673 2.8E-03 RP11-256I9.2   
rs1446109 2 80,391,930 2.8E-03 CTNNA2 6.0E-03 
rs364331 9 32,039,631 2.8E-03     
rs456699 16 82,391,190 2.8E-03 RP11-483P21.2   
rs815846 9 83,412,725 2.8E-03 TLE1 8.9E-03 
rs10488578 7 20,708,193 2.8E-03 ABCB5 1.0E-03 
rs4645956 8 128,819,394 2.8E-03 RP11-1136L8.1   
rs748445 4 6,006,173 2.8E-03 C4orf50   
rs7845577 8 80,063,146 2.8E-03     
rs4697205 4 20,733,627 2.8E-03 KCNIP4 5.5E-04 
rs1536761 13 46,485,423 2.8E-03     
rs1654658 19 59,886,493 2.9E-03     
rs2201554     2.9E-03     
rs1324751 13 104,784,307 2.9E-03     
rs4408557 16 77,920,300 2.9E-03     
rs7564226 2 129,017,050 2.9E-03     
rs2893386 13 110,456,068 2.9E-03     
rs732010 17 64,554,335 2.9E-03 ABCA9   
rs630973 9 14,370,945 2.9E-03 NFIB   
rs9826966 3 18,712,800 2.9E-03 AC105750.1   
rs2955195     2.9E-03     
rs6542824 2 109,411,568 2.9E-03 SH3RF3   
rs762625 1 201,411,924 2.9E-03 CHI3L1   
rs3988342 8 17,010,348 2.9E-03 EFHA2   
rs1422673 5 150,419,181 2.9E-03 TNIP1   
rs6788677 3 60,111,967 2.9E-03 FHIT 6.4E-04 
rs9378384 6 3,753,854 2.9E-03     
rs10513361 3 151,328,079 2.9E-03 RP11-167H9.4   
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rs6742210 2 40,469,024 2.9E-03 SLC8A1 8.9E-04 
rs2018728 10 44,837,353 2.9E-03 RP11-285G1.8   
rs6571907 14 38,752,236 2.9E-03 RP11-407N17.2   
rs12533743 7 24,435,064 2.9E-03     
rs560227 1 187,902,915 2.9E-03 RN5S73   
rs2971007 2 100,549,959 2.9E-03 PDCL3   
rs7098143 10 83,329,037 2.9E-03     
rs7515377 1 75,215,414 2.9E-03     
rs2216588 5 170,214,294 2.9E-03     
rs2383716 9 26,767,330 2.9E-03 RP11-18A15.1   
rs9503867 6 3,927,524 2.9E-03 RP3-406P24.1   
rs7557980 2 222,422,055 2.9E-03     
rs642722 6 74,327,295 2.9E-03 RP11-505P4.7   
rs16900289 6 157,926,844 3.0E-03 RP11-193H22.2   
rs10929183 2 237,293,840 3.0E-03     
rs7682973 4 5,996,007 3.0E-03     
rs174313 22 16,381,375 3.0E-03 DNAJA1P6   
rs897405 6 68,867,259 3.0E-03     
rs40184 5 1,448,077 3.0E-03 SLC6A3   
rs7656054 4 28,089,513 3.0E-03 RP11-123O22.1   
rs2380902 9 3,807,537 3.0E-03     
rs30882     3.0E-03     
rs1361636 10 25,757,917 3.0E-03 GPR158 3.5E-03 
rs7045369 9 19,444,906 3.0E-03 RP11-363E7.4   
rs1860447 17 64,543,052 3.0E-03 ABCA9   
rs6830109 4 21,101,543 3.0E-03 KCNIP4 5.5E-04 
rs1975802 16 66,843,348 3.0E-03 RP11-96D1.7   
rs6539999 16 85,636,503 3.0E-03     
rs7025945 9 31,960,850 3.0E-03     
rs9652250 13 82,059,194 3.0E-03     
rs1970288 10 24,334,617 3.0E-03 KIAA1217 1.4E-04 
rs4238915 16 25,643,984 3.0E-03 HS3ST4 4.3E-03 
rs6775393 3 189,987,692 3.0E-03 LPP 9.8E-04 
rs7098268 10 6,944,186 3.0E-03     
rs1122059 16 77,920,325 3.0E-03     
rs1769463 14 86,581,817 3.0E-03     
rs4755819 11 44,336,365 3.0E-03     
rs214950 6 152,750,003 3.0E-03 SYNE1 4.8E-03 
rs874838 2 85,275,202 3.0E-03 TCF7L1 6.2E-03 
rs449851 9 70,174,192 3.0E-03 PGM5   
rs17348854 8 4,811,985 3.0E-03 CSMD1 8.6E-05 
108 
 
rs162297 6 167,375,129 3.0E-03 FGFR1OP   
rs1998517 9 8,502,133 3.0E-03 PTPRD 4.7E-03 
rs7131752 12 79,999,969 3.0E-03 ACSS3   
rs12116744 1 160,447,080 3.0E-03 NOS1AP   
rs4274995 5 162,331,039 3.1E-03     
rs12675592     3.1E-03 RP11-134O21.1   
rs870427 10 133,889,881 3.1E-03 STK32C   
rs10112327 8 41,152,710 3.1E-03     
rs12962998 18 40,094,447 3.1E-03     
rs7205107 16 48,138,708 3.1E-03 ZNF423 8.5E-03 
rs7631529 3 39,261,829 3.1E-03     
rs2810442 13 75,639,902 3.1E-03     
rs13353497 3 46,573,381 3.1E-03 LRRC2   
rs3780354 9 36,198,626 3.1E-03 CLTA   
rs2127355 10 62,204,222 3.1E-03 CDK1   
rs4752744 11 1,674,842 3.1E-03 KRTAP5-6   
rs7704562 5 153,387,590 3.1E-03 FAM114A2   
rs8046811 16 8,385,232 3.1E-03     
rs958309 16 83,324,471 3.1E-03 USP10   
rs2753338 1 86,707,624 3.1E-03 CLCA1   
rs4493419 3 5,453,865 3.1E-03     
rs704649 1 243,667,431 3.1E-03 KIF26B 1.9E-03 
rs661827 13 68,322,752 3.1E-03     
rs13188129 5 180,052,650 3.1E-03 OR2AI1P   
rs517315 3 171,948,066 3.1E-03 CLDN11   
rs198178 16 24,128,125 3.1E-03 PRKCB   
rs7836666 8 143,257,639 3.1E-03     
rs4260187 2 213,397,743 3.1E-03 AC093865.1   
rs2088170 12 65,068,679 3.1E-03 GRIP1 1.0E-03 
rs10104977 8 119,793,078 3.1E-03     
rs1254722 6 2,524,404 3.1E-03     
rs7752020 6 164,924,604 3.1E-03     
rs13219162 6 15,124,166 3.1E-03 RP11-146I2.1   
rs1558308 7 23,703,035 3.1E-03 C7orf46   
rs4921416 5 161,109,151 3.1E-03 GLRXP3   
rs8071475 17 55,328,702 3.1E-03 RPS6KB1   
rs1877447 9 8,711,943 3.1E-03 PTPRD 4.7E-03 
rs6717256 2 77,625,651 3.1E-03 LRRTM4   
rs1859275 7 8,552,281 3.1E-03 NXPH1 2.6E-03 
rs1993802 3 112,078,092 3.1E-03     
rs2124209 9 3,809,902 3.1E-03 GLIS3   
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rs6073045 20 41,375,700 3.1E-03     
rs9288037 2 180,078,538 3.1E-03 ZNF385B 7.5E-03 
rs11968578 6 162,122,933 3.1E-03 PARK2 8.8E-05 
rs2553578 14 35,794,358 3.1E-03     
rs4746209 10 76,042,043 3.1E-03 ADK   
rs2812661 10 34,159,820 3.1E-03     
rs1452425 2 18,265,913 3.1E-03 KCNS3   
rs10515241 5 95,988,347 3.1E-03 CTD-2337A12.1   
rs299098 5 68,755,507 3.1E-03 MARVELD2   
rs245883 7 29,154,471 3.2E-03 CPVL   
rs884432 3 133,414,672 3.2E-03 CPNE4   
rs1000810 6 52,642,890 3.2E-03 RP1-152L7.5   
rs9838734 3 173,485,649 3.2E-03 FNDC3B 2.5E-03 
rs2391298 13 105,923,806 3.2E-03     
rs9321599 6 137,760,226 3.2E-03     
rs4933300 10 85,446,164 3.2E-03     
rs2110398 2 60,353,988 3.2E-03     
rs628957 11 75,509,963 3.2E-03 UVRAG   
rs4752161 10 120,203,154 3.2E-03     
rs3789867 9 116,915,509 3.2E-03 TNC 7.3E-03 
rs328753 12 70,472,924 3.2E-03 RP11-2H8.2   
rs10781655 12 131,554,987 3.2E-03     
rs10521320 16 54,133,662 3.2E-03 RP11-212I21.4 2.2E-03 
rs4605746 5 54,248,473 3.2E-03     
rs2921449 10 74,161,815 3.2E-03 MCU   
rs9379840 6 10,964,087 3.2E-03 TMEM14B   
rs663319 11 120,512,584 3.2E-03 TECTA   
rs318961 11 130,869,705 3.2E-03 NTM   
rs10919649 1 187,969,811 3.2E-03     
rs4362766 3 180,163,136 3.2E-03     
rs978716 20 58,928,466 3.2E-03     
rs17742423 6 73,588,333 3.2E-03 KCNQ5   
rs7104942 11 107,443,788 3.2E-03 CUL5   
rs12639674 4 14,171,117 3.2E-03 LINC00504   
rs1164624 5 74,178,621 3.2E-03 FAM169A   
rs8059056 16 76,324,079 3.2E-03 NUDT7   
rs1473822 9 8,716,153 3.2E-03 PTPRD 4.7E-03 
rs17329096 19 39,159,672 3.3E-03     
rs10513812 3 188,388,188 3.3E-03     
rs16842042 3 135,975,279 3.3E-03 EPHB1   
rs2756109 10 101,548,736 3.3E-03 ABCC2   
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rs431370 4 31,056,923 3.3E-03     
rs2271716 11 113,820,182 3.3E-03 REXO2   
rs4410448 3 110,295,956 3.3E-03 MORC1 3.6E-03 
rs7806681 7 17,194,647 3.3E-03     
rs430072 9 26,407,714 3.3E-03     
rs11130760 3 60,171,577 3.3E-03 FHIT 6.4E-04 
rs1028308 6 27,237,736 3.3E-03     
rs2817458 6 156,990,541 3.3E-03     
rs4540845     3.3E-03 AP005135.2   
rs2716454 11 24,710,115 3.3E-03 LUZP2 2.5E-03 
rs2064175 6 18,689,151 3.3E-03     
rs4431442 6 100,320,236 3.3E-03     
rs2049819 7 142,236,056 3.3E-03     
rs13118771 4 3,735,553 3.3E-03 AC141928.1   
rs597131 9 32,527,141 3.3E-03 TOPORS   
rs13223065 7 3,606,138 3.3E-03 SDK1   
rs150385 18 54,063,403 3.3E-03 NEDD4L   
rs7564926 2 212,670,237 3.3E-03 ERBB4 1.1E-03 
rs1462845 3 118,425,700 3.3E-03 LSAMP   
rs659406 1 64,028,606 3.3E-03 RP4-597J3.1   
rs731710 16 86,442,048 3.3E-03 SLC7A5   
rs9394708 6 40,708,020 3.3E-03     
rs2121053 1 66,761,087 3.3E-03     
rs1328857 6 73,414,549 3.3E-03 KCNQ5-IT1   
rs1372117 2 129,719,058 3.3E-03 AC079586.1   
rs9342947 6 73,222,052 3.3E-03     
rs2274512 14 32,899,031 3.3E-03 NPAS3 3.2E-04 
rs1925054 13 54,473,384 3.3E-03     
rs1407376 9 76,952,269 3.3E-03 OSTF1   
rs10418296 19 58,594,425 3.3E-03 ZNF765   
rs2029046 14 40,319,704 3.3E-03     
rs7333151 13 72,517,230 3.3E-03     
rs1108029 16 27,123,267 3.3E-03 JMJD5   
rs2252268 20 59,419,864 3.3E-03 CDH4 4.6E-04 
rs1406 19 35,006,952 3.3E-03 CCNE1   
rs7595482 2 38,106,517 3.3E-03 AC016689.1 8.4E-04 
rs8013122 14 35,500,214 3.3E-03 RP11-116N8.1   
rs7395920 11 1,920,888 3.3E-03 TNNT3   
rs3176774 12 9,808,373 3.3E-03 CD69   
rs7656798 4 75,606,837 3.3E-03     
rs672046 1 96,650,333 3.4E-03     
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rs7527078 1 4,590,753 3.4E-03     
rs9354868 6 63,043,165 3.4E-03 KHDRBS2   
rs2259969 9 78,132,776 3.4E-03 PCSK5 9.0E-03 
rs2906649 7 101,363,758 3.4E-03 CUX1 6.7E-03 
rs7149088 14 26,690,636 3.4E-03 RP11-384J4.2   
rs1344375 2 80,508,405 3.4E-03 CTNNA2 6.0E-03 
rs7198494 16 79,652,592 3.4E-03 RP11-303E16.8   
rs11738161 5 180,052,616 3.4E-03 OR2AI1P   
rs12992095 2 32,515,047 3.4E-03 BIRC6   
rs2543016 18 41,217,724 3.4E-03     
rs868421 8 138,668,249 3.4E-03     
rs6544336 2 40,481,216 3.4E-03 SLC8A1 8.9E-04 
rs8051651 16 58,280,250 3.4E-03     
rs6869332 5 60,165,118 3.4E-03 ELOVL7   
rs2368251 10 28,014,785 3.4E-03 MKX 6.8E-03 
rs943043 10 25,434,343 3.4E-03     
rs9973235 19 4,798,713 3.4E-03 PLIN3   
rs329076     3.4E-03 EGFEM1P   
rs2839798 12 61,552,251 3.4E-03 PPM1H 5.0E-03 
rs2381609 9 7,462,661 3.4E-03 RP11-87M1.1   
rs1000468     3.4E-03     
rs702718 5 57,794,308 3.4E-03 PLK2   
rs2705044 8 17,366,532 3.4E-03 ADAM24P   
rs1293044 6 70,290,602 3.4E-03     
rs34186 7 31,716,818 3.4E-03 PPP1R17   
rs1530439 10 63,315,965 3.4E-03     
rs15677 11 107,482,699 3.4E-03 RP11-144G7.2   
rs2289221 15 90,925,162 3.4E-03 RP11-386M24.3   
rs10085000 4 156,186,681 3.4E-03     
rs2959802 8 6,459,403 3.4E-03 CTD-2541M15.1 2.0E-03 
rs1702161 15 88,281,590 3.4E-03 RP11-493E3.2   
rs4688021 3 120,846,256 3.4E-03 POPDC2   
rs1981522 7 25,655,960 3.4E-03 AC003090.1   
rs2735246 3 126,961,752 3.4E-03 GS1-388B5.8   
rs1022909 13 107,468,774 3.4E-03     
rs2110699 14 88,974,191 3.4E-03 RP11-33N16.3   
rs3793179 7 158,152,317 3.4E-03 NCAPG2   
rs6064592 20 55,788,953 3.4E-03     
rs954197 9 2,473,942 3.4E-03 RP11-125B21.2   
rs1917286 7 51,536,912 3.4E-03     
rs577876 6 161,843,145 3.4E-03 PARK2 8.8E-05 
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rs2135488 13 70,515,776 3.4E-03 LINC00348   
rs9295730 6 27,236,785 3.4E-03     
rs890125 11 29,972,772 3.4E-03     
rs2862079 3 154,694,531 3.5E-03 RP11-23D24.2   
rs9909324 17 55,401,538 3.5E-03 RNFT1   
rs3778229 6 161,564,530 3.5E-03 AGPAT4 3.3E-03 
rs1111367 10 20,313,589 3.5E-03 PLXDC2 6.4E-03 
rs1955985 14 43,649,706 3.5E-03 RP11-305B6.3   
rs183376 4 13,910,107 3.5E-03     
rs6937168 6 85,187,128 3.5E-03 RP1-90L14.1   
rs2950 6 11,458,251 3.5E-03 NEDD9   
rs11114788 12 80,123,692 3.5E-03 ACSS3   
rs213207 6 33,349,147 3.5E-03 VPS52   
rs10055973 5 180,052,524 3.5E-03 OR2AI1P   
rs9862715 3 61,011,332 3.5E-03 FHIT 6.4E-04 
rs11185546 3 197,787,935 3.5E-03 FBXO45   
rs1078373 19 36,492,970 3.5E-03 TSHZ3   
rs3111643 5 53,722,645 3.5E-03 RP11-461C13.1   
rs1152944 12 68,684,239 3.5E-03 RP11-611E13.2   
rs2168358 15 90,875,894 3.5E-03     
rs4968318 17 42,806,893 3.5E-03 C17orf57   
rs11257622 10 12,335,345 3.5E-03 CDC123   
rs1889380 14 56,055,419 3.5E-03 RP11-624J12.1   
rs2220602 5 29,131,883 3.5E-03     
rs4945876 6 111,522,333 3.5E-03 SLC16A10   
rs2177308 17 44,564,860 3.5E-03 B4GALNT2   
rs3733397 4 4,900,303 3.5E-03     
rs234853 11 2,807,404 3.5E-03 KCNQ1 3.8E-03 
rs533045 1 187,929,464 3.5E-03     
rs747417 8 41,277,161 3.5E-03 SFRP1   
rs928195 13 111,913,111 3.5E-03     
rs1528430 2 151,042,707 3.5E-03 RND3   
rs6564744 16 78,765,658 3.5E-03 RP11-525K10.3   
rs842304 9 7,672,601 3.5E-03     
rs1674815 7 16,714,742 3.5E-03 BZW2   
rs4515870 10 21,791,617 3.5E-03     
rs754048 11 132,520,788 3.6E-03 OPCML 2.4E-04 
rs2812234 13 50,185,815 3.6E-03 DLEU7 7.8E-03 
rs7082368 10 20,290,116 3.6E-03 PLXDC2 6.4E-03 
rs2355597 5 22,439,701 3.6E-03 CDH12 5.3E-03 
rs7091304 10 21,597,792 3.6E-03     
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rs4558864     3.6E-03     
rs7629257 3 165,959,187 3.6E-03 RP11-71H9.1   
rs2163050 2 41,680,242 3.6E-03 AC010739.1   
rs1407045 6 26,584,134 3.6E-03 BTN2A1   
rs1471239 12 83,524,053 3.6E-03     
rs6904395 6 2,388,180 3.6E-03     
rs872288 2 45,968,529 3.6E-03 PRKCE   
rs4979816 10 79,901,867 3.6E-03 RP11-90J7.3   
rs7770766 6 5,330,325 3.6E-03 FARS2   
rs720651 13 25,129,946 3.6E-03 ATP8A2   
rs17663979 5 72,865,786 3.6E-03     
rs6789646 3 129,698,465 3.6E-03 RP11-475N22.4   
rs4927600 2 1,340,999 3.6E-03 SNTG2 7.5E-03 
rs2566758 1 68,405,071 3.6E-03 RP11-518D3.3   
rs12756859 1 68,781,782 3.6E-03 RP4-694A7.4   
rs12463274 19 14,819,042 3.6E-03     
rs12955031 18 62,401,259 3.6E-03 CDH19 1.7E-04 
rs918498 5 150,439,981 3.6E-03 TNIP1   
rs10470540 3 193,152,780 3.6E-03 RP11-655G22.2   
rs11646219 16 85,654,078 3.6E-03 RP11-134D3.1   
rs2549513 16 78,108,228 3.6E-03 RP11-467I17.1   
rs12585282 13 108,857,114 3.6E-03     
rs1057091 8 6,487,952 3.6E-03 CTD-2541M15.1 2.0E-03 
rs979525 9 28,470,661 3.6E-03 LINGO2 2.2E-03 
rs7120230 11 70,617,976 3.6E-03 SHANK2   
rs7577867 2 128,609,678 3.6E-03 AC108059.4   
rs7544722 1 72,179,997 3.6E-03 NEGR1   
rs1503673 3 115,430,553 3.6E-03 RP11-553L6.3   
rs2818849 10 58,347,388 3.7E-03     
rs1053230 1 239,821,971 3.7E-03 OPN3   
rs2485945 1 2,873,792 3.7E-03     
rs3106818 3 170,458,317 3.7E-03 MECOM   
rs6979475 7 24,884,499 3.7E-03 OSBPL3   
rs277344 1 75,092,849 3.7E-03     
rs7795793 7 17,192,132 3.7E-03     
rs12741316 1 238,672,355 3.7E-03 FMN2 2.3E-03 
rs12199650     3.7E-03 MCM3   
rs7680019 4 22,165,683 3.7E-03     
rs1435192 18 39,314,102 3.7E-03     
rs611652 12 5,110,030 3.7E-03     
rs7917682 10 73,845,889 3.7E-03 MICU1   
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rs4334286 16 80,270,325 3.7E-03 CMIP   
rs4771519 13 105,495,523 3.7E-03     
rs7143959 14 50,315,416 3.7E-03 NIN   
rs276504 6 137,394,212 3.7E-03 IL20RA   
rs11720523 3 71,627,860 3.7E-03 FOXP1 2.2E-03 
rs251069 5 29,116,075 3.7E-03     
rs9381218 6 42,846,727 3.7E-03 KIAA0240   
rs1386866 3 164,154,735 3.7E-03     
rs2305862 12 100,281,661 3.7E-03 UTP20   
rs7339421 13 101,576,026 3.7E-03 FGF14 2.6E-03 
rs2342845 14 55,424,344 3.7E-03     
rs1073644 10 77,705,677 3.7E-03 C10orf11   
rs7077721 10 91,739,092 3.7E-03     
rs1527757 2 156,475,079 3.7E-03     
rs796985 6 24,556,040 3.7E-03 GPLD1   
rs8050142 16 78,651,415 3.7E-03     
rs1157067 9 9,187,812 3.7E-03 PTPRD 4.7E-03 
rs3828712 6 158,847,639 3.7E-03 TULP4   
rs11756366 6 153,893,287 3.7E-03     
rs7020545     3.7E-03     
rs2827641 21 22,917,993 3.7E-03     
rs11116190 12 75,837,346 3.7E-03     
rs9567204 13 42,970,438 3.7E-03 ENOX1   
rs157350 5 156,072,147 3.7E-03 SGCD   
rs9521239 13 108,684,428 3.8E-03     
rs181662 10 119,372,445 3.8E-03     
rs12340535 9 3,400,838 3.8E-03 RFX3   
rs8061885 16 48,143,565 3.8E-03 ZNF423 8.5E-03 
rs9342910 6 72,753,745 3.8E-03 RIMS1   
rs6861772 5 55,307,378 3.8E-03 IL6ST   
rs471377 18 39,265,343 3.8E-03     
rs10789262 1 41,210,004 3.8E-03     
rs7589480 2 81,311,990 3.8E-03     
rs1598997 3 39,960,397 3.8E-03 MYRIP   
rs12633941 3 39,967,978 3.8E-03 MYRIP   
rs7459662 8 29,802,177 3.8E-03 RP11-94H18.1   
rs10892301 11 118,240,686 3.8E-03     
rs1017002 7 8,717,957 3.8E-03 NXPH1 2.6E-03 
rs1750836 1 7,443,514 3.8E-03 CAMTA1 8.8E-06 
rs1009671 2 37,946,350 3.8E-03 LINC00211   
rs8127595 21 37,271,110 3.8E-03 HLCS   
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rs2078527 6 25,382,624 3.8E-03 LRRC16A   
rs11678304 2 81,362,633 3.8E-03     
rs984119 9 10,630,526 3.8E-03     
rs9564466 13 67,936,455 3.8E-03     
rs16939801 18 12,737,129 3.8E-03     
rs4683428 3 140,951,811 3.8E-03     
rs1035533 16 82,208,011 3.8E-03 CDH13 1.9E-03 
rs2768395 1 72,174,618 3.8E-03 NEGR1   
rs1535564 13 25,165,518 3.8E-03 ATP8A2   
rs3808864 9 35,805,613 3.8E-03 SPAG8   
rs2214976 7 25,688,838 3.8E-03 AC003090.1   
rs654894 6 153,885,996 3.8E-03     
rs1930386 9 80,756,308 3.8E-03     
rs12131051 1 187,931,480 3.8E-03     
rs1218486 10 14,425,271 3.8E-03 FRMD4A   
rs704014 10 80,502,780 3.8E-03 ZMIZ1 1.7E-03 
rs886836 7 25,695,009 3.8E-03 CTA-242H14.1   
rs6033079 20 11,201,554 3.8E-03 RP4-734C18.1   
rs277606 9 34,775,308 3.8E-03     
rs7581641 2 8,543,557 3.8E-03     
rs1386288 3 151,326,866 3.8E-03 RP11-167H9.4   
rs1976437 1 187,905,803 3.9E-03 RN5S73   
rs7150477 14 97,738,741 3.9E-03 RP11-61O1.1   
rs267339 6 104,985,242 3.9E-03     
rs10951092 7 25,705,885 3.9E-03 AC003090.1   
rs996139 6 115,695,172 3.9E-03     
rs2724785 10 12,493,038 3.9E-03 CAMK1D 2.1E-03 
rs3112586 16 51,241,545 3.9E-03 RP11-297L17.1   
rs6030188 20 34,987,036 3.9E-03 SAMHD1   
rs6761200 2 18,189,686 3.9E-03 KCNS3   
rs1126644 1 158,915,173 3.9E-03 RP11-404F10.2   
rs7851558 9 3,361,304 3.9E-03 RFX3   
rs849923 7 29,455,521 3.9E-03 CHN2 3.9E-04 
rs4747964 10 12,217,003 3.9E-03 SEC61A2   
rs556808 4 75,290,591 3.9E-03 MTHFD2L 5.0E-04 
rs10046843 9 34,621,159 3.9E-03 ARID3C   
rs1353005 4 54,940,654 3.9E-03 RP11-231C18.2   
rs1477018 16 50,615,390 3.9E-03 RP11-152O14.5   
rs11116589 12 83,676,432 3.9E-03     
rs4841511 8 11,116,669 3.9E-03     
rs10020207 4 58,401,219 3.9E-03     
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rs7764728 6 14,776,436 3.9E-03     
rs946808 9 81,309,730 3.9E-03 RP11-375O18.2   
rs11620185 13 107,215,219 3.9E-03 FAM155A 5.4E-04 
rs11104713 12 86,918,902 3.9E-03 C12orf50 7.5E-03 
rs955738 2 179,483,397 3.9E-03 CCDC141   
rs7603075 2 41,686,382 3.9E-03     
rs1296513 10 91,671,324 3.9E-03 RP11-478K7.2   
rs7629791 3 129,701,100 3.9E-03 RP11-475N22.4   
rs9385517 6 99,357,637 3.9E-03     
rs8049837 16 29,996,939 3.9E-03 PPP4C   
rs470039 22 45,951,921 3.9E-03 TBC1D22A   
rs929873 16 72,014,878 3.9E-03 RP11-140I24.1   
rs960908 9 19,448,939 3.9E-03 RP11-363E7.3   
rs7639810 3 169,526,023 3.9E-03 EGFEM1P   
rs2413979 15 48,008,638 3.9E-03 ATP8B4   
rs7635505 3 64,624,234 3.9E-03 ADAMTS9 1.2E-03 
rs12191536 6 49,335,964 3.9E-03     
rs1022034 12 87,442,874 3.9E-03 KITLG   
rs2036535 17 28,775,126 4.0E-03 ASIC2 3.3E-03 
rs6951428 7 142,305,806 4.0E-03     
rs7193701 16 66,742,661 4.0E-03 NFATC3   
rs10827831 10 38,150,819 4.0E-03 RP11-162G10.1   
rs4690912 4 159,891,509 4.0E-03     
rs1001396 7 4,685,157 4.0E-03 FOXK1   
rs199635 6 72,282,724 4.0E-03     
rs6118746 20 9,749,670 4.0E-03 PAK7   
rs10759371 9 111,626,418 4.0E-03 PALM2   
rs2976290 8 26,098,961 4.0E-03     
rs1990602 7 12,088,321 4.0E-03     
rs1020265 4 4,378,813 4.0E-03 RP11-265O12.1   
rs7602256 2 150,741,717 4.0E-03 AC016682.1   
rs7515865 1 169,648,370 4.0E-03     
rs7865406 9 35,167,345 4.0E-03 UNC13B   
rs2151779 14 56,077,176 4.0E-03 RP11-624J12.1   
rs10508415 10 10,747,950 4.0E-03     
rs1914609 4 18,429,784 4.0E-03     
rs10818289 9 121,033,329 4.0E-03 DBC1 9.3E-03 
rs1530793 16 53,005,467 4.0E-03     
rs10498688 6 17,930,753 4.0E-03 KIF13A 1.1E-03 
rs263315 2 157,747,471 4.0E-03     
rs7662460 4 28,090,156 4.0E-03 RP11-123O22.1   
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rs11717776 3 199,053,956 4.0E-03 LRCH3   
rs1171627 10 61,130,981 4.0E-03 SLC16A9   
rs1862504 16 26,429,776 4.0E-03     
rs17722373 6 49,271,152 4.0E-03     
rs11190578 10 102,228,943 4.0E-03 WNT8B   
rs2298075 10 102,237,398 4.0E-03 WNT8B   
rs10249873 7 91,663,104 4.0E-03 AC000120.7   
rs8004799 14 50,853,500 4.0E-03 LINC00519   
rs2033348 1 68,347,517 4.0E-03 RP11-518D3.1   
rs9511692 13 24,679,352 4.0E-03 RPL23AP69   
rs6914262 6 154,356,609 4.0E-03     
rs6708183 2 78,238,254 4.0E-03     
rs904510 13 67,986,542 4.0E-03     
rs4725029 7 7,796,040 4.0E-03 AC006465.3   
rs7027828 9 20,214,476 4.0E-03     
rs658230 10 6,548,569 4.1E-03 PRKCQ 2.1E-03 
rs10905785 10 10,765,693 4.1E-03     
rs2909277 18 26,352,432 4.1E-03     
rs742019 22 47,094,527 4.1E-03     
rs396648 1 30,765,592 4.1E-03     
rs4632572 3 106,314,295 4.1E-03     
rs10250643 7 24,502,175 4.1E-03     
rs2913788 5 177,690,370 4.1E-03 COL23A1   
rs10783046 1 96,688,425 4.1E-03 EEF1A1P11   
rs4376154 4 134,044,421 4.1E-03 RP11-404I7.2   
rs2287270 2 15,568,019 4.1E-03 NBAS   
rs1959936 14 40,578,949 4.1E-03     
rs9930956 16 2,025,296 4.1E-03 SLC9A3R2   
rs176127 18 60,951,384 4.1E-03     
rs4937333 11 127,835,730 4.1E-03 ETS1 8.7E-03 
rs1434477 9 26,744,019 4.1E-03 RP11-18A15.1   
rs1854042 13 21,269,252 4.1E-03     
rs2585833 17 53,379,612 4.1E-03 CUEDC1   
rs6887452 5 148,763,960 4.1E-03 IL17B   
rs6795768 3 173,500,799 4.1E-03 FNDC3B 2.5E-03 
rs4471130 9 29,743,415 4.1E-03     
rs4627208 13 70,909,008 4.1E-03 DACH1   
rs528001 1 187,961,920 4.1E-03     
rs7761494 6 74,782,377 4.1E-03     
rs1499570 6 119,871,818 4.1E-03     
rs6662147 1 91,839,182 4.1E-03 RP11-91I11.1   
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rs8060494 16 78,808,972 4.1E-03 RP11-525K10.3   
rs859548 7 39,025,282 4.1E-03 POU6F2 5.4E-03 
rs6938648 6 3,954,503 4.1E-03     
rs4300522 13 67,007,248 4.2E-03     
rs983121 9 12,479,681 4.2E-03     
rs17087900 13 63,972,138 4.2E-03     
rs12205310 6 26,713,843 4.2E-03     
rs1624281 10 30,029,188 4.2E-03 RP11-192N10.2   
rs7662456 4 63,897,510 4.2E-03 RP11-553E5.1   
rs4959569 6 1,478,446 4.2E-03     
rs2189460 7 8,549,029 4.2E-03 NXPH1 2.6E-03 
rs453585 3 18,609,876 4.2E-03     
rs604168 12 67,957,425 4.2E-03 CPSF6   
rs9930698 16 77,892,824 4.2E-03     
rs1736058 8 11,708,450 4.2E-03 FDFT1   
rs7664704 4 160,085,626 4.2E-03 C4orf45 3.1E-03 
rs11644803 16 58,771,222 4.2E-03     
rs9521936 13 110,234,390 4.2E-03     
rs2070844 5 149,803,978 4.2E-03 RPS14   
rs1446372 13 68,673,098 4.2E-03     
rs6003620 22 21,995,356 4.2E-03 AP000343.2   
rs1355781 3 133,083,145 4.2E-03 CPNE4 1.5E-03 
rs712332 14 36,336,400 4.2E-03 RP11-81F13.1 5.5E-03 
rs4626584 8 52,824,649 4.2E-03 PXDNL 3.0E-03 
rs1351518 11 107,119,468 4.2E-03 CTD-2651C21.3   
rs2155945 18 27,537,143 4.2E-03     
rs6086103 20 7,489,572 4.2E-03     
rs7821932 8 124,699,533 4.2E-03 CTD-2552K11.2   
rs10486076 7 13,721,999 4.2E-03     
rs7159869 14 50,390,000 4.2E-03 RP11-218E20.2   
rs1890854 13 68,285,687 4.2E-03     
rs11647213 16 85,228,015 4.2E-03 RP11-463O9.6   
rs9326078 1 68,224,976 4.2E-03 RP11-518D3.1   
rs4584211 9 77,746,957 4.2E-03 PCSK5 9.0E-03 
rs1959930 14 40,565,658 4.2E-03     
rs4687833 3 120,159,182 4.2E-03 IGSF11 2.0E-05 
rs6118062 20 8,035,581 4.2E-03     
rs917526 5 134,954,974 4.2E-03 CTC-321K16.1   
rs1959730 14 82,471,511 4.2E-03     
rs10460872 3 168,232,433 4.2E-03     
rs10771180 12 8,940,500 4.2E-03     
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rs11679483 2 161,232,395 4.2E-03     
rs2138599 11 21,070,884 4.2E-03 NELL1 1.2E-03 
rs382854 6 8,960,568 4.2E-03     
rs1507160 3 154,600,394 4.3E-03 RP11-23D24.2   
rs7919387 10 85,427,803 4.3E-03 RP11-344L13.2   
rs4948491 10 63,366,895 4.3E-03 ARID5B 1.7E-03 
rs2494928 1 69,342,987 4.3E-03 RP11-424D14.1   
rs9859634 3 65,599,769 4.3E-03 MAGI1 7.6E-03 
rs11816696 10 25,402,896 4.3E-03     
rs2300077 6 133,072,185 4.3E-03 VNN1   
rs1158541 12 13,737,940 4.3E-03 GRIN2B 8.6E-03 
rs2765440 10 90,259,547 4.3E-03 RNLS   
rs12586346 14 57,536,347 4.3E-03 C14orf37   
rs4694691 4 75,602,196 4.3E-03     
rs650329 18 42,533,890 4.3E-03 ST8SIA5   
rs2077820 2 79,007,802 4.3E-03     
rs1447522 2 30,145,982 4.3E-03 AC016907.3   
rs11877408 18 62,399,126 4.3E-03 CDH19 1.7E-04 
rs7951076 11 3,847,429 4.3E-03 STIM1   
rs9325808 8 17,257,500 4.3E-03 MTMR7   
rs2169641 3 82,823,888 4.3E-03     
rs10827292 10 34,145,360 4.3E-03     
rs7207403 17 44,565,505 4.3E-03 B4GALNT2   
rs7568281 2 192,452,056 4.3E-03 DNAJB1P1   
rs1327504 9 18,893,330 4.3E-03 ADAMTSL1 1.1E-03 
rs2067678 3 169,423,008 4.3E-03     
rs9874286 3 169,425,673 4.3E-03     
rs12414710 10 33,995,752 4.3E-03     
rs4407257 2 117,540,267 4.3E-03     
rs9925302 16 85,223,804 4.3E-03 RP11-463O9.6   
rs10920503 1 201,082,609 4.3E-03 RP11-480I12.5   
rs9341423 6 74,224,127 4.3E-03 MTO1   
rs10485541 20 15,646,025 4.3E-03 MACROD2 4.1E-03 
rs9818534 3 185,960,449 4.3E-03 RP11-329B9.1   
rs7122702 11 120,013,510 4.4E-03 GRIK4   
rs2948286 8 8,167,570 4.4E-03     
rs12495947 3 127,254,388 4.4E-03 SLC41A3   
rs9458257 6 161,783,940 4.4E-03 PARK2 8.8E-05 
rs1361115 1 235,388,592 4.4E-03 RYR2 5.4E-04 
rs6736347 2 125,214,817 4.4E-03 CNTNAP5   
rs719721 20 50,408,904 4.4E-03 RP4-723E3.1   
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rs7223092 17 28,355,538 4.4E-03     
rs2070454 22 22,426,674 4.4E-03 VPREB3   
rs1327510 9 13,743,249 4.4E-03     
rs1330351 9 116,880,743 4.4E-03 TNC 7.3E-03 
rs10505836 12 19,179,775 4.4E-03 PLEKHA5   
rs8180086 3 152,520,570 4.4E-03 MED12L   
rs1915282 12 72,153,974 4.4E-03 RP11-314D7.4   
rs632177 6 7,852,138 4.4E-03 TXNDC5   
rs2156283 18 48,684,273 4.4E-03 DCC 7.6E-03 
rs2576542     4.4E-03 RP11-212I21.2   
rs874952 2 65,462,029 4.4E-03 SPRED2   
rs11664283 18 640,968 4.4E-03 C18orf56   
rs10982926 9 117,608,644 4.4E-03     
rs2382688 7 102,891,644 4.4E-03 CTB-107G13.1   
rs2881068 2 45,955,890 4.4E-03 PRKCE   
rs10497193 2 158,417,924 4.4E-03 ACVR1   
rs9498701 6 102,336,911 4.4E-03 GRIK2 9.7E-04 
rs10870381 10 39,098,677 4.4E-03 RP11-453N3.1   
rs13196989 6 184,373 4.4E-03     
rs1582029 9 17,233,746 4.4E-03 CNTLN   
rs1056984 20 60,989,487 4.4E-03 DIDO1   
rs12261792 10 11,949,902 4.4E-03 RP11-401F24.4   
rs2049581 2 156,738,975 4.4E-03     
rs2039803 9 109,751,762 4.4E-03     
rs2271058 19 4,803,106 4.4E-03 PLIN3   
rs791881 10 89,398,226 4.4E-03 RP11-57C13.6   
rs4772933 13 107,458,063 4.5E-03     
rs7961199 12 13,515,616 4.5E-03     
rs633719 9 9,516,138 4.5E-03 PTPRD 4.7E-03 
rs2787136     4.5E-03     
rs1158542 14 40,443,450 4.5E-03     
rs2967436 19 41,739,312 4.5E-03 ZNF529   
rs830605 3 71,691,966 4.5E-03 FOXP1 2.2E-03 
rs2654417 3 106,285,277 4.5E-03     
rs17678470 13 100,639,945 4.5E-03 NALCN 2.2E-03 
rs850509 12 109,726,744 4.5E-03     
rs9810554 3 82,076,783 4.5E-03     
rs10778943 12 82,062,811 4.5E-03     
rs1539089 10 102,211,414 4.5E-03 WNT8B   
rs181649 10 119,366,617 4.5E-03     
rs2887041 10 25,477,868 4.5E-03     
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rs11001617 10 77,549,112 4.5E-03 C10orf11   
rs12141361 1 14,599,072 4.5E-03     
rs4787367 16 26,255,281 4.5E-03 AC009158.1   
rs316 8 19,862,716 4.5E-03 LPL   
rs1012775 7 24,815,354 4.5E-03 OSBPL3   
rs6466523 7 114,748,659 4.5E-03     
rs1949880 7 39,062,913 4.5E-03 POU6F2 5.4E-03 
rs7100857 10 44,918,561 4.5E-03 RP11-445N18.4   
rs631871 2 165,028,234 4.5E-03     
rs7324781 13 95,032,754 4.5E-03 DZIP1   
rs6783997 3 110,179,807 4.5E-03 MORC1 3.6E-03 
rs2246219 3 110,141,846 4.5E-03 GUCA1C   
rs10791048 11 129,162,426 4.5E-03 RP11-507F16.1   
rs886834 7 28,987,861 4.5E-03     
rs6976396 7 28,789,977 4.5E-03 CREB5 2.4E-04 
rs17319192 8 3,032,637 4.5E-03 CSMD1 8.6E-05 
rs4473785 5 172,918,217 4.6E-03 CTB-33O18.1   
rs1483632 3 177,516,393 4.6E-03     
rs12209342 6 65,936,970 4.6E-03 EYS 4.5E-04 
rs4371513 3 64,609,618 4.6E-03 ADAMTS9 1.2E-03 
rs10099847 8 3,030,072 4.6E-03 CSMD1 8.6E-05 
rs721590 8 134,599,750 4.6E-03 ST3GAL1   
rs9868350 3 146,840,283 4.6E-03     
rs951043 12 79,725,769 4.6E-03 LIN7A   
rs1016126 1 72,208,991 4.6E-03 NEGR1   
rs331702 5 124,854,142 4.6E-03 RP11-756H20.1   
rs10503002 18 51,260,200 4.6E-03 TCF4 6.1E-03 
rs1862560 5 28,769,666 4.6E-03     
rs980798 1 187,938,851 4.6E-03     
rs3752864 17 42,826,227 4.6E-03 C17orf57   
rs1324188 9 13,597,227 4.6E-03     
rs697199 12 102,566,866 4.6E-03 STAB2 1.7E-03 
rs1359712 9 87,506,706 4.6E-03 AGTPBP1   
rs955619 14 83,206,531 4.6E-03     
rs17598689 2 63,088,057 4.6E-03 EHBP1   
rs10757753 9 28,506,764 4.6E-03 LINGO2 2.2E-03 
rs1494913 8 108,957,826 4.6E-03     
rs2049974 22 35,272,269 4.6E-03     
rs1425316 4 58,210,076 4.6E-03 RP11-4O3.1   
rs734584 14 39,744,190 4.6E-03     
rs724291 7 33,765,662 4.6E-03     
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rs1993853 10 67,443,315 4.6E-03 CTNNA3 8.7E-04 
rs2723891 12 89,482,389 4.6E-03     
rs17044607 12 76,878,115 4.6E-03 NAV3 1.2E-03 
rs1465727 12 127,972,538 4.6E-03 GLT1D1   
rs7219526 17 9,236,034 4.6E-03 STX8 8.5E-04 
rs1340363 10 72,849,622 4.6E-03 CDH23 4.7E-03 
rs891943 5 149,667,306 4.6E-03 ARSI   
rs1328413 9 81,011,093 4.6E-03     
rs1927432 6 167,121,023 4.6E-03 RPS6KA2   
rs4679302 3 128,110,471 4.6E-03 CHCHD6   
rs702045 3 126,332,460 4.6E-03 SLC12A8   
rs328847 9 7,674,244 4.6E-03     
rs6945120 7 46,981,927 4.6E-03 AC004870.4   
rs17751083 12 96,037,531 4.6E-03 RP11-541G9.1   
rs1995892 11 75,323,598 4.7E-03 UVRAG   
rs3887078 8 41,047,280 4.7E-03     
rs7861296 9 28,616,095 4.7E-03 LINGO2 2.2E-03 
rs7893862 10 126,733,086 4.7E-03 CTBP2 3.7E-03 
rs1074282 2 117,711,193 4.7E-03     
rs9465985 6 21,293,569 4.7E-03 CDKAL1 3.6E-03 
rs9881418 3 144,954,522 4.7E-03 SLC9A9 1.6E-04 
rs923757 10 25,397,590 4.7E-03     
rs7107024 11 108,408,545 4.7E-03 RP11-25I9.2   
rs310282     4.7E-03 RP11-175E9.1   
rs1561 17 8,204,059 4.7E-03 AC135178.1   
rs3861699 1 84,303,705 4.7E-03     
rs6796074 3 103,316,740 4.7E-03 ZPLD1   
rs9985400 3 141,329,869 4.7E-03 CLSTN2 1.3E-03 
rs2776932 10 33,632,412 4.7E-03 NRP1 2.9E-04 
rs2832861 21 30,716,253 4.7E-03 KRTAP13-3   
rs901363 6 159,098,333 4.7E-03 SYTL3   
rs13387889 2 128,604,678 4.7E-03 UGGT1   
rs10946673 6 24,231,293 4.7E-03 NRSN1   
rs512384 21 39,909,757 4.7E-03 C21orf88   
rs884540 9 8,250,902 4.7E-03     
rs11861057 16 81,065,551 4.7E-03     
rs1346860 2 82,181,397 4.7E-03     
rs7028831 9 80,703,417 4.7E-03     
rs2230805 9 106,663,850 4.7E-03 ABCA1 6.8E-03 
rs4745511 9 77,952,115 4.7E-03 PCSK5 9.0E-03 
rs788219 10 27,513,241 4.7E-03 MASTL   
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rs2858223 22 31,349,789 4.7E-03 SYN3   
rs6589804 11 119,666,851 4.8E-03 POU2F3   
rs242965 10 119,240,201 4.8E-03 EMX2OS   
rs7853898 9 26,757,510 4.8E-03 RP11-18A15.1   
rs11218544 11 121,544,262 4.8E-03 RP11-820L6.1   
rs9364622 6 162,236,323 4.8E-03 PARK2 8.8E-05 
rs10483709 14 58,522,894 4.8E-03 RP11-112J1.2   
rs2720016 3 165,145,085 4.8E-03     
rs10483222 22 42,880,277 4.8E-03 PARVB   
rs4627206 13 67,959,686 4.8E-03     
rs6606825 15 20,614,243 4.8E-03 NIPA1   
rs4272631 1 105,056,444 4.8E-03     
rs2110328 7 20,114,240 4.8E-03 AC005062.2   
rs4846689 1 219,444,058 4.8E-03     
rs949365 11 78,208,368 4.8E-03 ODZ4 6.5E-03 
rs4777882 15 91,785,205 4.8E-03 RP11-266O8.1   
rs2894593 2 226,898,561 4.8E-03     
rs2275516 9 1,043,910 4.8E-03 DMRT2   
rs4692196 4 26,949,002 4.8E-03     
rs10801655 1 187,866,774 4.8E-03     
rs480113 9 109,791,503 4.8E-03     
rs1929129 9 111,352,337 4.8E-03     
rs2288403 11 129,243,199 4.8E-03 NFRKB   
rs4675431 2 204,814,338 4.8E-03     
rs9461448 6 28,371,700 4.8E-03 PGBD1   
rs6895622 5 72,660,292 4.8E-03     
rs7539465 1 96,452,588 4.8E-03     
rs1898866 4 161,529,827 4.8E-03     
rs10858677 12 86,909,653 4.8E-03 C12orf50 7.5E-03 
rs956187 1 96,679,097 4.8E-03     
rs1929408 9 11,942,796 4.8E-03     
rs1018654 9 7,226,712 4.8E-03     
rs6476920 9 4,885,947 4.8E-03     
rs1621211 11 120,378,286 4.8E-03     
rs12570033 10 133,984,693 4.8E-03 STK32C   
rs6737959     4.8E-03 AC018682.6   
rs3783113 13 109,632,747 4.8E-03 COL4A1 3.1E-03 
rs196034 6 22,151,788 4.8E-03     
rs7498882 16 28,124,106 4.8E-03 XPO6   
rs4408788 20 4,143,591 4.8E-03     
rs754819 9 21,616,573 4.8E-03     
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rs9505900 6 169,448,612 4.8E-03     
rs9456490 6 160,318,320 4.8E-03 IGF2R   
rs9833473 3 80,174,096 4.8E-03     
rs6061612 20 59,540,967 4.8E-03 CDH4 4.6E-04 
rs10508096 13 102,258,865 4.8E-03 BIVM   
rs6020739 20 48,828,918 4.8E-03     
rs8079768 17 65,626,554 4.8E-03 AC002539.1 1.5E-03 
rs9984655 21 35,803,301 4.8E-03 RUNX1   
rs1376983 3 56,189,120 4.8E-03 ERC2   
rs7942029 11 113,329,075 4.8E-03     
rs2459067 10 123,785,063 4.8E-03 TACC2   
rs2198935 2 81,257,733 4.8E-03     
rs1997634 22 25,839,769 4.8E-03     
rs4921165 5 160,212,958 4.8E-03 ATP10B   
rs8058389 16 86,488,782 4.9E-03 GS1-21A4.1   
rs6481032 10 55,162,168 4.9E-03     
rs10048789 2 128,775,665 4.9E-03 HS6ST1   
rs1528799 2 51,536,268 4.9E-03 AC007682.1   
rs10864479 1 10,891,317 4.9E-03     
rs9927943 16 59,131,895 4.9E-03     
rs1483622 3 177,490,277 4.9E-03     
rs10509475 10 85,203,345 4.9E-03     
rs1577665 9 26,336,141 4.9E-03     
rs756913 7 24,506,297 4.9E-03     
rs1814370 9 18,843,257 4.9E-03 ADAMTSL1 1.1E-03 
rs2847254 18 12,717,224 4.9E-03 PSMG2   
rs9309819 3 78,930,722 4.9E-03 ROBO1   
rs4599384 4 48,013,147 4.9E-03     
rs11176179 12 65,118,988 4.9E-03 GRIP1 1.0E-03 
rs7080655 10 44,823,480 4.9E-03 RP11-285G1.8   
rs712322 14 21,059,681 4.9E-03 AE000658.22   
rs10810738 9 17,213,492 4.9E-03 CNTLN   
rs138646 22 26,719,012 4.9E-03 TTC28   
rs2006902 16 77,595,532 4.9E-03 RP11-319G9.5 3.1E-03 
rs1413336 9 82,133,946 4.9E-03     
rs1843786 3 78,967,414 4.9E-03 ROBO1   
rs7356656 5 2,717,214 4.9E-03     
rs9033 16 65,739,500 4.9E-03 B3GNT9   
rs931401 2 36,138,443 4.9E-03     
rs733918 18 6,932,295 4.9E-03 LAMA1   
rs11631489 15 85,042,215 4.9E-03 AGBL1 1.8E-03 
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rs2890856 9 9,190,590 4.9E-03 PTPRD 4.7E-03 
rs321225 9 20,210,838 4.9E-03     
rs2106503 7 103,763,225 4.9E-03 LHFPL3 8.7E-04 
rs3778135 6 129,549,602 4.9E-03 RP11-73O6.4 2.4E-03 
rs288637 16 61,248,592 4.9E-03     
rs8126757 21 45,672,710 4.9E-03 COL18A1 2.6E-03 
rs12119007 1 245,284,850 4.9E-03 ZNF670   
rs6954232 7 9,674,747 4.9E-03     
rs569230 4 20,098,122 4.9E-03 SLIT2   
rs13073410 3 134,704,642 4.9E-03     
rs2748220 5 149,744,486 5.0E-03 TCOF1   
rs4559036 5 160,209,255 5.0E-03 ATP10B 3.7E-03 
rs10112963 8 102,231,893 5.0E-03     
rs1866168 10 60,031,568 5.0E-03 BICC1 7.8E-03 
rs10785024 12 72,056,061 5.0E-03 RP11-314D7.4   
rs9371769 6 154,349,428 5.0E-03     
rs7086661 10 130,495,599 5.0E-03     
rs1554277 12 75,098,696 5.0E-03     
rs840418 13 72,775,303 5.0E-03     
rs501957 17 27,338,617 5.0E-03 SUZ12   
rs4401960 9 20,028,477 5.0E-03     
rs936960 15 56,539,169 5.0E-03 RP11-355N15.1   
rs655937 18 61,108,446 5.0E-03     
rs906065 18 61,141,520 5.0E-03     
rs9882054 3 169,414,907 5.0E-03     
rs41348 7 28,683,373 5.0E-03 CREB5 2.4E-04 
rs1780138 10 38,541,660 5.0E-03 RP11-508N22.8   
rs11751802 6 5,355,151 5.0E-03 FARS2   
rs12234501 7 8,738,675 5.0E-03 NXPH1 2.6E-03 
rs4662763 2 128,469,956 5.0E-03 SAP130   
rs1339249 9 77,818,018 5.0E-03 PCSK5 9.0E-03 
rs254870 5 171,000,864 5.0E-03     
rs7032583 9 85,380,931 5.0E-03     
rs766455 8 82,040,988 5.0E-03 PAG1   
rs4870821 8 123,950,371 5.0E-03 ZHX2   
rs7937715 11 129,818,391 5.0E-03     
rs2399786 10 12,255,186 5.0E-03 SEC61A2   
rs2016588 6 159,345,695 5.0E-03 RSPH3   
rs1545909 9 7,645,364 5.0E-03     
rs2275886 9 21,007,743 5.0E-03 PTPLAD2   
rs9524260 13 93,311,791 5.0E-03 GPC6 1.0E-03 
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rs1295107 1 6,001,979 5.1E-03 KCNAB2   
rs10224816 7 9,678,184 5.1E-03     
rs7002825 8 101,740,397 5.1E-03 SNX31   
rs2241954 16 54,936,479 5.1E-03 GNAO1   
rs2066219 13 68,428,665 5.1E-03     
rs9257694 6 29,382,465 5.1E-03 OR14J1   
rs7044578 9 20,876,882 5.1E-03 KIAA1797   
rs10900213 10 45,224,720 5.1E-03 ALOX5   
rs2428158 5 135,341,751 5.1E-03     
rs2539669 2 59,648,113 5.1E-03 AC007131.2   
rs4131051 5 97,537,826 5.1E-03     
rs7910211 10 80,898,384 5.1E-03     
rs11216360 11 116,718,399 5.1E-03 CEP164   
rs524207 6 52,194,855 5.1E-03     
rs1962674 3 155,356,264 5.1E-03 ARHGEF26   
rs1769465 14 86,587,947 5.1E-03     
rs929544 7 9,819,192 5.1E-03     
rs2986267 9 7,463,692 5.1E-03 RP11-87M1.1   
rs12349982 9 90,128,943 5.1E-03 RP11-350G13.1   
rs1971830 2 35,172,516 5.1E-03 AC012593.1   
rs6131768 20 15,975,036 5.1E-03 MACROD2 4.1E-03 
rs6672784 1 238,274,416 5.1E-03 FMN2   
rs4925145 17 18,038,743 5.1E-03 ALKBH5   
rs11001742 10 77,777,156 5.1E-03 C10orf11   
rs4884906 13 70,279,527 5.1E-03     
rs6439474 3 135,483,237 5.1E-03     
rs1876868 15 58,344,233 5.1E-03     
rs1929403 9 11,880,199 5.1E-03     
rs13437290 6 167,131,680 5.1E-03 RPS6KA2   
rs2399422 3 113,554,624 5.1E-03 CD200 2.6E-03 
rs13146316 4 4,406,675 5.1E-03 NSG1   
rs622173 11 1,842,723 5.1E-03 AC051649.12 1.1E-03 
rs6480643 10 74,204,180 5.1E-03 MCU   
rs10817781 9 99,369,961 5.1E-03 TMOD1   
rs210179 6 33,593,214 5.1E-03     
rs6925772 6 12,128,227 5.1E-03 HIVEP1   
rs2831178 21 28,135,194 5.1E-03     
rs2898501 8 20,354,398 5.1E-03     
rs1115219 3 134,977,707 5.1E-03 TF   
rs7145106     5.1E-03     
rs2293286 6 161,470,989 5.1E-03 AGPAT4   
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rs10519010 15 58,339,218 5.1E-03     
rs758951 4 24,363,205 5.1E-03     
rs4936050 11 127,826,464 5.1E-03     
rs228832 20 49,493,555 5.1E-03 NFATC2   
rs404284 7 101,396,787 5.1E-03 CUX1 6.7E-03 
rs10485540 20 15,645,748 5.1E-03 MACROD2 4.1E-03 
rs13086288 3 142,031,775 5.2E-03     
rs11036814 11 5,301,168 5.2E-03 AC104389.28   
rs6414353 3 144,459,441 5.2E-03     
rs9315500 13 37,006,472 5.2E-03     
rs11011294 10 37,961,076 5.2E-03     
rs12727900 1 186,768,771 5.2E-03 RP11-669M2.1   
rs2829949 21 26,144,693 5.2E-03     
rs1033871 13 108,629,670 5.2E-03 MYO16-AS1 3.3E-03 
rs3817077 7 25,556,981 5.2E-03 AC091705.1   
rs9324220 13 112,790,596 5.2E-03 MCF2L   
rs974179 4 14,784,134 5.2E-03 RP11-665G4.1   
rs10466280 10 12,231,939 5.2E-03 SEC61A2   
rs10102337 8 22,704,701 5.2E-03 RP11-459E5.1 1.7E-03 
rs324519 9 9,028,430 5.2E-03 PTPRD 4.7E-03 
rs6024783 20 54,317,745 5.2E-03     
rs12433087 14 25,659,936 5.2E-03 RP11-314P15.2   
rs2144676 20 59,964,839 5.2E-03 TAF4   
rs12921771 16 80,722,684 5.2E-03 RP11-510J16.5   
rs4374305 19 14,815,503 5.2E-03 OR7A10   
rs2780894 1 65,081,964 5.2E-03 JAK1   
rs9837084 3 152,221,445 5.2E-03 CLRN1-AS1   
rs4842610 12 87,335,820 5.2E-03     
rs6839295 4 6,017,702 5.2E-03 C4orf50   
rs1970331 13 111,876,993 5.2E-03     
rs13057591 22 41,745,525 5.2E-03 PACSIN2   
rs1232597 20 10,553,631 5.2E-03 C20orf94   
rs1825651 6 76,983,174 5.2E-03     
rs2039523 6 52,174,886 5.2E-03     
rs6798107 3 198,639,494 5.2E-03     
rs11757721 6 169,164,340 5.2E-03     
rs12528760 6 66,900,502 5.2E-03     
rs10753848 1 197,542,817 5.2E-03 RP11-382E9.1   
rs7086222 10 77,768,797 5.2E-03 C10orf11   
rs1247488 10 77,675,236 5.2E-03 C10orf11   
rs1889326 9 112,301,821 5.3E-03 SVEP1 5.0E-03 
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rs2744734 1 22,422,316 5.3E-03     
rs2534795 6 29,619,320 5.3E-03 GPR53P   
rs2816323 1 224,250,217 5.3E-03 C1orf55   
rs2102956 12 117,615,105 5.3E-03     
rs13100658     5.3E-03     
rs206816 2 31,498,487 5.3E-03     
rs4262613 1 232,165,075 5.3E-03 SLC35F3   
rs3738226 1 165,878,450 5.3E-03 RCSD1   
rs4491677 2 128,505,674 5.3E-03 SAP130   
rs1161901 6 891,665 5.3E-03     
rs283838 2 79,117,211 5.3E-03     
rs11163016 1 80,680,736 5.3E-03     
rs2306706 4 186,664,865 5.3E-03 PDLIM3   
rs10149335 14 49,937,222 5.3E-03 RP11-247L20.3   
rs1809889 12 123,367,179 5.3E-03 RP11-522N14.1   
rs2554506 8 3,806,491 5.3E-03 CSMD1 8.6E-05 
rs11376 14 50,274,746 5.3E-03 NIN   
rs1509177 1 95,771,870 5.3E-03 RP11-286B14.1   
rs1443002 18 26,230,812 5.3E-03     
rs1343660 12 80,215,275 5.3E-03 RP11-121G22.3 4.0E-03 
rs2150855 9 28,402,544 5.3E-03 LINGO2 2.2E-03 
rs741192 22 19,316,010 5.3E-03 SMPD4P1   
rs2170614 6 2,589,629 5.3E-03 RP11-145H9.3   
rs2882825 6 67,084,250 5.3E-03     
rs2388050 10 7,455,780 5.3E-03 SFMBT2 6.1E-03 
rs11896903 2 104,081,758 5.3E-03     
rs6830266 4 178,479,392 5.3E-03 NEIL3   
rs9295089 6 159,383,952 5.3E-03 TAGAP   
rs1112573 14 77,915,081 5.3E-03 NRXN3   
rs4467099 16 11,450,395 5.3E-03 CTD-3088G3.5   
rs2489686 10 42,189,775 5.3E-03     
rs978993 7 15,642,160 5.3E-03 MEOX2   
rs7618160 3 89,718,321 5.3E-03 RP11-91A15.1   
rs859068 1 95,124,503 5.3E-03 SLC44A3   
rs4463269 6 151,903,921 5.3E-03 C6orf97 1.8E-03 
rs4488795 3 29,355,715 5.3E-03 RBMS3 5.9E-04 
rs10506885 12 81,873,327 5.3E-03 TMTC2   
rs4319778 16 77,110,455 5.4E-03 WWOX 3.1E-03 
rs330676 5 123,232,291 5.4E-03     
rs330679 5 123,233,993 5.4E-03     
rs7863087 9 71,619,570 5.4E-03 RP11-109D9.3   
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rs8128258 21 19,370,336 5.4E-03     
rs476663 3 151,932,573 5.4E-03     
rs4959338 6 5,345,657 5.4E-03 FARS2   
rs1624390 6 162,296,972 5.4E-03 PARK2 8.8E-05 
rs7985622 13 65,243,299 5.4E-03     
rs1942418 18 45,637,241 5.4E-03 MYO5B 6.6E-03 
rs355321 18 31,319,287 5.4E-03 INO80C   
rs17692544 9 26,587,540 5.4E-03     
rs9511834 13 25,092,059 5.4E-03 ATP8A2   
rs6872806 5 41,371,807 5.4E-03 PLCXD3   
rs331679 19 6,799,220 5.4E-03 VAV1 2.4E-03 
rs2275895 1 201,047,153 5.4E-03 KDM5B-AS1   
rs3943166 6 76,986,284 5.4E-03     
rs4238264 13 108,060,380 5.4E-03 MYO16 3.3E-03 
rs2622781 18 39,335,330 5.4E-03     
rs1554279 9 109,769,058 5.4E-03 RP11-272G11.1   
rs17546413 13 88,080,427 5.4E-03 RP11-360A9.2   
rs177773 4 3,631,009 5.4E-03     
rs4744188 9 94,990,282 5.4E-03 WNK2 5.9E-03 
rs753687 11 44,317,366 5.4E-03     
rs10878946 12 67,928,582 5.4E-03 CPSF6   
rs10501575 11 84,245,672 5.4E-03 DLG2 4.9E-03 
rs9368002 6 18,646,024 5.4E-03     
rs4805994 19 39,333,496 5.4E-03     
rs9505109 6 7,219,353 5.4E-03 RP11-69L16.4   
rs2771994 9 134,714,722 5.4E-03 AK8   
rs10496654 2 126,519,270 5.4E-03     
rs2480933 9 116,904,430 5.4E-03 TNC 7.3E-03 
rs3789868 9 116,915,502 5.4E-03 TNC 7.3E-03 
rs2132082 4 14,564,496 5.4E-03 AC006296.3   
rs2240090 7 51,064,468 5.4E-03 COBL 4.1E-03 
rs10438342 15 30,189,338 5.4E-03 CHRNA7   
rs419473 2 225,637,345 5.4E-03     
rs1885927 9 746,415 5.4E-03     
rs10109281 8 55,568,620 5.5E-03     
rs4731330 7 126,234,800 5.5E-03 GRM8 1.6E-03 
rs13092591 3 163,937,546 5.5E-03     
rs859088 1 95,114,753 5.5E-03 SLC44A3   
rs11152120 18 54,919,779 5.5E-03     
rs1488171 3 164,186,242 5.5E-03     
rs7989455 13 21,279,204 5.5E-03     
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rs6930033 6 29,431,884 5.5E-03 OR5V1   
rs1077773 7 17,409,204 5.5E-03 AC019117.1   
rs707104 2 155,030,329 5.5E-03 AC009227.3   
rs6029495 20 39,047,713 5.5E-03     
rs4264315 14 50,798,106 5.5E-03     
rs1535618 9 110,215,428 5.5E-03     
rs7086311 10 27,432,015 5.5E-03 ANKRD26   
rs2274634 10 27,474,489 5.5E-03 YME1L1   
rs768505 10 71,224,480 5.5E-03     
rs7485624 12 20,508,680 5.5E-03 PDE3A   
rs10895193 11 101,137,143 5.5E-03 RP11-748H22.2   
rs1492506 4 40,067,757 5.5E-03     
rs7543449 1 187,984,282 5.5E-03     
rs9295924     5.5E-03 LINC00243   
rs12760768 1 165,885,957 5.5E-03 RCSD1   
rs6801757 3 110,291,677 5.5E-03 MORC1 3.6E-03 
rs837550 16 54,119,967 5.5E-03 LPCAT2 2.2E-03 
rs1650 10 18,942,808 5.5E-03 NSUN6 3.7E-03 
rs7903919 10 67,440,952 5.5E-03 CTNNA3 8.7E-04 
rs6775137 3 193,649,843 5.5E-03 FGF12 6.3E-03 
rs1547960 7 120,732,453 5.5E-03     
rs2274352 10 13,741,677 5.5E-03 RP11-295P9.3   
rs638501 6 10,488,442 5.5E-03     
rs12253574 10 83,310,878 5.5E-03     
rs4128664 10 47,173,619 5.5E-03 CTGLF11P   
rs10902882 10 124,894,601 5.5E-03 HMX3   
rs7034380 9 14,898,056 5.5E-03 FREM1   
rs13284716 9 111,372,846 5.6E-03     
rs7168069 15 66,411,450 5.6E-03 ITGA11   
rs902633 10 133,793,790 5.6E-03 JAKMIP3 7.0E-03 
rs6583830 10 94,388,098 5.6E-03 KIF11   
rs480774 6 6,968,671 5.6E-03     
rs2837156 21 40,048,557 5.6E-03 IGSF5   
rs2451576 6 77,180,387 5.6E-03     
rs7961978 12 8,594,842 5.6E-03 RP11-561P12.5   
rs10510165 3 1,225,310 5.6E-03 CNTN6 3.9E-03 
rs7517671 1 207,185,511 5.6E-03     
rs7968026 12 83,754,187 5.6E-03     
rs960761 4 187,884,344 5.6E-03 FAT1   
rs3796139 3 99,861,391 5.6E-03 RP11-569H14.1   
rs7635103 3 187,316,453 5.6E-03 DGKG   
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rs1032757 5 81,975,074 5.6E-03     
rs1907348 10 77,854,822 5.6E-03 C10orf11   
rs745034 9 13,776,493 5.6E-03     
rs3801306 7 36,447,372 5.6E-03 ANLN   
rs480958     5.6E-03 AP002954.4   
rs4655059 1 22,608,493 5.6E-03     
rs10975175 9 5,534,405 5.6E-03 PDCD1LG2   
rs7921016 10 20,341,676 5.6E-03 PLXDC2 6.4E-03 
rs6886199 5 112,927,149 5.6E-03 YTHDC2 4.0E-03 
rs4597272 15 35,712,784 5.6E-03     
rs6093416 20 39,048,197 5.6E-03     
rs7999900 13 107,795,019 5.6E-03     
rs7732831 5 32,697,591 5.6E-03     
rs3732191 2 47,893,789 5.6E-03 FBXO11   
rs1336336 9 26,798,023 5.6E-03 RP11-337A23.6   
rs162005 18 22,701,784 5.6E-03 AQP4   
rs4764997 12 99,733,862 5.6E-03 ANO4   
rs10275615 7 18,062,346 5.6E-03     
rs4679786 3 151,918,374 5.6E-03 RP11-103G8.1   
rs2029001 3 110,211,360 5.6E-03 MORC1 3.6E-03 
rs7653651 3 110,263,521 5.6E-03 MORC1 3.6E-03 
rs1456767 8 40,999,658 5.6E-03     
rs2076706 22 24,504,168 5.6E-03 MYO18B   
rs618751 1 4,562,392 5.6E-03     
rs1528805 2 51,591,897 5.6E-03 AC080091.1   
rs649526 15 40,223,294 5.6E-03 PLA2G4F   
rs8005104 14 49,950,227 5.7E-03 MAP4K5   
rs11734695 4 6,473,961 5.7E-03 PPP2R2C   
rs884025 17 74,965,704 5.7E-03 RBFOX3   
rs708486 14 51,810,721 5.7E-03 PTGDR   
rs6706062 2 120,650,568 5.7E-03 AC012363.4   
rs825191 1 64,480,599 5.7E-03 UBE2U 6.6E-03 
rs9845043 3 118,393,014 5.7E-03 LSAMP   
rs27223 5 59,788,397 5.7E-03 PDE4D   
rs11645312 16 25,458,337 5.7E-03     
rs2958522 8 145,995,756 5.7E-03 ZNF517   
rs7914814 10 94,372,930 5.7E-03 KIF11   
rs1761285 9 71,270,137 5.7E-03 APBA1   
rs9597069 13 54,461,091 5.7E-03     
rs4809258 20 62,256,817 5.7E-03 MYT1   
rs16914086 9 100,028,298 5.7E-03 TBC1D2   
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rs1411060 9 37,036,091 5.7E-03 RP11-297B17.2   
rs4610795 8 145,852,141 5.7E-03 ARHGAP39   
rs11583257 1 3,904,110 5.7E-03 RP13-614K11.2   
rs704308 1 184,509,298 5.7E-03     
rs8018219 14 93,555,707 5.7E-03     
rs7939158 11 130,672,353 5.7E-03 AP002856.5   
rs10162514 14 47,105,557 5.7E-03 MDGA2   
rs12401392 1 101,668,533 5.7E-03     
rs10493972 1 102,075,419 5.7E-03 OLFM3 2.6E-04 
rs649649 9 9,564,336 5.7E-03 PTPRD 4.7E-03 
rs10283145 8 10,278,821 5.7E-03 MSRA 8.7E-03 
rs549427 11 113,590,069 5.7E-03 ZBTB16   
rs10498286 14 25,957,294 5.7E-03     
rs370534 22 21,587,051 5.7E-03 IGLC6   
rs321739     5.7E-03     
rs2302442     5.7E-03 MAGI2   
rs12414156 10 56,612,592 5.7E-03 PCDH15   
rs2605242 4 48,605,727 5.7E-03 OCIAD2   
rs6564738 16 78,727,594 5.7E-03 RP11-525K10.1   
rs1861739 22 45,510,714 5.7E-03 CERK   
rs9606282 22 18,580,513 5.7E-03     
rs7763526 6 155,849,971 5.7E-03     
rs1806760 9 71,247,826 5.7E-03 APBA1   
rs7023148 9 10,674,803 5.8E-03     
rs889764 16 87,360,910 5.8E-03 PIEZO1   
rs10945799 6 162,512,797 5.8E-03 PARK2 8.8E-05 
rs1888420 21 22,501,004 5.8E-03 AP000705.7   
rs464805 22 21,581,857 5.8E-03 IGLC4   
rs9965494 18 6,082,174 5.8E-03 L3MBTL4 8.6E-03 
rs1007266 1 60,006,335 5.8E-03 RP4-782L23.1   
rs2246083 1 201,047,787 5.8E-03 KDM5B-AS1   
rs2203919 3 168,222,279 5.8E-03 AC092965.1   
rs6434026 2 184,015,156 5.8E-03     
rs2572349 4 48,606,785 5.8E-03 OCIAD2   
rs9398918 6 130,087,370 5.8E-03 RP11-73O6.4   
rs2057588 13 71,363,953 5.8E-03     
rs7774958 6 107,600,111 5.8E-03 PDSS2   
rs732803 8 141,039,000 5.8E-03 TRAPPC9   
rs17010281 2 124,056,775 5.8E-03     
rs17723697 9 1,625,184 5.8E-03     
rs4877706 9 84,565,274 5.8E-03     
133 
 
rs873224 8 142,600,146 5.8E-03 AC138647.1   
rs9565596 13 80,115,492 5.8E-03     
rs4823617 22 46,003,908 5.8E-03     
rs2175075 13 75,656,049 5.8E-03     
rs1870105 2 160,846,898 5.8E-03 RBMS1 6.1E-04 
rs1000989 13 109,625,304 5.8E-03 COL4A1 3.1E-03 
rs12596308 16 29,598,697 5.8E-03 QPRT   
rs761076 1 165,886,606 5.8E-03 RCSD1   
rs272110 2 131,262,790 5.8E-03     
rs7615318 3 49,962,479 5.8E-03 RBM6   
rs1832312 10 24,335,334 5.8E-03 KIAA1217 1.4E-04 
rs2820899 9 7,198,342 5.8E-03     
rs7157202 14 58,945,345 5.8E-03     
rs4901055 14 50,296,750 5.8E-03 NIN   
rs7653603 3 152,472,732 5.8E-03 SETP11   
rs389694 9 20,184,147 5.8E-03     
rs7300317 12 50,918,840 5.8E-03 KRT7   
rs1507864 4 48,300,385 5.9E-03 FRYL   
rs7834389 8 23,621,823 5.9E-03 RP11-175E9.1   
rs12293101 11 5,292,175 5.9E-03 OR51B3P   
rs205117 16 25,473,468 5.9E-03     
rs1994575 10 55,163,697 5.9E-03     
rs12541335 8 22,144,377 5.9E-03 PHYHIP   
rs10512395 9 111,283,142 5.9E-03 PTPN3   
rs9320730 6 120,354,028 5.9E-03     
rs4683870 3 103,316,759 5.9E-03 ZPLD1   
rs4539216     5.9E-03 RP11-108B14.4   
rs312462 17 6,854,376 5.9E-03 RNASEK   
rs6773689 3 173,514,057 5.9E-03 FNDC3B 2.5E-03 
rs4977545 9 19,502,746 5.9E-03 SLC24A2 3.7E-03 
rs827297 10 72,370,659 5.9E-03 RP11-432J9.6   
rs13200559 6 56,750,279 5.9E-03 DST   
rs9442813 6 73,301,649 5.9E-03 AL445568.1   
rs389177     5.9E-03     
rs10027212 4 30,585,306 5.9E-03 PCDH7   
rs13241564 7 9,016,318 5.9E-03     
rs9304028 18 9,007,786 5.9E-03 RP11-143J12.1   
rs10828906 10 18,881,801 5.9E-03 NSUN6 3.7E-03 
rs2654247 3 106,287,891 5.9E-03     
rs2883423 2 51,586,377 5.9E-03 AC007682.1   
rs9283872 6 22,033,470 5.9E-03     
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rs2415439 14 37,647,766 5.9E-03 CTD-2058B24.2   
rs9316020 13 42,892,291 5.9E-03 ENOX1   
rs1074201 13 87,815,648 5.9E-03     
rs2963154 5 142,722,730 5.9E-03 NR3C1 4.3E-03 
rs1037855 4 43,622,591 5.9E-03     
rs10882091 10 94,364,357 5.9E-03 KIF11   
rs4640872 6 165,195,024 5.9E-03     
rs9360979 6 76,900,873 5.9E-03     
rs7871216 9 36,235,759 5.9E-03 CLTA   
rs179083 14 29,880,418 6.0E-03     
rs1433825 9 18,786,886 6.0E-03 ADAMTSL1 1.1E-03 
rs10490851 3 145,606,091 6.0E-03     
rs1707469 3 147,343,995 6.0E-03 PLOD2 8.3E-03 
rs12988659 2 40,496,130 6.0E-03 SLC8A1 8.9E-04 
rs7718156 5 172,028,971 6.0E-03 NEURL1B   
rs7117189 11 122,054,424 6.0E-03 UBASH3B   
rs4132589 13 25,122,025 6.0E-03 ATP8A2   
rs11090233 22 22,020,325 6.0E-03     
rs7901348 10 63,349,287 6.0E-03 ARID5B 1.7E-03 
rs7341836 9 115,543,671 6.0E-03     
rs7114211 11 44,404,498 6.0E-03     
rs6786617 3 155,336,359 6.0E-03 ARHGEF26   
rs7095243 10 24,640,924 6.0E-03 RP11-429A24.4 1.4E-04 
rs199169 5 8,639,300 6.0E-03     
rs7380706 5 178,894,478 6.0E-03     
rs923926 9 14,755,030 6.0E-03 FREM1   
rs3760372 17 42,735,001 6.0E-03 RP11-290H9.4   
rs1217745 5 71,281,720 6.0E-03     
rs13296976 9 9,347,444 6.0E-03 PTPRD 4.7E-03 
rs533810 6 167,109,679 6.0E-03 RPS6KA2   
rs480025 1 187,897,346 6.0E-03 RN5S73   
rs4490947 9 15,088,969 6.0E-03     
rs2237848 8 17,918,884 6.0E-03 PCM1   
rs13068081 3 56,267,869 6.0E-03 ERC2   
rs1447563 2 46,490,868 6.0E-03     
rs1377095 15 85,061,729 6.0E-03 AGBL1 1.8E-03 
rs6471171 8 134,991,862 6.1E-03     
rs3015480 14 50,269,942 6.1E-03 NIN   
rs4741304 9 13,478,608 6.1E-03 RP11-536O18.1   
rs7102167 11 1,394,679 6.1E-03 BRSK2   
rs4506892 16 80,196,410 6.1E-03 CMIP   
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rs721087 2 4,942,340 6.1E-03     
rs896771 7 157,788,887 6.1E-03 PTPRN2 1.7E-03 
rs2292609 2 166,104,049 6.1E-03 CSRNP3   
rs612183 9 15,272,158 6.1E-03 TTC39B   
rs11761859 7 24,825,775 6.1E-03 OSBPL3   
rs2369105 4 4,403,987 6.1E-03 NSG1   
rs7645818 3 36,505,422 6.1E-03 STAC   
rs7734427 5 74,363,824 6.1E-03 GCNT4   
rs1934775 6 9,939,516 6.1E-03 OFCC1   
rs1962543 9 29,999,444 6.1E-03     
rs3936194 4 1,589,489 6.1E-03 FAM53A   
rs10890809 11 107,462,687 6.1E-03 CUL5   
rs4571789 9 77,007,222 6.1E-03 U6   
rs2474606 10 38,491,647 6.1E-03 RP11-508N22.6   
rs10958672 8 41,274,498 6.1E-03 SFRP1   
rs4911287 20 31,090,952 6.1E-03 BPIFB6   
rs2111110 16 54,634,636 6.1E-03     
rs948138 11 102,006,875 6.1E-03 RP11-817J15.2   
rs310602 20 61,579,614 6.1E-03     
rs1341740 9 15,840,604 6.1E-03 C9orf93   
rs2354391 6 156,436,700 6.1E-03     
rs10505545 8 130,646,449 6.1E-03 CCDC26   
rs12033458 1 18,330,155 6.1E-03 IGSF21 7.1E-03 
rs10510305 3 5,437,347 6.1E-03     
rs7089809 10 57,398,714 6.1E-03     
rs451664 9 26,360,564 6.1E-03     
rs17017378 2 79,717,878 6.1E-03 CTNNA2 6.0E-03 
rs1931371 9 95,178,378 6.1E-03 U6   
rs4261301 11 57,871,560 6.1E-03 OR5B10P   
rs17761890 12 72,647,245 6.1E-03     
rs2028211 2 127,618,127 6.1E-03     
rs2294998 20 60,994,578 6.1E-03 DIDO1   
rs7092964 10 128,737,210 6.1E-03 DOCK1 5.5E-04 
rs9325388 3 198,586,306 6.1E-03     
rs1074894 22 33,310,085 6.1E-03 RP1-101G11.2   
rs7813807 8 41,033,884 6.1E-03     
rs592398 13 108,677,223 6.2E-03     
rs2125566 22 33,108,009 6.2E-03     
rs6824576     6.2E-03     
rs9503013 6 1,652,398 6.2E-03 GMDS   
rs6494223 15 30,183,749 6.2E-03 CHRNA7   
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rs2700592 3 100,614,099 6.2E-03     
rs7561383 2 40,427,711 6.2E-03 SLC8A1 8.9E-04 
rs4950025 1 97,489,867 6.2E-03 DPYD-AS1   
rs767478 4 30,239,480 6.2E-03     
rs1446271 9 12,036,260 6.2E-03     
rs8047113 16 83,867,391 6.2E-03     
rs491106 1 187,950,736 6.2E-03     
rs7994590 13 60,945,769 6.2E-03     
rs10509845     6.2E-03     
rs2220182 9 7,609,121 6.2E-03     
rs42386 16 8,354,976 6.2E-03 RP11-568A19.1   
rs10958409 8 55,489,644 6.2E-03     
rs34736 5 96,193,646 6.2E-03 CTD-2260A17.2   
rs2057374 9 38,271,314 6.2E-03     
rs10487590 7 7,243,788 6.2E-03 C1GALT1 5.7E-03 
rs10762795 10 80,075,943 6.2E-03 RP11-90J7.3   
rs3117148 6 159,373,801 6.2E-03 TAGAP   
rs11898149 2 98,019,838 6.2E-03     
rs10493669 1 80,727,323 6.2E-03     
rs11821606 11 94,836,868 6.2E-03     
rs7853954 9 38,389,721 6.2E-03 ALDH1B1   
rs17798906 2 117,555,176 6.2E-03     
rs916954 20 51,292,709 6.2E-03 TSHZ2 6.7E-04 
rs8043658 16 85,521,537 6.2E-03     
rs1340589 1 67,696,979 6.2E-03     
rs2770712 9 7,239,055 6.2E-03     
rs9603096 13 36,238,240 6.2E-03     
rs1983011 3 178,859,580 6.2E-03 LINC00578   
rs6972852 7 2,424,235 6.2E-03 CHST12   
rs4841154 8 9,352,928 6.2E-03 RP11-375N15.1   
rs10937705 4 6,234,085 6.2E-03 JAKMIP1   
rs6985907 8 13,638,013 6.2E-03     
rs3759589 14 50,122,718 6.2E-03 ATL1   
rs400345 16 82,885,995 6.2E-03 RP11-558A11.2 7.6E-03 
rs4432683 3 54,255,177 6.2E-03 CACNA2D3 7.3E-05 
rs2760217 1 161,907,797 6.2E-03     
rs881950 3 150,628,104 6.3E-03     
rs6590598 11 131,173,745 6.3E-03 NTM   
rs9867793 3 67,243,323 6.3E-03     
rs1000016 2 235,355,721 6.3E-03     
rs727422 11 120,673,388 6.3E-03 SC5DL   
137 
 
rs2577098 18 4,499,325 6.3E-03     
rs9573095 13 72,545,361 6.3E-03 KLF5   
rs7995886 13 50,266,987 6.3E-03 DLEU7 7.8E-03 
rs4525696 2 85,791,511 6.3E-03     
rs1532010 18 20,182,039 6.3E-03 OSBPL1A   
rs914405 9 137,311,515 6.3E-03     
rs2509961 11 62,067,485 6.3E-03 RP11-864I4.4   
rs3823267 6 1,722,853 6.3E-03 GMDS   
rs1371091 3 60,988,473 6.3E-03 FHIT 6.4E-04 
rs902856 4 40,075,664 6.3E-03 RNU7-74P   
rs9533481 13 42,887,185 6.3E-03 ENOX1   
rs6921388 6 27,188,184 6.3E-03 U2   
rs797810 7 83,434,619 6.3E-03 SEMA3A 4.1E-03 
rs7904837 10 128,222,450 6.3E-03 C10orf90   
rs1461917 11 37,513,473 6.3E-03     
rs3009559 10 74,120,325 6.3E-03 MCU   
rs6480640 10 74,200,213 6.3E-03 MCU   
rs1722791 15 21,503,831 6.3E-03     
rs1972947 2 183,878,598 6.3E-03     
rs1405969 2 49,529,832 6.3E-03     
rs2905503 11 60,607,228 6.3E-03     
rs4704166     6.3E-03 GCNT4   
rs2665272 16 52,684,118 6.3E-03 FTO   
rs12578013 11 122,525,441 6.3E-03 CLMP   
rs9521198 13 108,636,331 6.3E-03 MYO16-AS1 3.3E-03 
rs3813135 19 15,448,345 6.3E-03 PGLYRP2   
rs7759626 6 1,304,689 6.3E-03     
rs727345 10 31,939,079 6.3E-03 RP11-472N13.2   
rs9812681 3 173,481,044 6.3E-03 FNDC3B 2.5E-03 
rs789239 3 130,116,498 6.3E-03 ACAD9   
rs6722778 2 128,475,570 6.3E-03 SAP130   
rs10486608 7 29,178,576 6.3E-03 CPVL   
rs6959914 7 57,834,528 6.3E-03 RP11-548K12.7   
rs522409 3 167,766,851 6.3E-03 RP11-450H5.1   
rs2422173 2 75,631,476 6.3E-03 FAM176A 2.6E-03 
rs9572198 13 69,075,552 6.4E-03     
rs12525751 6 109,444,416 6.4E-03 SESN1   
rs885821 10 72,028,661 6.4E-03 PRF1   
rs506380 10 83,439,664 6.4E-03     
rs983093 10 83,477,461 6.4E-03     
rs2947658     6.4E-03 RP11-379B18.5   
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rs7941030 11 122,027,585 6.4E-03 UBASH3B   
rs12446940 16 3,902,621 6.4E-03     
rs328845     6.4E-03     
rs7147755 14 47,248,356 6.4E-03     
rs9543561 13 73,769,467 6.4E-03     
rs13105217 4 65,064,629 6.4E-03     
rs729424 6 33,752,011 6.4E-03 ITPR3   
rs8049156 16 25,370,548 6.4E-03 CYCSP39   
rs6919391 6 26,716,304 6.4E-03     
rs4732529 7 83,473,522 6.4E-03 SEMA3A 4.1E-03 
rs9851203 3 56,017,268 6.4E-03 ERC2   
rs12811136 12 131,603,653 6.4E-03 FBRSL1   
rs4689381 4 6,308,089 6.4E-03     
rs4972052 2 88,359,658 6.4E-03     
rs2029413 6 152,715,782 6.4E-03 SYNE1 4.8E-03 
rs666134 3 120,816,966 6.4E-03 PLA1A   
rs9784675 5 132,097,638 6.4E-03 KIF3A 4.0E-05 
rs1017266 7 8,912,697 6.4E-03     
rs2030592 15 35,102,817 6.4E-03 RP11-29M5.1   
rs4090570 19 46,807,966 6.4E-03 CEACAMP3   
rs2581578 8 2,111,101 6.4E-03 RP11-1049H7.1   
rs1972844 8 23,685,197 6.4E-03 RP11-175E9.1   
rs3862560 10 85,573,223 6.4E-03     
rs4676286 2 109,377,918 6.4E-03 SH3RF3   
rs41261 7 105,399,068 6.4E-03 CDHR3   
rs11879005 19 44,402,743 6.4E-03     
rs13317946 3 80,226,508 6.4E-03     
rs1883959 11 34,190,721 6.4E-03 ABTB2 1.2E-03 
rs2540554 7 91,063,578 6.4E-03     
rs2389049 13 93,260,101 6.4E-03 GPC6 1.0E-03 
rs12048529 1 90,859,695 6.4E-03     
rs4654465 1 4,854,635 6.5E-03     
rs17653196 13 68,422,613 6.5E-03     
rs2866712 16 74,946,942 6.5E-03 CNTNAP4   
rs1869156 3 56,318,391 6.5E-03 ERC2   
rs7086916     6.5E-03     
rs7124057 11 62,090,672 6.5E-03 EEF1G   
rs1781011 6 52,230,899 6.5E-03     
rs4242698 9 27,114,745 6.5E-03 TEK 7.4E-03 
rs3885388 1 167,280,052 6.5E-03 RP11-375F2.2   
rs7624567 3 149,044,993 6.5E-03 RP11-78O22.1   
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rs9828150 3 2,518,302 6.5E-03 CNTN4   
rs2616752 9 15,300,704 6.5E-03 TTC39B   
rs10142203 14 50,774,540 6.5E-03 TMX1   
rs12442329 15 85,056,724 6.5E-03 AGBL1 1.8E-03 
rs2789891 1 187,946,162 6.5E-03     
rs11642377 16 20,017,154 6.5E-03     
rs10425066 19 35,018,134 6.5E-03     
rs9612814 22 23,657,959 6.5E-03 TMEM211   
rs1750770 10 22,966,999 6.5E-03 PIP4K2A 7.1E-03 
rs7710178 5 155,946,409 6.5E-03 SGCD   
rs1777112 10 86,251,786 6.5E-03 FAM190B   
rs622200 11 113,533,984 6.5E-03 ZBTB16   
rs2390252 7 20,110,194 6.5E-03 AC005062.2   
rs2129446 10 3,723,386 6.5E-03     
rs830510 8 73,487,211 6.5E-03     
rs1276430 20 54,930,012 6.5E-03     
rs13267240 8 122,399,652 6.5E-03     
rs697216 12 100,178,691 6.5E-03     
rs4473985 7 49,609,214 6.5E-03     
rs9972695 16 80,268,484 6.5E-03 CMIP   
rs1393001 2 105,691,340 6.5E-03     
rs9965599 18 75,021,193 6.5E-03 ATP9B   
rs17768434 14 37,111,621 6.5E-03 RP11-356O9.1   
rs853256 3 64,290,504 6.5E-03 PRICKLE2   
rs2762699 1 42,809,287 6.5E-03 RP11-163G10.4   
rs1389976 8 108,959,180 6.5E-03     
rs7315833 12 125,459,435 6.6E-03 RP5-944M2.1   
rs2194295 16 74,798,976 6.6E-03     
rs4686799 3 187,933,930 6.6E-03 KNG1   
rs323689     6.6E-03     
rs1903595 8 14,433,852 6.6E-03 SGCZ 5.9E-04 
rs10799329 1 224,181,122 6.6E-03 PYCR2   
rs4624521 3 128,157,844 6.6E-03 CHCHD6   
rs10996824 10 67,437,424 6.6E-03 CTNNA3 8.7E-04 
rs12782894 10 34,006,326 6.6E-03     
rs4885065 13 72,547,636 6.6E-03 KLF5   
rs13032261 2 226,976,835 6.6E-03     
rs504384 1 187,954,827 6.6E-03     
rs2216974 7 24,021,536 6.6E-03     
rs1935286 1 165,820,854 6.6E-03     
rs2504011 10 33,177,557 6.6E-03 C10orf68   
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rs1355784     6.6E-03 CPNE4   
rs7996418 13 111,930,016 6.6E-03     
rs1842636 9 32,100,777 6.6E-03     
rs4240725 12 80,039,177 6.6E-03 RP11-543H12.1   
rs10936485 3 167,547,230 6.6E-03     
rs554653 6 6,492,486 6.6E-03 LY86-AS1   
rs4783095 16 81,073,474 6.6E-03     
rs27813 16 47,970,032 6.6E-03 C16orf78 8.5E-03 
rs6912202 6 77,005,395 6.6E-03     
rs923553 6 77,109,051 6.6E-03     
rs9289675 3 145,608,722 6.6E-03     
rs2170176 8 20,357,815 6.6E-03     
rs4822857 22 25,832,567 6.6E-03     
rs996062 7 124,154,815 6.6E-03     
rs9301679 13 89,938,730 6.6E-03 RP11-158A8.1   
rs6925813 6 160,221,348 6.6E-03     
rs8069696 17 62,004,935 6.6E-03 PRKCA 9.3E-03 
rs7101509 11 130,487,858 6.6E-03 AP002806.1   
rs984903 2 81,212,504 6.6E-03     
rs10485518 20 15,061,008 6.6E-03 MACROD2 4.1E-03 
rs4299072 14 64,775,011 6.6E-03 CTD-2509G16.3   
rs3006664 10 32,472,024 6.6E-03     
rs3736964 10 7,824,930 6.7E-03 ITIH2 2.2E-03 
rs1519662 2 100,510,050 6.7E-03     
rs1667783     6.7E-03     
rs1501281 3 160,260,909 6.7E-03 IQCJ-SCHIP1   
rs10496117 2 64,541,169 6.7E-03 LGALSL   
rs6475372 9 1,984,204 6.7E-03     
rs7049103 9 3,814,004 6.7E-03 GLIS3   
rs9347479 6 161,422,084 6.7E-03 MAP3K4 9.1E-03 
rs615545 7 18,358,396 6.7E-03 HDAC9   
rs816203 12 116,495,371 6.7E-03 KSR2 2.6E-04 
rs1381251 3 138,429,828 6.7E-03     
rs10813878 9 32,849,234 6.7E-03 RP11-462B18.3   
rs501878 10 6,566,503 6.7E-03 PRKCQ 2.1E-03 
rs10893370 11 124,697,053 6.7E-03 PKNOX2   
rs2505024 6 77,153,728 6.7E-03     
rs7664215 4 95,548,180 6.7E-03     
rs10492428 13 25,179,281 6.7E-03 ATP8A2   
rs10777276 12 89,815,815 6.7E-03     
rs1562045 9 13,764,329 6.7E-03     
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rs1026900 6 149,288,218 6.7E-03 UST   
rs17590608 6 167,106,014 6.7E-03 RPS6KA2   
rs7587138 2 46,510,593 6.7E-03 AC018682.6   
rs6040486 20 11,187,118 6.7E-03 RP4-734C18.1   
rs2182667 13 73,314,882 6.7E-03 KLF12   
rs6489016 12 124,862,044 6.7E-03     
rs877616     6.7E-03     
rs9365729 6 164,910,428 6.7E-03     
rs6569585 6 129,516,639 6.7E-03 BMPR1APS1 2.4E-03 
rs4719607 7 2,626,477 6.7E-03     
rs6717876 2 81,216,889 6.7E-03     
rs11784810 8 24,482,929 6.7E-03 RP11-624C23.1   
rs1858886 12 109,744,939 6.7E-03     
rs10052431 5 13,886,009 6.8E-03 DNAH5 9.3E-04 
rs7760528 6 20,550,333 6.8E-03 E2F3 9.3E-03 
rs2858729 22 31,325,281 6.8E-03 SYN3   
rs1986466 9 30,008,156 6.8E-03     
rs9399121 6 135,145,917 6.8E-03     
rs872606 13 97,690,672 6.8E-03 FARP1   
rs12554063 9 111,357,283 6.8E-03     
rs7544426 1 109,977,503 6.8E-03 RP5-1160K1.6   
rs741664 7 131,720,594 6.8E-03 PLXNA4 6.4E-03 
rs12938678 17 24,734,553 6.8E-03     
rs10800783 1 199,718,475 6.8E-03 CSRP1   
rs10011689 4 11,184,945 6.8E-03     
rs219176 2 33,083,590 6.8E-03 LTBP1   
rs4076553 1 41,665,843 6.8E-03     
rs9879974 3 80,966,560 6.8E-03     
rs17179281 14 37,118,858 6.8E-03 RP11-356O9.1   
rs4753826 11 107,363,852 6.8E-03     
rs896253 16 84,377,703 6.8E-03 COX4NB   
rs3786944 19 3,129,372 6.8E-03 S1PR4   
rs40277 5 135,359,799 6.8E-03     
rs4823882 22 45,629,789 6.8E-03 TBC1D22A   
rs4743992 9 92,259,388 6.8E-03     
rs4408145 1 41,682,317 6.8E-03     
rs2280580 3 120,830,090 6.8E-03 PLA1A   
rs946646 1 179,421,458 6.8E-03 RP11-540K16.2   
rs638230 9 9,562,790 6.8E-03 PTPRD 4.7E-03 
rs4296182 14 50,731,917 6.8E-03     
rs2900964 19 13,413,763 6.8E-03 CACNA1A 8.5E-03 
142 
 
rs2210455 20 9,867,383 6.8E-03     
rs4847368 1 95,149,626 6.8E-03 CNN3 1.8E-03 
rs2375256 9 1,159,485 6.8E-03 RP11-341G2.1   
rs703712 12 100,205,204 6.8E-03 UTP20   
rs9344826 6 89,283,373 6.8E-03     
rs7194648 16 72,284,372 6.9E-03     
rs9300636 13 100,362,458 6.9E-03 NALCN-AS1   
rs867744 6 85,878,413 6.9E-03     
rs936769 9 7,671,711 6.9E-03     
rs4521641 6 8,872,893 6.9E-03     
rs11860152 16 84,374,825 6.9E-03 COX4NB   
rs1886237 6 161,804,620 6.9E-03 PARK2 8.8E-05 
rs90192 11 116,564,557 6.9E-03 SIDT2   
rs6869617 5 124,389,487 6.9E-03     
rs1876869 15 58,344,343 6.9E-03     
rs11989071 8 25,853,544 6.9E-03 AC090103.1   
rs1532122 5 66,833,479 6.9E-03 RP11-434D9.1   
rs12669134 7 23,755,075 6.9E-03 STK31 3.0E-03 
rs2561143 5 38,307,208 6.9E-03 EGFLAM   
rs2594499 2 46,287,756 6.9E-03     
rs10496653 2 126,486,008 6.9E-03     
rs9301495 13 88,214,498 6.9E-03     
rs10484153 14 82,734,864 6.9E-03     
rs17406451 2 43,485,980 6.9E-03 THADA 1.1E-03 
rs2333562 17 55,188,728 6.9E-03 VMP1   
rs877885 18 44,495,161 6.9E-03 CTIF   
rs1381640 14 46,197,769 6.9E-03     
rs4801332 19 61,749,068 6.9E-03 ZFP28 3.5E-03 
rs1125825 4 27,625,465 6.9E-03     
rs10496347 2 100,431,642 6.9E-03     
rs7939247 11 127,831,260 6.9E-03 ETS1   
rs7020007 9 14,525,343 6.9E-03 RP11-408A13.2   
rs4075798 5 2,176,985 6.9E-03     
rs10812643 9 27,680,090 6.9E-03     
rs2341264 1 73,956,997 6.9E-03 RP11-275A6.2   
rs7760923 6 77,000,235 6.9E-03     
rs2695109 2 178,509,996 6.9E-03 PDE11A   
rs12314621 12 44,134,997 6.9E-03     
rs371346 18 42,504,953 6.9E-03     
rs6441449 3 163,557,476 6.9E-03     
rs1008746 5 167,591,276 6.9E-03 ODZ2 2.5E-03 
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rs4922665 11 23,680,342 6.9E-03     
rs12677076 8 20,328,401 6.9E-03     
rs12130139 1 245,608,675 6.9E-03     
rs6797432 3 190,108,582 6.9E-03     
rs10243603 7 31,554,143 6.9E-03 CCDC129 5.4E-03 
rs1339446 1 188,000,602 6.9E-03     
rs4796915 18 11,218,713 6.9E-03     
rs2282457 10 5,767,329 6.9E-03 FAM208B   
rs10815044 9 4,630,712 6.9E-03 SPATA6L 7.4E-04 
rs4950392 1 145,203,172 6.9E-03 CHD1L   
rs4771031 13 26,289,249 6.9E-03     
rs6071491 20 59,117,976 6.9E-03     
rs2870477 19 62,036,725 6.9E-03 PEG3   
rs10485205 6 157,238,666 7.0E-03 ARID1B 4.8E-03 
rs10901042 7 154,697,319 7.0E-03     
rs1601360 2 151,555,468 7.0E-03 AC023469.2   
rs1168292 12 65,018,927 7.0E-03 HELB   
rs6456735 6 26,682,128 7.0E-03     
rs2107785 7 80,802,211 7.0E-03 AC004866.1   
rs1341626 10 119,160,671 7.0E-03     
rs804267 8 11,666,650 7.0E-03 NEIL2   
rs2035987 9 14,744,010 7.0E-03 FREM1   
rs1962044 8 35,009,528 7.0E-03     
rs7867067 9 8,880,946 7.0E-03 PTPRD 4.7E-03 
rs770457 12 76,641,418 7.0E-03     
rs998022 12 67,955,492 7.0E-03 CPSF6   
rs6039459 20 940,713 7.0E-03     
rs4389424 3 23,652,529 7.0E-03     
rs850942 12 13,039,758 7.0E-03 HEBP1   
rs6133869 20 10,268,196 7.0E-03 HIGD1AP15   
rs1713434 14 19,951,367 7.0E-03 TEP1   
rs3759704     7.0E-03     
rs10164749 2 20,336,328 7.0E-03 PUM2   
rs1233492 6 29,566,456 7.0E-03 RPS17P1   
rs32056 5 156,006,717 7.0E-03 SGCD   
rs383815 3 192,657,909 7.0E-03 PYDC2   
rs7335635 13 35,814,985 7.0E-03 SPG20   
rs7010127 8 3,115,425 7.0E-03 CSMD1 8.6E-05 
rs2035481 16 87,947,857 7.0E-03 ANKRD11   
rs6953890 7 46,960,870 7.0E-03 AC004901.1   
rs2143725 20 50,346,145 7.0E-03 RP4-723E3.1   
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rs13178332 5 57,865,837 7.0E-03     
rs1420686 16 48,785,487 7.0E-03 PAPD5   
rs1327990 6 4,259,879 7.0E-03     
rs1776503 14 51,757,619 7.0E-03     
rs1995549 16 77,541,637 7.0E-03 WWOX 3.1E-03 
rs2153445 6 102,425,032 7.0E-03 GRIK2 9.7E-04 
rs12001341 9 85,393,066 7.0E-03     
rs910425 6 170,494,116 7.0E-03 FAM120B   
rs4948235 10 61,055,737 7.1E-03     
rs11640609 16 21,596,245 7.1E-03 OTOA   
rs1354719 1 63,940,620 7.1E-03     
rs2249871 17 67,252,248 7.1E-03     
rs40512 5 59,841,224 7.1E-03 PDE4D   
rs1018155 6 39,840,410 7.1E-03     
rs535176 10 44,067,065 7.1E-03     
rs10273448 7 35,738,028 7.1E-03 AC018647.3   
rs1144949 12 67,547,311 7.1E-03 CPM   
rs8048539 16 78,261,653 7.1E-03 AC009159.1   
rs911087 14 25,882,608 7.1E-03     
rs4286772 6 22,830,587 7.1E-03     
rs4782742 16 81,573,151 7.1E-03 CTD-3253I12.1 1.9E-03 
rs10247874 7 30,842,648 7.1E-03 INMT-FAM188B   
rs6991834 8 3,115,506 7.1E-03 CSMD1 8.6E-05 
rs1464500 12 24,280,927 7.1E-03 RP11-444D3.1 7.7E-04 
rs11645023 16 78,483,635 7.1E-03     
rs2394180 6 29,913,178 7.1E-03     
rs12699725 7 15,500,240 7.1E-03 AGMO 1.6E-03 
rs9950834 18 42,548,720 7.1E-03 ST8SIA5   
rs534286 9 110,840,055 7.1E-03 TMEM245   
rs7703727 5 176,990,043 7.1E-03 RP11-1277A3.2   
rs7960860 12 117,532,673 7.1E-03     
rs2930732 9 7,648,953 7.1E-03     
rs6476322 9 32,031,861 7.1E-03     
rs9785096 8 41,212,307 7.1E-03     
rs762066 14 50,374,445 7.1E-03     
rs12004815 9 98,353,833 7.1E-03 CDC14B   
rs10018304 4 83,120,969 7.1E-03 RP11-689K5.3   
rs11082399 18 40,364,087 7.1E-03     
rs6077004 20 6,390,961 7.1E-03 RP11-199O14.1   
rs1468263 17 27,171,997 7.1E-03     
rs6505423 17 30,032,439 7.1E-03     
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rs4681901 3 58,680,914 7.1E-03 C3orf67   
rs12619539 2 169,958,048 7.1E-03     
rs2273697 10 101,553,805 7.1E-03 ABCC2   
rs2838956 21 45,769,452 7.1E-03 SLC19A1   
rs2855736 12 11,872,565 7.1E-03 ETV6 1.0E-03 
rs7958091 12 117,579,622 7.1E-03     
rs10818896 9 100,214,009 7.1E-03 GABBR2   
rs1359480 13 107,413,961 7.1E-03     
rs17291274 13 81,065,943 7.2E-03     
rs218204 2 33,204,540 7.2E-03 LTBP1   
rs2581965 4 22,244,178 7.2E-03     
rs1857649 9 20,998,725 7.2E-03 PTPLAD2   
rs995030 12 87,414,802 7.2E-03 KITLG   
rs3751834 16 77,573,909 7.2E-03 WWOX 3.1E-03 
rs10497310 2 167,717,651 7.2E-03 XIRP2 6.8E-03 
rs4881403     7.2E-03 RP11-499O7.5   
rs7873669 9 9,876,403 7.2E-03 PTPRD 4.7E-03 
rs218203 2 33,204,034 7.2E-03 LTBP1   
rs1833710 5 147,947,939 7.2E-03 HTR4   
rs4838594 10 49,339,148 7.2E-03 ARHGAP22   
rs2065585 1 63,186,989 7.2E-03     
rs9901648 17 76,650,303 7.2E-03 BAIAP2   
rs10486748 7 50,993,431 7.2E-03 RP4-724E13.2   
rs234146 14 97,224,265 7.2E-03 RP11-76E12.1   
rs1010984 7 24,864,529 7.2E-03 OSBPL3   
rs4332113 8 132,925,828 7.2E-03     
rs1997885 22 41,513,706 7.2E-03 GOLGA2P4   
rs3759614 14 22,906,941 7.2E-03 EFS   
rs1457788 8 133,389,718 7.2E-03 KCNQ3 2.0E-03 
rs1873164 2 179,461,794 7.2E-03 CCDC141   
rs11790439 9 108,764,188 7.2E-03 ZNF462   
rs4281084 8 31,614,916 7.2E-03 NRG1   
rs1471745 15 57,361,535 7.2E-03 MYO1E 4.2E-03 
rs2359536 10 20,939,614 7.2E-03     
rs1953478 14 43,735,132 7.2E-03 RP11-305B6.3   
rs7783211 7 82,609,331 7.2E-03 PCLO 6.2E-03 
rs2802487 10 43,984,530 7.2E-03     
rs7767396 6 44,035,028 7.2E-03     
rs8047994 16 61,986,281 7.2E-03 RP11-368L12.1   
rs1350166 12 67,922,581 7.2E-03 CPSF6   
rs11877669 18 44,568,382 7.2E-03 CTIF   
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rs10763756 10 30,112,791 7.2E-03     
rs10080213 5 52,805,736 7.2E-03     
rs1001262 5 179,740,232 7.2E-03     
rs9992707 4 186,078,904 7.2E-03 #N/A   
rs11564006 7 27,314,122 7.3E-03     
rs1209438 16 53,138,749 7.3E-03     
rs4868790 5 166,681,168 7.3E-03 ODZ2 2.5E-03 
rs2174403 16 77,486,959 7.3E-03 RP11-319G9.3 3.1E-03 
rs4245284     7.3E-03     
rs3019626 11 61,564,848 7.3E-03     
rs1209001 7 91,278,295 7.3E-03 CTB-104F4.2   
rs1397988 18 40,276,800 7.3E-03     
rs2700996 7 37,335,714 7.3E-03 ELMO1 5.1E-03 
rs495083 9 119,356,717 7.3E-03     
rs2511317 11 90,196,005 7.3E-03 RP11-660M18.2   
rs13088432 3 77,044,375 7.3E-03 ROBO2   
rs1341032 9 74,541,943 7.3E-03 RP11-28P17.3   
rs4664352 2 161,244,689 7.3E-03     
rs11685766 2 28,683,575 7.3E-03 PLB1   
rs7910260 10 60,280,925 7.3E-03     
rs9428757 1 237,118,548 7.3E-03     
rs6451872 5 20,694,307 7.3E-03 RP11-774D14.1   
rs7636173 3 165,938,827 7.3E-03 RP11-71H9.1   
rs1915275 1 237,214,414 7.3E-03     
rs17328231 1 95,791,119 7.3E-03 RP11-286B14.1   
rs11179382 12 71,500,424 7.3E-03     
rs1438650 13 68,379,734 7.3E-03     
rs742146 22 35,250,780 7.3E-03 EIF3D 2.6E-03 
rs2018682 22 19,647,432 7.3E-03 XXbac-B135H6.15   
rs6426244 1 245,619,172 7.3E-03     
rs543262 2 169,372,473 7.3E-03 NOSTRIN   
rs2810047 14 96,946,958 7.3E-03     
rs12894942 14 97,402,628 7.3E-03     
rs1553975 3 132,999,266 7.3E-03 CPNE4 1.5E-03 
rs1437731 2 240,297,565 7.3E-03     
rs8133357 21 21,439,390 7.3E-03 NCAM2   
rs7041770 9 35,523,348 7.3E-03 RUSC2   
rs931725 2 227,054,278 7.3E-03     
rs7357583 8 19,296,766 7.3E-03 SH2D4A   
rs1936547 13 80,051,349 7.3E-03     
rs12506698 4 137,357,811 7.4E-03 RP11-775H9.2   
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rs1676884 11 74,673,280 7.4E-03 ARRB1   
rs1356224 2 13,114,377 7.4E-03     
rs471799 6 12,803,957 7.4E-03     
rs4896067 6 134,873,179 7.4E-03 RP11-557H15.3   
rs2746167     7.4E-03     
rs726739 20 12,142,424 7.4E-03     
rs13029158 2 52,225,047 7.4E-03 AC007682.1   
rs6092192 20 53,855,033 7.4E-03     
rs4075492 8 2,507,431 7.4E-03 RP11-134O21.1   
rs4676435 2 241,096,674 7.4E-03 ANKMY1 6.3E-03 
rs6798963 3 169,644,283 7.4E-03 EGFEM1P   
rs7561779     7.4E-03 SLC8A1   
rs9371379 6 155,954,368 7.4E-03     
rs42733 7 28,428,869 7.4E-03 CREB5 2.4E-04 
rs1537625 10 7,650,512 7.4E-03 ITIH5   
rs3739593 9 474,336 7.4E-03 RP11-165F24.5   
rs17698657 9 28,109,660 7.4E-03 LINGO2 2.2E-03 
rs1867977 10 73,204,962 7.4E-03 CDH23 4.7E-03 
rs3912519 16 50,440,889 7.4E-03     
rs1016091 1 34,697,183 7.4E-03     
rs4701131 5 178,915,052 7.4E-03 RUFY1 7.1E-03 
rs1037690 5 41,448,858 7.4E-03 PLCXD3   
rs4347211 1 205,044,963 7.4E-03 IL19   
rs966097 9 78,000,164 7.4E-03 PCSK5 9.0E-03 
rs1006049 2 71,030,168 7.4E-03 AC007040.7   
rs7733389 5 178,907,603 7.4E-03 RUFY1   
rs1388372 8 127,005,334 7.4E-03 RP11-622O11.2   
rs890228 8 6,647,873 7.4E-03     
rs4744904 9 71,302,087 7.4E-03 RP11-470P21.2   
rs42714 7 28,421,758 7.4E-03 CREB5 2.4E-04 
rs966855 5 33,735,534 7.4E-03 ADAMTS12   
rs850511 12 109,724,204 7.4E-03     
rs1469773 9 26,756,179 7.4E-03 RP11-18A15.1   
rs4952981     7.4E-03 THADA   
rs9637407 3 151,181,271 7.5E-03 RP11-651P23.4   
rs10181522 2 50,493,827 7.5E-03 NRXN1 2.3E-04 
rs7852392 9 115,479,570 7.5E-03 RP11-18B16.2   
rs2108780 7 7,259,417 7.5E-03 AC005532.5   
rs4843668 16 86,263,115 7.5E-03 JPH3   
rs4234306 3 156,584,525 7.5E-03 PLCH1   
rs2068028 7 4,446,209 7.5E-03     
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rs1860312 19 2,524,995 7.5E-03 GNG7 4.6E-03 
rs9347879 6 164,935,251 7.5E-03     
rs10192647 2 8,548,532 7.5E-03     
rs10016365 4 114,050,334 7.5E-03 ANK2 4.2E-04 
rs9656946 8 124,683,548 7.5E-03     
rs2889090 2 137,708,944 7.5E-03 THSD7B 5.0E-03 
rs2659615 11 132,225,458 7.5E-03 OPCML 2.4E-04 
rs1735969 21 22,044,472 7.5E-03 AP000475.2   
rs10902221 11 792,379 7.5E-03 SLC25A22   
rs1267070 2 161,696,729 7.5E-03 AC009313.1   
rs2121698 2 46,563,075 7.5E-03 AC018682.6   
rs1434262 9 8,693,733 7.5E-03 RP11-134K1.3 4.7E-03 
rs6715733 2 127,477,188 7.5E-03     
rs3091619 20 44,758,167 7.5E-03     
rs11011346     7.5E-03     
rs4354609 10 24,356,140 7.5E-03 KIAA1217 1.4E-04 
rs4588237 2 47,796,406 7.5E-03 AC006509.6   
rs9300597     7.5E-03 PCCA   
rs956053 3 10,997,826 7.5E-03     
rs2345962 1 162,008,412 7.5E-03 RP4-640E24.1   
rs10167178 2 129,718,195 7.5E-03 AC079586.1   
rs1993094 7 25,811,535 7.5E-03     
rs12615002 2 40,474,891 7.5E-03 SLC8A1 8.9E-04 
rs2921448 10 74,160,029 7.5E-03 MCU   
rs4745960 10 64,387,046 7.5E-03     
rs1378796 3 158,614,482 7.5E-03 VEPH1   
rs4855216 3 165,487,506 7.5E-03     
rs790455 12 91,139,496 7.5E-03     
rs2024585 6 160,255,007 7.5E-03     
rs10492086 12 100,712,072 7.5E-03 GNPTAB   
rs4712580 6 21,173,805 7.6E-03 CDKAL1 3.6E-03 
rs6890341 5 27,105,871 7.6E-03 CDH9   
rs4342076 3 147,371,183 7.6E-03     
rs6252 12 28,002,340 7.6E-03 RP11-993B23.3   
rs3816263 17 7,924,882 7.6E-03 ALOX12B 1.3E-03 
rs2882444 13 89,800,666 7.6E-03     
rs2381617 9 7,488,487 7.6E-03     
rs1030191 5 166,676,280 7.6E-03 ODZ2 2.5E-03 
rs130407 22 30,802,930 7.6E-03 SLC5A1   
rs4867041 5 30,588,718 7.6E-03     
rs2214020 5 9,905,860 7.6E-03 RP11-447B18.1   
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rs1901565 9 28,045,900 7.6E-03 LINGO2 2.2E-03 
rs4801695 19 61,457,272 7.6E-03 ZSCAN5A   
rs3764465 18 46,825,370 7.6E-03 SMAD4   
rs7513441 1 72,196,705 7.6E-03 NEGR1   
rs11767716 7 3,092,767 7.6E-03 AC024028.1   
rs555267 18 39,246,696 7.6E-03     
rs4055434 6 164,109,891 7.6E-03     
rs7540116 1 169,660,411 7.6E-03     
rs12752933 1 190,897,781 7.6E-03 RGS13   
rs2327221 6 10,143,861 7.6E-03 OFCC1   
rs10199719 2 148,875,899 7.6E-03 MBD5   
rs1475183 13 25,185,826 7.6E-03 ATP8A2   
rs2301677 7 17,292,583 7.6E-03 AC003075.4   
rs4811450     7.6E-03     
rs9328072 6 1,773,164 7.6E-03 GMDS   
rs7556828 2 46,516,676 7.6E-03 AC018682.6   
rs1469863 17 37,220,613 7.6E-03 LEPREL4   
rs4774478 15 61,221,816 7.6E-03 LACTB   
rs10743542 12 8,936,937 7.6E-03     
rs1360382 9 23,369,719 7.6E-03     
rs10512302 9 104,487,695 7.6E-03     
rs4371145 16 80,847,418 7.6E-03     
rs4740969 9 8,912,286 7.6E-03 PTPRD 4.7E-03 
rs16920176 8 57,061,690 7.6E-03 LYN   
rs11768582 7 82,668,636 7.6E-03     
rs11750078 5 132,692,272 7.6E-03 FSTL4 1.2E-03 
rs965432 2 158,819,527 7.6E-03 CCDC148 3.0E-03 
rs17119719 8 14,436,692 7.6E-03 SGCZ 5.9E-04 
rs1762529 10 33,008,086 7.6E-03 C10orf68   
rs9318814 13 81,349,619 7.6E-03     
rs11008980 10 32,902,186 7.6E-03 CCDC7   
rs6134919 20 13,510,481 7.6E-03 TASP1   
rs2221511 18 59,530,380 7.7E-03 SERPINB11   
rs1078019 4 38,131,334 7.7E-03 RP11-83C7.2   
rs6782741 3 119,894,154 7.7E-03     
rs11104732 12 87,002,119 7.7E-03 CEP290   
rs4714261 6 39,647,185 7.7E-03 KIF6   
rs2828665 21 24,275,166 7.7E-03     
rs10093667 8 26,760,792 7.7E-03 ADRA1A   
rs4801473 19 62,551,402 7.7E-03 ZNF304   
rs11167068 8 142,618,960 7.7E-03     
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rs2001456 6 100,545,730 7.7E-03 RP11-14I4.3   
rs6483140 11 91,053,707 7.7E-03     
rs9814976 3 41,190,800 7.7E-03     
rs8048583 16 31,187,037 7.7E-03 ITGAM   
rs12431159 13 99,873,865 7.7E-03 PCCA   
rs4985702 17 16,977,947 7.7E-03 MPRIP   
rs2683556 10 71,304,127 7.7E-03 COL13A1 8.9E-03 
rs525455 10 13,143,291 7.7E-03 RP11-730A19.2   
rs2298629 18 45,572,077 7.7E-03 ACAA2   
rs12084355 1 99,222,557 7.7E-03 LPPR5   
rs9402168 6 130,108,429 7.7E-03 RP11-73O6.4   
rs2738173 8 6,728,348 7.7E-03 GS1-24F4.2   
rs17415614 5 143,121,215 7.7E-03 CTB-57H20.1   
rs1293151 20 52,384,991 7.7E-03     
rs10776644 10 49,660,087 7.7E-03 WDFY4 1.0E-03 
rs6590453 11 129,745,971 7.7E-03 RP11-121M22.1   
rs270327 6 153,852,496 7.7E-03     
rs4723037 7 30,966,625 7.7E-03 GHRHR   
rs2821505 9 9,762,724 7.7E-03 PTPRD 4.7E-03 
rs1767777 6 11,033,789 7.7E-03 TMEM14B   
rs2792218 9 77,796,917 7.7E-03 PCSK5 9.0E-03 
rs1339252 9 77,797,479 7.7E-03 PCSK5 9.0E-03 
rs12654791 5 179,744,794 7.7E-03     
rs1351188 11 134,410,991 7.7E-03     
rs4886250     7.7E-03     
rs2022991 6 162,168,159 7.7E-03 PARK2 8.8E-05 
rs2569865 6 1,474,786 7.7E-03     
rs181706 21 28,122,934 7.7E-03     
rs9874501 3 167,902,738 7.7E-03     
rs1983666 22 24,745,565 7.7E-03 MYO18B   
rs9635033 13 79,956,028 7.7E-03     
rs1397590 16 47,717,543 7.8E-03     
rs1598828 15 27,582,448 7.8E-03 FAM189A1   
rs2924331 18 51,297,301 7.8E-03 TCF4 6.1E-03 
rs7839802 8 14,418,884 7.8E-03 SGCZ 5.9E-04 
rs1996483 3 167,607,628 7.8E-03     
rs8088451 18 45,526,032 7.8E-03     
rs10743549 12 8,943,104 7.8E-03     
rs6880335 5 50,788,219 7.8E-03 CTD-2335O3.3   
rs10210385 2 58,851,216 7.8E-03 AC007092.1   
rs169271 20 51,342,873 7.8E-03 TSHZ2 6.7E-04 
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rs2481031 6 160,676,719 7.8E-03     
rs1969888 13 105,648,715 7.8E-03     
rs719082 7 24,483,720 7.8E-03     
rs408109 8 37,217,210 7.8E-03     
rs10887335 10 86,367,249 7.8E-03     
rs11633343 15 47,911,577 7.8E-03 FGF7   
rs9864901 3 147,005,074 7.8E-03     
rs2149131 13 26,291,325 7.8E-03     
rs881500 15 61,458,525 7.8E-03 CA12   
rs4237861 12 70,953,954 7.8E-03 AC087886.1 1.6E-03 
rs9984281 21 34,663,726 7.8E-03 AP000320.6 7.0E-03 
rs1224391 9 21,381,698 7.8E-03 RP11-354P17.15   
rs1168338 12 65,045,636 7.8E-03 GRIP1 1.0E-03 
rs9295235 6 164,217,031 7.8E-03     
rs9911131 17 55,066,785 7.8E-03 CLTC-IT1   
rs2381800 9 8,425,110 7.8E-03 PTPRD 4.7E-03 
rs10175110 2 49,500,618 7.8E-03     
rs10484546 6 29,432,578 7.8E-03 OR5V1   
rs1529764 7 131,729,953 7.8E-03 PLXNA4 6.4E-03 
rs1391530 11 80,399,957 7.8E-03     
rs2275496 9 110,681,448 7.8E-03 IKBKAP   
rs4361224 3 39,312,604 7.8E-03     
rs9531108 13 80,218,134 7.8E-03     
rs960962 20 20,301,515 7.8E-03 INSM1   
rs9840567 3 169,708,327 7.8E-03 EGFEM1P   
rs256822 5 155,864,858 7.8E-03 SGCD   
rs13091735 3 169,749,953 7.8E-03 EGFEM1P   
rs588918 11 116,361,852 7.8E-03 SIK3   
rs1351452 11 116,448,564 7.8E-03 SIK3   
rs4076927 3 46,705,753 7.8E-03 ALS2CL   
rs7322446 13 63,756,181 7.8E-03     
rs519813 4 20,130,091 7.8E-03 SLIT2   
rs2147829 14 90,233,622 7.8E-03 RP11-661G16.2   
rs1039596 5 134,441,399 7.8E-03 CTC-203F4.1   
rs10867879 9 71,481,798 7.8E-03 RP11-109D9.4   
rs1958909 14 52,514,477 7.8E-03     
rs4720945 7 11,187,371 7.8E-03     
rs10046283 6 109,525,763 7.8E-03 SESN1   
rs4736935 8 41,144,341 7.8E-03     
rs10151230 14 43,541,226 7.8E-03 RP11-305B6.3   
rs2724178 2 168,904,383 7.8E-03     
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rs378322 2 70,616,413 7.8E-03 TGFA   
rs2194505 2 161,671,500 7.9E-03 AC009313.1   
rs1487721 11 45,131,106 7.9E-03 PRDM11   
rs7928370 11 8,681,844 7.9E-03 RPL27A   
rs2075292 11 116,237,722 7.9E-03 SIK3   
rs2757599 6 7,557,267 7.9E-03 SNRNP48   
rs7229783 18 56,434,182 7.9E-03     
rs7081464 10 37,923,943 7.9E-03     
rs4700810 5 178,924,400 7.9E-03 RUFY1 7.1E-03 
rs11674865 2 1,846,247 7.9E-03 MYT1L 1.6E-03 
rs3768574 1 22,226,697 7.9E-03 LINC00339   
rs12424159 12 127,755,894 7.9E-03 TMEM132C   
rs2027394 9 4,059,657 7.9E-03 RP11-70J12.1 3.3E-04 
rs2263000 10 26,066,791 7.9E-03     
rs1635627 8 5,594,564 7.9E-03     
rs2106553 6 67,065,007 7.9E-03     
rs7595911 2 104,621,738 7.9E-03     
rs6749383 2 104,626,334 7.9E-03     
rs268289 10 43,918,152 7.9E-03     
rs9834043 3 146,853,092 7.9E-03     
rs1570896 13 100,386,483 7.9E-03 LINC00411   
rs1538903 14 49,927,228 7.9E-03 CDKL1   
rs11084990 19 2,960,220 7.9E-03 TLE2   
rs7193788 16 81,213,661 7.9E-03 CDH13   
rs4268898 2 24,343,917 7.9E-03 ITSN2   
rs9375796 6 131,382,691 7.9E-03 EPB41L2   
rs4595452 10 55,589,070 7.9E-03 PCDH15 4.8E-03 
rs12644632 4 43,608,222 7.9E-03     
rs3925075 16 31,255,249 7.9E-03 ITGAM   
rs611908 11 74,694,735 7.9E-03 ARRB1   
rs1820497 12 72,967,266 7.9E-03 RP11-81H3.2   
rs1424231 16 78,264,252 7.9E-03 RP11-345M22.1   
rs3798221 6 160,918,138 7.9E-03 LPA   
rs6061036 20 29,982,229 7.9E-03 TTLL9 3.5E-04 
rs455929 22 21,613,083 7.9E-03     
rs1528847 12 117,690,683 7.9E-03 RP11-357K6.1   
rs11768076 7 30,795,564 7.9E-03 INMT-FAM188B   
rs1757095 9 116,888,215 7.9E-03 TNC 7.3E-03 
rs7095717 10 61,718,225 7.9E-03 ANK3   
rs1403724 3 150,500,084 7.9E-03 RP11-206M11.7   




Table 5.  Genome-wide PBAT results.  The top 1% most significant results are organized by 
significance and annotated by gene name if the snp fall within a gene.  In addition, for genes 
that contain significant SNPs, I have also annotated the minimum pvalue observed in our 
published GWAS for that gene. 
 
 
Table 6. Integrated association results.  This table summarizes any gene that was implicated 
in two or more association tests.  Shared SNP indicates that the same marker was implicated in 
at least two tests.  No annotation in this column means that different SNPs were identified by 
different tests. 
Gene Chr Gene Start Gene Stop Min P count min p count min p count min p
HDAC4 2 239,969,864 240,323,348 5.9E-05 1 2.2E-04 5 5.9E-05 2 6
HTR4 5 147,830,595 148,056,798 4.0E-04 2 1.7E-03 1 4.0E-04 2 2 yes
PPARGC1B 5 149,109,861 149,234,585 2.4E-04 1 1.9E-03 1 2.4E-04 2 2
GRIA1 5 152,869,175 153,193,240 1.4E-08 1 2.8E-03 2 1.4E-08 4 2.3E-04 3 7
FAM114A2 5 153,369,688 153,418,496 6.9E-05 1 3.1E-03 1 6.9E-05 2 1 yes
SGCD 5 155,297,354 156,194,499 5.3E-05 7 1.1E-03 1 5.3E-05 2 7 yes
MCM3 6 52,128,807 52,149,582 9.3E-06 1 3.7E-03 1 9.3E-06 2 1 yes
TMEM14A 6 52,535,907 52,551,386 1.0E-06 2 7.7E-04 2 1.0E-06 2 2 yes
DST 6 56,322,785 56,819,426 5.6E-06 1 5.9E-03 1 5.6E-06 2 1 yes
KHDRBS2 6 62,390,139 62,996,132 2.0E-05 1 3.4E-03 1 2.0E-05 2 1 yes
EYS 6 64,429,876 66,417,118 2.2E-05 1 4.6E-03 1 2.2E-05 2 1 yes
RIMS1 6 72,596,406 73,112,845 5.9E-07 2 5.1E-04 3 5.9E-07 2 3 yes
KCNQ5 6 73,331,520 73,908,574 2.0E-07 1 3.2E-03 1 2.0E-07 1 3.5E-04 3 2 yes
RP11-73O6.4 6 126,112,111 130,461,627 5.3E-05 3 4.9E-03 2 5.3E-05 2 3 yes
EPB41L2 6 131,160,487 131,384,462 7.8E-06 1 7.9E-03 1 7.8E-06 2 1 yes
VNN1 6 133,002,729 133,035,188 1.4E-05 2 2.3E-03 2 1.4E-05 2 2 yes
AHI1 6 135,604,670 135,830,219 6.1E-05 1 1.8E-04 1 6.1E-05 2 1 yes
IL20RA 6 137,321,108 137,366,298 4.6E-05 1 3.7E-03 1 4.6E-05 2 1 yes
ERI1 8 8,859,657 8,974,256 5.3E-05 1 5.3E-05 1 2.8E-04 2 2
TNKS 8 9,413,424 9,639,856 2.8E-04 1 1.8E-03 1 2.8E-04 2 2
MSRA 8 9,911,778 10,286,401 1.0E-07 4 4.5E-04 3 1.0E-07 2 3.6E-05 3 6 yes
XKR6 8 10,753,555 11,058,875 1.8E-04 1 2.6E-03 1 1.8E-04 2 2
FDFT1 8 11,653,082 11,696,818 1.6E-07 2 1.7E-03 2 1.6E-07 1 4.9E-04 3 3 yes
SGCZ 8 13,947,373 15,095,848 7.7E-05 4 1.3E-03 3 7.7E-05 2 7
KANK1 9 470,291 746,105 1.6E-07 3 6.2E-05 3 1.6E-07 2 4 yes
GLIS3 9 3,824,127 4,348,392 2.1E-04 2 3.1E-03 1 2.1E-04 2 3
SEC61A2 10 12,171,636 12,211,960 3.8E-05 3 3.9E-03 2 3.8E-05 2 3 yes
FRMD4A 10 13,685,706 14,504,141 3.7E-05 2 3.7E-05 1 4.2E-04 2 3
KIAA1217 10 23,983,675 24,836,772 3.3E-04 3 3.0E-03 1 3.3E-04 2 4
HS3ST4 16 25,703,347 26,149,009 1.5E-04 3 2.0E-03 1 1.5E-04 2 4
XPO6 16 28,109,300 28,223,241 4.7E-04 1 4.8E-03 1 4.7E-04 2 2
ITGAM 16 31,271,311 31,344,190 1.1E-04 2 7.7E-03 1 1.1E-04 2 3
FTO 16 53,737,875 54,155,853 5.1E-04 1 6.3E-03 1 5.1E-04 2 2
L3MBTL4 18 5,954,705 6,414,910 3.5E-04 2 1.9E-03 1 3.5E-04 2 3
CTIF 18 46,065,417 46,389,588 9.1E-05 2 6.9E-03 1 9.1E-05 2 2 yes
DCC 18 49,867,158 51,062,269 1.5E-04 1 4.4E-03 5 1.5E-04 2 6
TCF4 18 52,889,562 53,332,018 2.5E-04 2 4.6E-03 1 2.5E-04 2 2 yes
ATP8B1 18 55,313,658 55,470,327 7.9E-05 1 3.7E-04 1 7.9E-05 2 1 yes
NEDD4L 18 55,711,619 56,068,772 3.1E-04 2 5.5E-04 1 3.1E-04 2 3



































































































      
6 52128807 52149582 MCM3 9.3E-
06 
Integrated yes     
6 52535907 52551386 TMEM14A 1.0E-
06 
Integrated       




      
6 56322785 56819426 DST 5.6E-
06 
Integrated yes     
6 62390139 62996132 KHDRBS2 2.0E-
05 
Integrated       
6 64429876 66417118 EYS 2.2E-
05 
Integrated     4.5E-
04 




yes   8.9E-
03 
6 72596406 73112845 RIMS1 5.9E-
07 
Integrated yes     
6 73331520 73908574 KCNQ5 2.0E-
07 




























































Integrated       
8 8859657 8974256 ERI1 5.3E-
05 
Integrated       
8 9413424 9639856 TNKS 2.8E-
04 
Integrated       
8 9911778 10286401 MSRA 1.0E-
07 




8 10753555 11058875 XKR6 1.8E-
04 
Integrated       
8 11653082 11696818 FDFT1 1.6E-
07 
Integrated yes     
8 13947373 15095848 SGCZ 7.7E-
05 
Integrated     5.9E-
04 
9 470291 746105 KANK1 1.6E-
07 
Integrated     4.4E-
04 
9 3824127 4348392 GLIS3 2.1E-
04 
Integrated     3.3E-
04 
10 12171636 12211960 SEC61A2 3.8E-
05 
Integrated   GO:000247
4 
  
10 13685706 14504141 FRMD4A 3.7E-
05 
Integrated yes     
10 23983675 24836772 KIAA1217 3.3E-
04 
Integrated     1.4E-
04 
16 25703347 26149009 HS3ST4 1.5E-
04 
Integrated     4.3E-
03 
16 28109300 28223241 XPO6 4.7E-
04 
Integrated       
16 31271311 31344190 ITGAM 1.1E-
04 
Integrated       
16 53737875 54155853 FTO 5.1E-
04 
Integrated       
18 5954705 6414910 L3MBTL4 3.5E-
04 
Integrated     8.6E-
03 
18 46065417 46389588 CTIF 9.1E-
05 
Integrated       
18 49867158 51062269 DCC 1.5E-
04 
Integrated     7.6E-
03 
18 52889562 53332018 TCF4 2.5E-
04 
Integrated yes   6.1E-
03 






      
18 55313658 55470327 ATP8B1 7.9E-
05 
Integrated       
18 55711619 56068772 NEDD4L 3.1E-
04 
Integrated yes     
 
Table 7. Summary of genes implicated in this study.  Any gene for which at least one SNP 
falling within its transcript exceeded the significance threshold for any test conducted in the 
course of this study is listed. The source of the evidence is additionally annotated, along with 
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additional evidence, such as expression in the hair follicle (HF), annotation in an immune 




Table 8. Distribution of GWAS risk alleles in our family cohort.  Our GWAS identified 16 
independent risk haplotypes.  Here I display the frequency of a single proxy SNP for each of 15 
haplotypes (one SNP was not typed in this study).  For some SNPs, the frequencies within 
families differ between affected and unaffected family members, which is what would be 
expected for a cosegregating variant.  However, for the majority of SNPs, allele frequencies do 
not vary between affected and unaffected family members, suggesting that these variants could 

















CTLA4_hap1 rs926169 2 204,430,997 A 0.44 0.42 0.46 0.47 0.39
CTLA4_hap2 rs3096851 2 204,472,127 C 0.35 0.36 0.36 0.37 0.31
IL21_hap3 rs7682241 4 123,743,325 A 0.41 0.42 0.42 0.40 0.34
ULBP6_hap4 rs9479482 6 150,399,705 A 0.71 0.76 0.63 0.68 0.57
ULBP3_hap5 rs2009345 6 150,431,441 G 0.50 0.60 0.38 0.50 0.39
STX17_hap6 rs10760706 9 101,763,513 G 0.31 0.29 0.34 0.38 0.31
IL2RA_hap7 rs4147359 10 6,148,445 A 0.37 0.39 0.33 0.39 0.33
IL2RA_hap8 rs3118470 10 6,141,719 G 0.33 0.35 0.31 0.38 0.30
ZNFN1A4_hap10 rs1701704 12 54,698,754 C 0.33 0.35 0.31 0.40 0.33
ERBB3_hap11 rs705708 12 54,775,180 G 0.49 0.48 0.48 0.47 0.53
BTNL2_hap12 rs3129963 6 32,488,186 A 0.88 0.91 0.86 0.93 0.83
BTNL2_hap13 rs1980493 6 32,471,193 A 0.94 0.94 0.94 0.94 0.85
HLA-DQA2_hap14 rs1794282 6 32,774,504 G 0.95 0.96 0.94 0.96 0.90
AGER_hap15 rs2070600 6 32,259,421 A 0.06 0.07 0.06 0.08 0.04
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Alopecia Areata (AA) is one of the most prevalent autoimmune diseases, in which 
immune destruction is targeted to the hair follicle.  Despite the prevalence of AA, there are no 
evidence-based treatments, which creates an enormous unmet medical need.1 Prior to our initial 
genome-wide association study (GWAS), the genetic basis of AA had remained largely 
unknown, creating barriers to the development of effective therapeutic strategies.  That first 
study implicated eight regions of the genome, seven of which had never previously been studied 
within the context of AA, and implicated several genes pivotal to immune response.  Here, I 
conduct a follow-up study, by the addition of 800 cases with mild AA to our initial cohort.  After 
stringent quality control filtering, I conducted association analysis of 443,349 SNPs in a cohort 
of 1801 cases and 3274 controls.  The increase in power achieved by this moderate increase in 
sample size has allowed me to identify an additional region of the genome that harbors risk 
alleles for AA, on chromosome 16p13.13.  This region demonstrated nominal significance in our 
initial GWAS (p=1.4x10-5), and was additionally found to have significant association in a 
candidate gene study conducted following our GWAS.  I next performed a case only analysis to 
identify markers with allele frequencies that differ between mild (n=1194) and severe (n=604) 
cases, and identified 6 SNPs with statistically significant association, all of which are located 
within the HLA class II region. Taken together, this study suggests that increasing sample sizes 
for GWAS in AA will continue to yield novel associations, as has been seen for other 
autoimmune diseases.  Furthermore, this study provides support to previous studies that found 
disease severity effects for loci within the HLA region. 
 
Introduction 
Alopecia areata (AA) is one of the most prevalent autoimmune diseases, with a lifetime 
risk of 1.7%.2 In AA, autoimmunity develops against the hair follicle, resulting in non-scarring 
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hair loss that may begin as patches, which can coalesce and progress to cover the entire scalp 
(alopecia totalis, AT) or eventually the entire body (alopecia universalis, AU).  The immune 
attack is focused at the end bulb and spares the stem cell niche, such that hair growth remains 
possible once the aberrant immune response subsides.  The disease waxes and wanes for 
many patients, leading to bouts of remission between disease relapses.  By convention, patients 
are considered to have severe disease when hair loss affects at least the entire scalp, if not the 
whole body, for at least one episode of hair loss. 
Our group conducted the first genome wide associated study, which identified 139 SNPs 
that exceeded our threshold for statistical significance (p≤5x10-7).3  That study confirmed 
association of AA with the Human Leukocyte Antigen (HLA) class II region, which had 
previously been associated with AA through candidate gene studies, and additionally implicated 
eight additional regions of the genome that had never before been studied within the context of 
AA. Most of the identified regions contain genes pivotal to immune response that had previously 
been studied within the context of other autoimmune diseases such as type 1 diabetes (T1D), 
celiac disease (CeD) and rheumatoid arthritis (RA), including CTLA4, IL-2/IL-21, IL-2RA, 
PTPN2, and Eos (IKZF4)/ERBB3.  One region contains ligands for the NKG2D receptor, an 
activator of cytotoxic lymphocytes, which had never before been implicated in human disease, 
ULBP3/ULBP6.  Finally two regions contain genes that are expressed in the hair follicle 
(PRDX5, STX17).  All of these associations have subsequently been confirmed in an 
independent cohort of unrelated AA patients and population matched controls through candidate 
gene studies.4-6  The genetic evidence from this study implicates disease mechanisms that are 
shared with other autoimmune disorders and suggests that therapeutic strategies targeted to 
these mechanism and efficacious for aligned diseases could be repositioned to treat AA, 
transforming the therapeutic landscape for this highly prevalent disease.7 
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GWAS in other autoimmune diseases unequivocally demonstrate that increases in 
sample size will yield novel genetic associations.  Currently, nearly 2700 GWAS in the 
genome.gov database of GWAS have reported sample sizes over 10,000, and four exceed a 
sample size of 100,000.  Among autoimmune diseases, two GWAS have more than 10,000 
samples and the largest to date was conducted for inflammatory bowel disease (IBD) with a 
sample size of more than 75,000.  In AA, we are limited in the number of patients available to 
participate in GWAS, in part because resources have not existed to conduct large-scale 
international ascertainment.  Our first GWAS utilized all the unrelated affected participants of the 
National Alopecia Areata Registry who self-reported European ancestry and had enrolled up to 
the time that we conducted our study.  Through collaboration with an international colleague, we 
were able to genotype an additional 800 cases with mild disease (hair loss never exceeded 
more than 75% of the scalp at any point in their lifetime).  I present here association analysis of 
this expanded GWAS cohort, in addition to a case only analysis that sought to identify disease 
alleles associated with disease severity. 
 
Materials and Methods 
Patient Population 
For the initial GWAS, cases were ascertained through the National Alopecia Areata 
Registry (NAAR), and control data were obtained from publically available data, as previously 
described.3  Briefly, there were two sources of control data.  First, a dataset was obtained from 
subjects enrolled in the New York Cancer Project8 and genotyped as part of previous studies.9  
Second, a dataset was obtained from the CGEMS breast10 and prostate11 cancer studies 
(http://cgems.cancer.gov/data/).  The controls were not expanded for this study.  The additional 
800 patients with mild disease were recruited from outpatient clinics, private dermatology 
practices and via AA self-support groups in Belgium and Germany.  Inclusion criteria followed 
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published guidelines,12 and additionally included diagnosis by a trained and experienced 
clinician.  Disease subtype for all patients in this study was determined according to the AA 
investigation assessment guidelines.12  All participants provided written informed consent and 
the study was conducted in accordance with the Declaration of Helsinki Principles.  The study 
was approved by the local IRB committees. 
 
Genotyping 
DNA was extracted from peripheral blood leukocytes by salting out with saturated NaCl 
solution according to standard methods, or by using a Chemagic Magnetic Separation Module I 
(Chemagen, Baesweiler, Germany) in accordance with the manufacturer’s instructions.  All 
cases were genotyped with the Illumina 610K chip. Controls were not genotyped within this 
study.  Data for the controls had been generated in other studies, as described above. These 
samples had all been genotyped with the Illumina 550K chip, at the center who genotyped our 
cases, as previously described.3   
 
Assessment of Data Quality 
Quality control (QC) was performed with Helix Tree software (Golden Helix). Only SNPs 
that had passed QC thresholds in the initial GWAS were used.3  Briefly, SNPs that were missing 
more than 5% data or did not appear to be in Hardy Weinberg Equilibrium in controls (p<0.01) 
had been removed.   Once this subset of SNPs was identified in the new set of cases, QC filters 
were applied and did not identify any additional poor quality SNPs, so analyses were performed 
on 463,308 SNPs.  Poor quality DNA was identified by filtering out samples missing more than 
5% data (n=35).  Estimates of genome-wide Identity by Descent (IBD) between pairs of samples 
were calculated to identify related individuals with the cohort.  This method identified 2 pairs of 
duplicate samples and 1 pair of related individuals; one sample from each of these three pairs 
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was removed. Principal components analysis (PCA) using 3568 ancestry informative markers 
(AIMs) was performed.7  This analysis identified 15 samples more than 6 standard deviations 
units from 5 components, and these were excluded from subsequent analysis. Visual inspection 
of a plot of the first two eigenvectors following exclusion of identified outliers confirmed 
comparable distributions between the cases and controls. 
  
Statistical Analysis 
Whole genome association tests were performed with Helix Tree software (Golden 
Helix). Reported association values were obtained with logistic regression assuming an additive 
genetic model, which assumes additive effects of the risk allele, namely that the risk for 
homozygotes is twice the risk of heterozygotes, and correcting for residual population 





In this study, I expanded our previously reported GWAS cohort by the addition of 800 
unrelated cases.  After stringent quality control filters to remove questionable samples and 
markers, my dataset contained 1801 cases, 1054 from the original cohort and 747 from our 
German colleagues, of which 1194 have mild AA and 604 have severe disease, characterized 
by total loss of scalp hair.  There were 3274 controls.  
The first analysis tested 443,349 SNPs for association with AA, comparing allele 
frequencies of cases with those of controls.  A total of eight regions in the genome exceeded my 
threshold for statistical significance (p<5x10-7) (Figure 1).  Seven of these regions demonstrated 
statistically significant association in our initial GWAS, including chromosomes 2q33.2 
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(CTLA4/ICOS); 4q27 (IL21/IL2); 6p21.32 (HLA), 6q25.1 (ULBP3/ULBP6); 9q31.1 (STX17); 
10p15.1 (IL2RA); and 11q13 (PRDX5).  A region on chromosome 16p13.13 only achieved 
nominal significance in our initial GWAS, but surpassed the threshold in this study.  A single 
SNP rs4451969 achieved significance (p=4.6x10-7; OR=1.21) (Figure 2).  Only one region 
identified in the initial GWAS failed to pass the threshold for statistical significance here, 
although it remained nominally significant (chromosome 12q13.2; minp=1.8x10-6). 
To investigate whether disease alleles can influence severity of disease, I conducted a 
case-only analysis, comparing allele frequencies among 604 patients with severe disease to 
those among 1194 patients with mild disease (Figure 3).  Only seven SNPs surpassed our 
threshold for statistical significance and these were all clustered within the HLA class II region 
(Table 1).   
 
Discussion 
The course of genetic discoveries across autoimmune diseases have been similar , such 
that an initial GWAS with approximately 1000 patients uncovered five to eight risk loci, and as 
subsequent GWAS and meta-analyses expanded to include up to 5000 patients, the number of 
bona fide risk loci increased (e.g., to approximately 40 in type 1 diabetes and more than 70 in 
Crohn´s disease [www.genome.gov/gwastudies]). The most recent meta analysis in Crohn’s 
disease included a cohort of 75,000 samples and identified a total of 163 risk loci.14  Sample 
size is thus clearly a determinant of the number of associations that GWAS can reveal for 
autoimmune diseases.  Our initial GWAS in AA contained just over 1000 cases and its findings 
likely represent just the tip of the iceberg.  In this study, we expanded our cohort with the 
addition of 800 cases and I conducted association analysis, which identified an additional 
significant locus.   
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The locus at chromosome 16p13.13 is gene dense, containing at least 13 unique coding 
transcripts within a 480Kb interval.  Several of these genes are most commonly discussed 
within the context of genetic associations to this region: class II, major histocompatibility 
complex, transactivator (CIITA), Dexi homolog (DEXI), C-type lectin domain family 16, member 
A (CLEC16A), suppressor of cytokine signaling 1 (SOCS1), transition protein 2 (TNP2), 
protamine 1 (PRM1), protamine 2 (PRM2), and protamine 3 (PRM3). The locus has been 
associated with six different autoimmune diseases through GWAS, including type 1 diabetes, 
celiac disease, Crohn’s disease, multiple sclerosis, ulcerative colitis and primary biliary cirrhosis 
(www.genome.gov/gwastudies).  In our initial GWAS, this locus achieved nominal significance, 
with a minimum p-value of 1.2x10-5 for SNP rs8060821.3  More recently, a candidate gene study 
in AA identified a statistically significant association at this locus for SNP rs998592 (p=2.45x10-
7).4 
Several of the genes at this locus have been implicated in immune functions, including 
CIITA and SOCS1.15-19 These genes are both known regulators of type I interferon-gamma 
mediated signaling via JAK-STAT cascade, a pathway that has been strongly implicated in AA 
pathology, by gene expression studies (A.M. Christiano and R.Clynes, personal 
communication). CIITA has also been implicated in Bare Lymphocyte Syndrome, Type II, which 
is characterized by the abnormal expression of HLA molecules.20  Despite the extensive 
literature citing disease associations with SNPs within and near CLEC16A, very little is known 
about its function.  Of interest, a recent study of this locus demonstrated that a number of 
GWAS–identified risk alleles within an intron of CLEC16A affect the expression of a neighboring 
gene, DEXI.21  Gene annotations in Ensembl database indicate that five genes within this locus 
have demonstrated expression in CD56+ NK cells: CIITA, CLEC16A, PRM1, PRM2, and TNP2 
within the GNF Gene Expression Atlas, a project that measured gene expression across 79 
different human cell or tissue types.22  Of all eight genes located at this locus, only CIITA is 
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observed to be differentially expressed in lesional scalp biopsies (A.M. Christiano, personal 
communication).  While this locus is clearly associated with increased risk for a set of 
autoimmune diseases, the exact causal mechanism remains unclear and it is possible that 
several different genes contribute to disease. 
It has previously been suggested that mild AA and severe AA may differ in their genetic 
architecture. .23,24  In order to address this question, I conducted a case only analysis, in which 
allele frequencies were compared between mild AA cases and severe AA cases.  Only the HLA 
region exceeded the threshold for statistical significance.  Several published studies have found 
that HLA associations are stronger for patients affected with severe AA than for those with mild 
AA.23,24  The lack of additional findings outside of the HLA region could suggest that the 
underlying genetic architecture is consistent between these two phenotypically dissimilar groups 
of patients, although it could also be interpreted to reflect a sample size that is insufficient to 
detect an effect and suggests that if such effects exist, they will be of small magnitude. 













Figures and Legends 
 
Figure 1. Manhattan plot for genome-wide tests of association.  The cohort of unrelated AA 
patients and controls is expanded to include 1801 cases and 3274 controls. Logistic regression 
is used to test 443,349 SNPs for association with AA.  Eight regions of the genome exceed my 
threshold for statistical signficance (p<5x10-7), indicated by the red line and include regions 
previously identified in our first GWAS on chromosomes 2, 4, 6, 9, 10, and 11, as well as a new 





Figure 2. Detailed map of associated SNPs and gene locations for chromosome 16p13.13.  
(a). A single SNP exceeded my threshold for statistical significance, indicated by the red line. 
The blue shading indicates the region shown in the transcript map, below. (b). Thirteen genes 






Figure 3. Manhattan plot for a case only genome-wide tests of association.  Logistic 
regression is used to test for differences in allele frequencies for 443,349 SNPs between AA 
patients with mild disease and AA patients with severe disease.  A single genomic region, 
located on chromosome 6, exceeds my threshold for statistical signficance (p<5x10-7), indicated 



















rs2856725 1.2E-10 A 0.81 0.70 0.61 
rs9275572 6.5E-12 G 0.80 0.68 0.59 
rs2647012 3.0E-10 G 0.81 0.70 0.61 
rs2856717 2.4E-10 C 0.81 0.70 0.62 
rs2858305 3.0E-10 A 0.81 0.70 0.62 
rs7192 2.1E-08 C 0.79 0.69 0.61 
 
Table 1.  Case-only results.  Analysis identified six SNPs that exceeded genome-wide 
significance, all of which cluster in the HLA class II region.  SNP ID is presented with pvalue 
from the association analysis.  For all six genetic markers, the frequency of the risk allele is 
greatest among severe cases of AA, decreased among mild cases of AA, and lowest among 
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Alopecia areata (AA) is the most prevalent autoimmune disease in the US.1,2 With a 
lifetime risk of 1.7%,3 it affects both genders with similar frequencies and people of all ages.4-6 
AA affects more individuals than most other autoimmune diseases combined, and yet despite its 
prevalence, there is an enormous unmet medical need,7 in part due to the dearth of information 
about the underlying pathogenesis. 
In AA, autoimmunity arises against the hair follicles in the skin, which causes hair loss 
associated with an aberrant accumulation of immune-response cells around the affected hair 
follicles. Prior to my study, evidence supporting a genetic basis for AA stemmed from multiple 
lines of research, including increased risk of disease in first degree relatives,4,8 twin studies,9,10 
and more recently, from our initial family-based linkage study11 and GWAS in a cohort of 
unrelated individuals.12  Importantly, our initial GWAS identified a set of 16 statistically 
independent risk haplotypes across 8 loci, implicating specific genes that increase risk of AA, all 
of which have been validated.13-15  
Genome wide genetic studies provide a robust strategy to gain critical insight into 
disease mechanisms, in particular when little is known about the underlying causes of disease.  
There are currently several methods for gene mapping, including family-based study designs 
and designs that utilize cohorts of unrelated affected and unaffected people.  Each experimental 
design is subject to limitations that arise from assumptions that are inherent to the method. 
Therefore, in order to gain a comprehensive understanding of the genetic architecture of AA, I 
proposed to use a multifaceted approach to gene mapping, employing complementary methods, 
linkage and GWAS, that leverage our family cohort as well as our collection of unrelated AA 
cases.  
First I proposed to conduct linkage and association tests in a cohort of AA families.  The 
probability that an allele will demonstrate cosegregation with disease in a family, is influenced 
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by a number of factors, including its frequency in the population and the level of genetic 
heterogeneity underlying the disease.  Furthermore, the variant must be strongly correlated with 
the phenotype, such that an individual who inherits that allele will most likely develop disease.  
Variants that have a strong disadvantageous effect on phenotype are likely to be under purifying 
selection and so we expect them to exist at low frequencies in the population.  I proposed to 
conduct analyses in a family cohort to identify disease genes that harbor rare variants. 
I further proposed to conduct genome-wide association tests in a cohort of unrelated AA 
cases and controls.  This method identifies disease alleles that are common in the population.  
For example, as of December 2012, the median risk allele frequency reported in the NIH 
database of GWAS findings is 0.35, and more than 99% of risk alleles have a population 
frequency greater than 1% (www.genome.gov/gwastudies), supporting the notion that GWAS 
identify disease variants that are common in the population. 
Emerging evidence suggests that the genetic architecture of common complex diseases 
involves both common and rare variants, and the empirical evidence is augmented with sound 
theoretical arguments.16-28 For autoimmune diseases in particular, associations with multiple 
alleles have been documented for a number of loci,12,29-32 and deep resequencing and fine 
mapping has identified both rare and common susceptibility variants at loci implicated initially by 
GWAS.29,30  Therefore, there is strong rationale for pursuing both methods in my search for AA 
genes.  At the very least, both methods would converge upon a set of genes that harbor rare 
and common variants.  Alternatively, it is possible that linkage methods could identify genes that 
are under purifying selection, creating a dearth of common variants and therefore remain 






Summary of Findings 
Family studies conducted here have confirmed the presence of rare disease variants in 
AA.  Statistically significant evidence for linkage is observed at 2q36.1-q37.3 (LOD=4.17) and 
nominal evidence is observed at 6p12.2-q15 (LOD=2.31) and 6q22.31-q24.1 (LOD=2.18).  An 
additional 17 regions exceed a LOD score of 1.  The cumulative size of all linkage regions in this 
study with LOD≥1 is 114,440,871 bp.  These regions contain 618 protein coding genes, whose 
transcripts account for 58,556,469 bp, or 51% of the regions.  It is estimated that the 20,000 
genes in the human genome span about 30Mb of DNA, or account for 1% of the genome.  Thus 
the linkage regions contain a much greater density of genes than expected, which suggests that 
variation in protein coding genes is driving evidence for linkage. 
Of the 618 protein coding genes within the linkage intervals, 14 are located within 
regions that achieved at least nominal significance (p≤0.001) in our previously published 
GWAS, 18 have been annotated as involved in an immune process in the Gene Ontology 
database, and 161 have been previously identified in a hair follicle gene expression experiment. 
In the linkage study, when I examined evidence for association with three analytic 
methods, I identified 71 SNPs with statistically significant association, 40 of which fell within a 
protein coding transcript, implicating a total of 26 genes. I next searched for nominal but 
consistent evidence for association by integrating the top1% most significant SNPs for each of 
the three methods, I identified 39 genes that are implicated by more than one association 
statistic, some of which additionally harbor one of the statistically significant SNPs.  Therefore, 
this study identifies a total of 47 genes that contain SNPs with evidence for association within 
our cohort of AA families. 
I next conducted follow-up to study to our initial GWAS, by expanding the size of our 
cohort with an additional 800 cases, such that the study contained a total of 1801 cases and 
3274 controls for which I had 443,349 typed SNPs.  While our initial GWAS identified eight 
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regions of the genome with statistically significant association, only seven remained statistically 
significant in this study.  A region on chromosome 12q13.2 fell below the threshold for 
significance (p<5x10-7).  Importantly, the increase in sample size allowed me to detect an 
additional statistically significant locus at chromosome 16p13.13. 
Finally, I investigated whether the genetic architecture for mild AA is different from 
severe AA, which is characterized by total loss of scalp or scalp and body hair.  I conducted a 
case only analysis and identified six SNPs whose frequencies were increased in severe cases 
relative to mild cases.  All six SNPs reside in the HLA class II region.  These results support 
previous studies that have observed similar findings. 33,34 
 
Implications of Findings 
Six of the genes implicated by association analyses in the AA family cohort are located 
with linkage disequilibrium blocks that achieved nominal significance in our GWAS (p<0.001): 
AHI1, KN motif and ankyrin repeat domains 1 (KANK1); eyes shut homolog (EYS); GLIS family 
zinc finger 3 (GLIS3), KIAA1217, and sarcoglycan, zeta (SGCZ).  GLIS3 is a particularly 
interesting candidate gene.  Rare mutations in this loci have been implicated in neonatal 
diabetes,35 while common variants confer risk to type 1 diabletes.36  Our GWAS in AA identified 
several loci that increase risk for both type 1 diabetes and AA.12,37 
Also of interest, a subset of associated genes maps to pathways that are also implicated 
by GWAS genes.  For example, our GWAS identified a statistically significant association with a 
SNP in peroxiredoxin 5 (PRDX5), which has a well-established role in response to oxidative 
stress.  Two additional genes that achieved nominal significance in the GWAS are also involved 
in the same physiological process, MICB and PARK2.  Association tests in our family cohort 
implicate pantetheinase (VNN1) and methionine sulfoxide reductase A isoform a (MSRA), both 
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of which are annotated as oxidative stress response genes in Gene Ontlology 
(http://www.geneontology.org/). 
The GWAS that I conducted in a cohort of unrelated individuals identified an additional 
associated locus, at 16p13.13, which contains several interesting candidate genes, including 
CLEC16A, DEXI, and SOCS1, among others.  This is the first time that this locus has been 
implicated for AA in a GWAS.  However, a candidate gene study published earlier this year 
tested a SNP at this locus that was nominally significant in our GWAS locus and found it to be 
significantly associated in an independent cohort of cases and controls.  Furthermore, 
statistically significant association at this locus has been identified with GWAS for a number of 
other autoimmune diseases, including type 1 diabetes, celiac disease, Crohn’s disease, multiple 
sclerosis, ulcerative colitis and primary biliary cirrhosis (www.genome.gov/gwastudies).   
My investigation into a genetic basis for disease severity only identified six SNPs, all 
within the HLA region.  Given the small size of my sample, which contains 1194 mild cases and 
604 severe cases, it is possible both that additional loci contribute to differences in disease 
severity, but their effects are too small to be detected here.  
 
Future research 
 The studies conducted here contribute evidence for the involvement of several additional 
loci that increase risk for AA.  My analyses in a family cohort suggest that there are rare variants 
contributing to disease etiology.  Recent studies have shown that whole exome sequencing in 
families is a powerful emerging technique to identify variants that underlie linkage evidence, 
both for Mendelian diseases38 and common chronic diseases.39  My studies presented here 
provide a way to prioritize variants identified in a whole exome sequencing study. Therefore, the 
next logical step would be to conduct such a study in our family cohort.  With regard to GWAS, 
the evidence that has emerged from GWAS in other autoimmune diseases suggests that 
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increasing the sample size will identify additional risk loci.  However, in AA, the major obstacle 
in leveraging GWAS to the extent that other autoimmune diseases have is the number of cases 
that have been ascertained for genetic studies.  A large international collaboration, modeled 
after consortia established for other diseases such as rheumatoid arthritis, type 1 diabetes, 
psoriasis, and inflammatory bowel disease, is urgently needed.  Both of these endeavors would 
substantially increase our understanding of AA etiology and open up novel avenues to explore 
for therapeutic interventions. 
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